https://flcube.com/hengrui-pharmaceuticals-wins-nmpa-clinical-trial-approval-for-shr-1179-first-in-class-biological-candidate-for-weight-management/2026-09-08T14:41:20+08:00https://flcube.com/hualan-bio-wins-nmpa-clinical-trial-approval-for-novel-influenza-mrna-vaccine-chinas-vaccine-major-pushes-into-mrna-platform/2026-09-08T14:13:43+08:00https://flcube.com/metis-therapeutics-partners-with-hengrui-pharma-deploying-aitem-ai-formulation-platform-at-chinas-leading-drugmaker/2026-09-08T14:08:52+08:00https://flcube.com/suzhou-asiflyer-biotechnology-secures-exclusive-worldwide-license-from-shanghaitech-university-for-ai-designed-recombinant-botulinum-toxin-patent/2026-09-08T14:02:51+08:00https://flcube.com/sun-novo-pharmaceutical-and-deepmed-technology-sign-strategic-pact-on-ai-driven-drug-rd-building-closed-loop-ai-design-wet-lab-validation-discovery-system/2026-09-08T12:57:33+08:00https://flcube.com/liaocheng-university-and-shanghai-maiboxing-biotechnology-sign-rmb-19-million-pact-to-co-develop-lcugz1007-next-generation-e-pdc-probody-drug-conjugate/2026-09-08T12:53:11+08:00https://flcube.com/clinical-stage-biopharma-revelyx-bio-launches-with-exclusive-global-license-for-yy003-ready-to-use-recombinant-botulinum-toxin-type-a/2026-09-08T12:48:19+08:00https://flcube.com/eton-pharmaceuticals-licenses-ausons-timolol-gel-asn001-for-north-america-potential-first-topical-therapy-for-infantile-hemangioma-in-the-u-s/2026-09-08T12:44:32+08:00https://flcube.com/china-medical-system-licenses-leios-therapeutics-injectable-fat-reduction-therapy-10xb-101-in-greater-china-alongside-strategic-equity-investment/2026-09-08T12:39:04+08:00https://flcube.com/china-biotechs-panboron-bnct-hospital-signs-strategic-pact-with-oncocare-cancer-centre-hk-launching-cross-border-bnct-oncology-cooperation/2026-09-08T12:33:08+08:00https://flcube.com/guangdong-taienkang-completes-capital-increase-in-procapzoom-secures-exclusive-china-rights-to-world-first-ocular-surface-cell-therapy-sz018/2026-09-08T12:24:47+08:00https://flcube.com/hepabio-therapeutics-raises-series-a-strategic-funding-from-triapex-to-advance-organoid-technology-and-next-generation-drug-rd-systems/2026-09-07T12:46:45+08:00https://flcube.com/nmpa-accepts-medilink-therapeutics-nda-for-tam-peli-self-developed-b7-h3-targeting-adc-for-relapsed-small-cell-lung-cancer/2026-09-07T12:41:24+08:00https://flcube.com/insilico-medicine-and-mobidrop-sign-strategic-partnership-to-advance-ai-ready-single-cell-data-for-drug-discovery/2026-09-07T12:38:27+08:00https://flcube.com/innovent-biologics-suzhou-base-passes-ema-on-site-inspection-securing-eu-gmp-certification-on-first-attempt/2026-09-07T12:34:08+08:00https://flcube.com/santens-atropine-eye-drops-ryjusea-wins-nda-acceptance-from-chinas-nmpa-for-myopia-progression/2026-09-07T12:29:46+08:00https://flcube.com/anglikang-pharmaceuticals-terminates-affinity-partnership-for-imd-1005-novel-tumor-microenvironment-activated-cd47-antibody/2026-09-07T12:23:52+08:00https://flcube.com/jenscares-lux-valve-plus-wins-hong-kong-approval-expanding-global-footprint-of-transcatheter-tricuspid-valve-replacement-system/2026-09-07T12:12:04+08:00https://flcube.com/tennor-therapeutics-reports-positive-phase-iia-top-line-results-for-tnp-2092-in-prosthetic-joint-infection-first-in-class-triple-target-candidate-advances-to-p/2026-09-07T12:05:52+08:00https://flcube.com/msds-keytruda-wins-nmpa-approval-for-perioperative-treatment-of-resectable-locally-advanced-hnscc-in-china/2026-09-04T16:52:19+08:00https://flcube.com/chinas-2026-nhsa-drug-negotiations-open-sept-5-with-parallel-commercial-insurance-innovative-drug-catalog-talks/2026-09-04T16:46:52+08:00https://flcube.com/trinomabs-retavibart-wins-nmpa-priority-approval-as-rsv-prevention-monoclonal-antibody-xinduotuo/2026-09-04T16:44:53+08:00https://flcube.com/xuanzhu-biopharmaceutical-signs-thailand-commercial-agreement-with-innobic-and-zaoan-for-bireociclib/2026-09-04T16:37:56+08:00https://flcube.com/bettas-ensartinib-wins-nmpa-approval-for-third-indication-as-adjuvant-therapy-in-alk-positive-nsclc/2026-09-04T16:31:31+08:00https://flcube.com/yipinhongs-ar882-meets-primary-endpoint-in-phase-3-gout-trial-outperforming-febuxostat-on-uric-acid-reduction/2026-09-04T16:25:29+08:00https://flcube.com/abbvies-etentamig-delivers-positive-phase-iii-cervino-results-in-triple-class-exposed-relapsed-refractory-multiple-myeloma/2026-09-04T16:22:35+08:00https://flcube.com/stoke-and-biogen-to-present-5-year-zorevunersen-data-in-dravet-syndrome-at-european-epilepsy-congress/2026-09-04T16:20:20+08:00https://flcube.com/typewriter-therapeutics-raises-usd-56-million-series-a-to-advance-tprt-rna-gene-insertion-platform-for-in-vivo-car-t-and-liver-diseases/2026-09-04T16:16:33+08:00https://flcube.com/nmpa-approves-eisais-lecanemab-subcutaneous-autoinjector-for-early-alzheimers-disease-in-china/2026-09-04T16:11:24+08:00https://flcube.com/kanghongs-conbercept-wins-nmpa-approval-for-fifth-indication-in-retinopathy-of-prematurity-rop/2026-09-04T16:04:49+08:00https://flcube.com/simceres-culevibart-wins-nmpa-approval-as-chinas-rsv-prevention-monoclonal-antibody-yingmule/2026-09-04T16:01:29+08:00https://flcube.com/genscript-proposes-probio-spin-off-for-standalone-listing-on-hkex-main-board/2026-09-04T15:57:11+08:00https://flcube.com/sino-biopharmaceuticals-gpc3-adc-tqb6426-gains-fda-ind-approval-for-advanced-malignant-tumors/2026-09-04T15:51:02+08:00https://flcube.com/fosun-pharmas-luvometinib-wins-nmpa-approval-for-nf1-associated-plexiform-neurofibromas-in-adults/2026-09-04T15:47:36+08:00https://flcube.com/takeda-and-belief-biomed-end-xinjiuning-commercialization-partnership-belief-biomed-to-advance-gene-therapy-independently/2026-09-04T15:44:07+08:00https://flcube.com/hengruis-drotokibart-bla-accepted-by-nmpa-for-moderate-to-severe-atopic-dermatitis/2026-09-04T15:36:45+08:00https://flcube.com/ganlees-gzc8072-wins-nmpa-ind-approval-for-once-weekly-oral-type-2-diabetes-candidate/2026-09-04T15:33:05+08:00https://flcube.com/nmpa-adds-metomidate-lometomidate-and-solriamfetol-to-psychotropic-drug-schedule-in-three-agency-regulatory-adjustment/2026-09-03T17:56:51+08:00https://flcube.com/neushen-therapeutics-closes-oversubscribed-series-b-exceeding-usd-80-million-to-accelerate-global-cns-pipeline/2026-09-03T17:55:04+08:00https://flcube.com/nmpa-expands-conformance-evaluations-to-eye-drops-patches-and-sprays-raising-the-bar-for-generic-drugs-in-non-oral-dosage-forms/2026-09-03T17:52:52+08:00https://flcube.com/hengrui-pharmaceuticals-oral-glp-1r-agonist-hrs-7535-nda-accepted-by-nmpa-for-type-2-diabetes-joining-chinas-incretin-race/2026-09-03T17:50:49+08:00https://flcube.com/keymed-biosciences-grants-aeira-exclusive-rights-to-stapokibart-across-18-southeast-and-central-asia-markets-securing-high-double-digit-royalties/2026-09-03T17:45:58+08:00https://flcube.com/zhongsheng-files-china-trial-application-to-expand-onradivir-into-high-risk-influenza-a-patients-broadening-its-first-in-class-pb2-inhibitor-franchise/2026-09-03T17:39:07+08:00https://flcube.com/pegbio-signs-rd-collaboration-with-sn-bioscience-to-pair-three-innovative-peptide-candidates-with-sna-long-acting-delivery-for-metabolic-diseases/2026-09-03T17:35:53+08:00https://flcube.com/cutia-therapeutics-cu-20101-bla-accepted-by-nmpa-for-moderate-to-severe-glabellar-lines-advancing-a-safer-botulinum-toxin-type-a/2026-09-03T17:29:16+08:00https://flcube.com/biocytogen-signs-non-exclusive-nanobody-licensing-deal-with-qilu-pharmaceutical-for-innovative-neurological-drug-rd/2026-09-03T17:24:38+08:00https://flcube.com/haixi-pharma-completes-phase-i-of-oral-hx9428-in-namd-with-visual-gains-files-ind-for-dme-phase-iia-as-fda-fast-track-asset-expands/2026-09-03T17:20:09+08:00https://flcube.com/hansohs-hs-20093-risvutatug-rezetecan-nda-accepted-by-nmpa-for-small-cell-lung-cancer-after-first-global-phase-iii-os-win-for-a-b7-h3-adc/2026-09-03T17:14:35+08:00https://flcube.com/ocumension-completes-enrollment-in-china-phase-iii-trial-of-ot-211-for-dry-eye-disease-aligned-with-global-comet-pivotal-program/2026-09-03T17:10:20+08:00https://flcube.com/medtronic-invests-usd-700-million-in-cornerstone-robotics-wins-distribution-rights-for-sentire-endoscopic-surgical-robot-outside-the-u-s/2026-09-03T17:07:31+08:00https://flcube.com/hutchmed-strikes-up-to-usd-1-295-billion-deal-with-gsk-for-hmpl-a830-its-first-in-class-kras-attc-cancer-candidate/2026-09-03T17:02:09+08:00https://flcube.com/everest-medicines-wins-nmpa-approval-for-etripamil-nasal-spray-cardamyst-in-psvt-bringing-er-free-arrhythmia-care-to-greater-china/2026-09-03T16:55:50+08:00https://flcube.com/nhsa-releases-version-3-0-drg-and-dip-grouping-schemes-setting-2027-deadline-for-chinas-disease-based-payment-overhaul/2026-09-02T15:28:17+08:00https://flcube.com/gsk-mrna-influenza-vaccine-candidate-shows-superior-immune-responses-in-phase-ii-versus-licensed-flu-shots/2026-09-02T15:26:23+08:00https://flcube.com/nmpa-tightens-drug-traceability-rules-mandating-full-chain-code-scanning-for-mahs-and-distributors/2026-09-02T15:23:42+08:00https://flcube.com/allergan-aesthetics-skinvive-by-juvederm-wins-nmpa-approval-for-perioral-wrinkles-backed-by-93-4-polss-responder-rate/2026-09-02T15:22:00+08:00https://flcube.com/beijing-huasu-wins-nmpa-clinical-trial-approval-for-methylphenidate-er-chewable-tablets-first-domestic-generic-for-adhd-treatment/2026-09-02T15:17:35+08:00https://flcube.com/novartis-remibrutinib-beats-teriflunomide-in-phase-iii-remodel-trials-for-relapsing-multiple-sclerosis/2026-09-02T15:13:28+08:00https://flcube.com/sys6010-earns-third-nmpa-breakthrough-therapy-designation-advancing-cspc-innovation-pharmaceuticals-egfr-adc-in-r-m-hnscc/2026-09-02T15:11:08+08:00https://flcube.com/huadong-medicine-and-heidelberg-pharma-expand-adc-collaboration-to-advance-next-generation-bispecific-conjugates/2026-09-02T15:07:22+08:00https://flcube.com/sino-biopharmaceuticals-cttq-grants-cipla-rights-to-tqb2102-her2-adc-in-emerging-markets-for-up-to-usd-123-million/2026-09-02T15:01:19+08:00https://flcube.com/gensci161-wins-nmpa-clinical-trial-acceptance-for-ctd-ild-expanding-bispecific-antibody-pipeline-of-changchun-high-new-technology/2026-09-02T14:57:57+08:00https://flcube.com/simcere-zaiming-licenses-sim0660-trispecific-antibody-to-roche-in-up-to-usd-1-53-billion-oncology-deal/2026-09-02T14:55:11+08:00https://flcube.com/nmpa-cde-issues-draft-guideline-to-reduce-or-replace-animal-testing-for-monoclonal-antibodies-opening-public-comment/2026-09-01T12:37:19+08:00https://flcube.com/shanghai-raass-sr604-enters-nmpa-cde-rare-disease-encouragement-program-for-hemophilia-and-factor-vii-deficiency-treatment/2026-09-01T12:35:19+08:00https://flcube.com/eisai-launches-leqembi-iqlik-subcutaneous-auto-injector-for-early-alzheimers-disease-in-the-united-states/2026-09-01T12:31:46+08:00https://flcube.com/trump-signs-nine-new-mfn-drug-pricing-agreements-expanding-pharma-deals-to-26-companies-covering-89-of-branded-market/2026-09-01T12:26:40+08:00https://flcube.com/laekna-doses-first-patient-in-phase-i-study-of-lae118-pi3k%ce%b1-inhibitor-for-advanced-solid-tumors-licensed-to-vasque-bio-for-up-to-usd-527-million/2026-09-01T12:20:38+08:00https://flcube.com/johnson-johnson-medtech-and-ced-medical-sign-third-strategic-cooperation-agreement-to-expand-neurointerventional-partnership-behind-qiangyida-stent/2026-09-01T12:17:01+08:00https://flcube.com/cspc-pharmaceutical-initiates-phase-i-trial-of-amylin-receptor-agonist-syh2092-for-weight-management-in-china/2026-09-01T12:11:47+08:00https://flcube.com/ocumension-therapeutics-completes-first-patient-enrollment-of-ot-202-phase-iii-trial-for-dry-eye-disease-in-china/2026-09-01T12:08:15+08:00https://flcube.com/eli-lilly-to-acquire-merida-biosciences-for-up-to-usd-2-875-billion-adding-mer511-precision-autoantibody-platform/2026-09-01T12:05:37+08:00https://flcube.com/china-npc-passes-medical-security-law-establishing-multi-tier-medical-insurance-framework-effective-2027/2026-09-01T12:02:18+08:00https://flcube.com/baheal-pharma-invests-rmb-40-million-in-jikun-medical-to-accelerate-jk1033-idiopathic-pulmonary-fibrosis-drug/2026-09-01T12:00:09+08:00https://flcube.com/westgene-and-create-sign-license-deal-to-co-develop-in-vivo-car-t-therapies/2026-08-31T21:08:45+08:00https://flcube.com/ascletis-doses-first-patient-in-global-phase-3-aurora-trial-of-oral-glp-1-candidate-asc30/2026-08-31T21:02:15+08:00https://flcube.com/mabwell-licenses-synusights-sst001-pet-tracer-for-%ce%b1-synuclein-imaging-in-greater-china/2026-08-31T20:58:48+08:00https://flcube.com/glubios-glb-005-wiz-degrader-enters-nmpa-rare-disease-pilot-for-%ce%b2-thalassemia/2026-08-31T14:19:30+08:00https://flcube.com/simnova-closes-nearly-rmb-400-million-series-b-to-advance-car-nk-candidate-snc103/2026-08-31T14:15:44+08:00https://flcube.com/leaderna-therapeutics-closes-series-a-led-by-grand-view-capital-to-advance-oligonucleotide-pipeline/2026-08-31T14:08:30+08:00https://flcube.com/eli-lilly-wins-fda-approval-for-mounjaro-cardiovascular-risk-reduction-in-type-2-diabetes/2026-08-31T14:03:27+08:00https://flcube.com/takeda-wins-fda-approval-for-mimrylo-first-in-class-hepcidin-mimetic-for-polycythemia-vera/2026-08-31T13:53:49+08:00https://flcube.com/fosun-pharmas-velinotamig-wins-nmpa-conditional-approval-for-relapsed-or-refractory-multiple-myeloma/2026-08-28T21:37:23+08:00https://flcube.com/duality-biologics-and-genentech-strike-global-adc-collaboration-with-usd-1b-milestone-potential/2026-08-28T21:12:47+08:00https://flcube.com/hutchmeds-fanregratinib-wins-nmpa-conditional-approval-for-fgfr2-rearranged-intrahepatic-cholangiocarcinoma/2026-08-28T21:05:41+08:00https://flcube.com/ausperbio-raises-usd-120m-series-c-to-advance-ahb-137-phase-iii-trial-and-oligonucleotide-pipeline/2026-08-28T20:59:39+08:00https://flcube.com/livzon-pharmaceuticals-lecankitug-wins-nmpa-approval-for-moderate-to-severe-plaque-psoriasis/2026-08-28T20:55:44+08:00https://flcube.com/tyk-medicines-asandeutertinib-wins-nmpa-conditional-approval-for-egfr-mutant-nsclc-with-cns-metastases/2026-08-28T20:52:07+08:00https://flcube.com/abbvie-submits-ema-application-for-skyrizi-subcutaneous-induction-in-crohns-disease/2026-08-28T20:48:48+08:00https://flcube.com/tuv-rheinland-and-united-imaging-sign-strategic-cooperation-mou-to-accelerate-global-market-access-for-medical-devices/2026-08-28T20:43:29+08:00https://flcube.com/immuneonco-doses-first-patient-in-phase-2-trial-of-imm2510-combo-for-first-line-hcc/2026-08-28T20:35:38+08:00https://flcube.com/asieris-wins-eu-ce-certification-for-apld-2304-the-worlds-first-portable-single-use-blue-light-flexible-cystoscope/2026-08-28T20:32:19+08:00https://flcube.com/china-health-report-nhc-data-shows-life-expectancy-at-79-25-years-as-health-spending-reaches-6-7-of-gdp/2026-08-28T20:26:57+08:00https://flcube.com/gileads-bixlenvo-wins-fda-approval-as-smallest-once-daily-single-tablet-hiv-regimen/2026-08-28T20:25:14+08:00https://flcube.com/roivants-lisraya-wins-fda-approval-as-first-targeted-therapy-for-dermatomyositis/2026-08-28T20:18:54+08:00https://flcube.com/hansoh-pharmaceutical-posts-35-8-profit-growth-in-1h-2026-as-innovative-drugs-reach-85-of-revenue-first-newco-out-licensing-deal-marked/2026-08-27T14:54:15+08:00https://flcube.com/hitgen-posts-52-revenue-growth-in-1h-2026-as-del-segment-surges-62-and-recurring-profit-jumps-43/2026-08-27T14:47:32+08:00https://flcube.com/cspcs-pd-1-il-15-bispecific-sys6090-jmt108-granted-fda-fast-track-for-mss-pmmr-metastatic-colorectal-cancer/2026-08-27T14:39:41+08:00https://flcube.com/insilico-medicine-swings-to-profitability-as-revenue-surges-287-in-1h-2026-rentosertib-advances-to-phase-3/2026-08-27T14:36:10+08:00https://flcube.com/huadong-medicines-ror1-adc-hdm2005-granted-fda-fast-track-designation-first-domestic-ror1-adc-to-achieve-the-status/2026-08-27T14:24:13+08:00https://flcube.com/micots-first-in-class-trkb-agonist-mt200605-meets-primary-endpoint-in-phase-2-acute-ischemic-stroke-trial/2026-08-27T14:21:15+08:00https://flcube.com/nmpa-suspends-sales-and-use-of-pierre-fabres-encorafenib-capsules-over-unapproved-manufacturing-change/2026-08-27T14:17:28+08:00https://flcube.com/chinas-nhsa-issues-guiding-opinions-establishing-unified-payment-management-for-long-term-care-insurance-ltci/2026-08-27T12:44:35+08:00https://flcube.com/junshi-biosciences-achieves-first-ever-semiannual-profitability-as-toripalimab-sales-surge-36/2026-08-27T12:40:49+08:00https://flcube.com/astellas-doses-first-patient-in-phase-3-trial-of-bispecific-asp2138-for-first-line-gastric-cancer/2026-08-27T12:34:01+08:00https://flcube.com/shionogi-terminates-collaboration-with-susmed-on-digital-insomnia-therapy-med-cbt-i/2026-08-27T12:29:21+08:00https://flcube.com/fda-approves-revolution-medicines-rasonque-daraxonrasib-an-oral-multi-selective-rason-inhibitor-for-metastatic-pancreatic-cancer/2026-08-27T12:21:09+08:00https://flcube.com/shionogi-launches-xocova-ensitrelvir-in-us-for-covid-19-post-exposure-prophylaxis-following-67-risk-reduction-in-global-trial/2026-08-26T13:42:56+08:00https://flcube.com/roches-vabysmo-wins-nmpa-approval-for-retinal-diseases-in-china-market-expansion/2026-08-26T13:42:25+08:00https://flcube.com/sanofi-reports-17-8-revenue-growth-in-q2-2026-driven-by-dupixent-and-pharma-launches/2026-08-26T13:41:59+08:00https://flcube.com/suzhou-forlong-biotechnology-advances-fl115-subcutaneous-injection-into-phase-1-clinical-trial-for-advanced-solid-tumors/2026-08-26T13:41:29+08:00https://flcube.com/hutchmed-reports-h1-2026-results-with-strong-oncology-growth-despite-overall-revenue-decline/2026-08-26T13:40:22+08:00https://flcube.com/wuxi-apptec-reports-38-9-revenue-growth-in-h1-2026-raises-full-year-guidance/2026-08-26T13:39:31+08:00https://flcube.com/abbvie-reports-10-2-revenue-growth-in-q2-2026-driven-by-strong-immunology-performance/2026-08-26T13:39:11+08:00https://flcube.com/innovent-biologics-reports-h1-2026-revenue-exceeding-rmb-8-2-billion-up-55-year-over-year/2026-08-26T13:38:42+08:00https://flcube.com/novo-nordisk-reports-q2-2026-net-sales-of-dkk-78-5b-driven-by-strong-semaglutide-performance-despite-portfolio-restructuring/2026-08-26T13:38:16+08:00https://flcube.com/sanofi-secures-european-commission-approval-for-menquadfi-pediatric-indication-extension-to-infants-from-six-weeks-of-age/2026-08-26T13:37:47+08:00https://flcube.com/allergan-aesthetics-botox-cosmetic-sbla-accepted-by-fda-for-masseter-muscle-prominence-poised-to-become-first-neurotoxin-indication/2026-08-26T13:37:20+08:00https://flcube.com/amgen-reports-q2-2026-revenue-of-10-05b-driven-by-26-growth-in-core-portfolio-despite-denosumab-decline/2026-08-26T13:36:50+08:00https://flcube.com/takeda-reports-q1-fy2026-revenue-of-jpy-1-22-trillion-outlines-growth-strategy-centered-on-three-key-pipeline-assets/2026-08-26T13:36:09+08:00https://flcube.com/bayer-reports-q2-2026-sales-of-eur-10-87b-driven-by-strong-nubeqa-and-kerendia-growth-despite-xarelto-and-eylea-patent-expirations/2026-08-26T13:35:30+08:00https://flcube.com/biogen-reports-q2-2026-revenue-of-2-74b-growth-portfolio-surges-24-led-by-strong-leqembi-and-skyclarys-performance/2026-08-26T13:35:03+08:00https://flcube.com/pfizer-reports-q2-2026-revenue-of-15-0b-raises-full-year-guidance-as-launched-and-acquired-products-surge-18/2026-08-26T13:34:33+08:00https://flcube.com/merck-reports-q2-2026-sales-of-16-6b-driven-by-keytruda-growth-and-winrevair-surge-as-company-raises-full-year-guidance/2026-08-26T13:34:06+08:00https://flcube.com/beone-medicines-reports-record-q2-2026-revenue-of-1-7b-driven-by-brukinsa-growth-and-raises-full-year-guidance/2026-08-26T13:33:42+08:00https://flcube.com/eli-lilly-reports-record-q2-2026-revenue-of-22-97b-driven-by-tirzepatide-blockbusters-and-raises-full-year-guidance/2026-08-26T13:32:18+08:00https://flcube.com/takeda-receives-fda-approval-for-orzeyful-oveporexton-first-oral-ox2r-agonist-for-narcolepsy-type-1-in-adults/2026-08-26T13:31:54+08:00https://flcube.com/astellas-reports-record-q1-fy2026-revenue-of-%c2%a5640-9b-driven-by-strategic-brands-growth-and-raises-full-year-outlook/2026-08-26T13:31:33+08:00https://flcube.com/gilead-sciences-reports-q2-2026-revenue-of-7-8b-driven-by-hiv-franchise-and-trodelvy-growth-despite-cell-therapy-decline/2026-08-26T13:31:08+08:00https://flcube.com/merck-secures-fda-acceptance-for-enflonsia-sbla-to-expand-rsv-prevention-through-second-season-in-high-risk-children/2026-08-26T13:30:44+08:00https://flcube.com/westlake-consortium-secures-nmpa-approval-for-iscartrelvir-novel-oral-3clpro-inhibitor-for-mild-to-moderate-covid-19/2026-08-26T13:30:17+08:00https://flcube.com/takeda-expands-revestive-approval-in-china-with-new-1-25-mg-specification-for-pediatric-short-bowel-syndrome-patients-as-young-as-4-months/2026-08-26T13:29:47+08:00https://flcube.com/daiichi-sankyo-enlists-innovent-biologics-as-exclusive-china-partner-for-vanflyta-flt3-inhibitor-in-aml/2026-08-26T13:29:21+08:00https://flcube.com/grand-pharmas-gpn01530-2-rdc-drug-snags-fda-fast-track-for-solid-tumor-diagnosis/2026-08-26T13:28:49+08:00https://flcube.com/wuxi-apptec-wins-preliminary-injunction-against-dod-1260h-designation/2026-08-26T13:28:21+08:00https://flcube.com/kelun-biotech-signs-commercialization-deal-with-new-frontier-health-for-sacituzumab-tirumotecan-in-hong-kong-and-macao/2026-08-26T13:27:57+08:00https://flcube.com/hopstem-biotech-completes-first-close-of-nearly-rmb-200-million-series-c-to-advance-ipsc-cell-therapy-pipeline-led-by-hnpc01/2026-08-26T13:27:30+08:00https://flcube.com/xtalpi-and-gan-lee-pharmaceuticals-ai-peptide-delivery-lab-recognized-as-beijing-key-laboratory-deepening-ai-powered-peptide-drug-rd-collaboration/2026-08-26T13:27:02+08:00https://flcube.com/beone-medicines-announces-imdelltra-tarlatamab-first-in-class-dll3-cd3-t-cell-engager-co-developed-with-amgen-enters-clinical-use-across-17-chinese-cities/2026-08-26T13:26:36+08:00https://flcube.com/hangzhou-eli-radiopharma-and-shanghai-smartlogic-sign-strategic-cooperation-agreement-to-advance-computation-driven-radiopharmaceutical-discovery-and-co-build-cyclic-peptide-platform/2026-08-26T13:26:02+08:00https://flcube.com/grit-biotechnology-and-drug-farm-sign-deep-collaboration-agreement-to-co-create-kunevo-an-ai-native-biotech-rd-platform-for-first-in-class-drug-discovery/2026-08-26T13:25:37+08:00https://flcube.com/cansino-biologics-reaches-cooperation-intent-with-pakistans-agp-limited-on-pcv13i-pneumococcal-vaccine/2026-08-26T13:25:07+08:00https://flcube.com/impact-therapeutics-signs-exclusive-deal-with-pharmanovia-for-senaparib-parp-inhibitor-across-66-countries-worth-up-to-eur-423-5-million/2026-08-26T13:24:43+08:00https://flcube.com/sanyou-biopharmaceuticals-signs-strategic-deal-with-baiyunshan-xihe-to-co-develop-novel-radiopharmaceuticals/2026-08-26T13:24:16+08:00https://flcube.com/msd-signs-oncology-collaboration-with-inventisbio-through-mcicc-to-accelerate-small-molecule-clinical-development/2026-08-26T13:23:49+08:00https://flcube.com/aureka-biotechnologies-closes-usd-100-million-series-b-to-scale-ai-native-biological-foundation-models-total-funding-nears-usd-200-million/2026-08-26T13:23:03+08:00https://flcube.com/nmpa-approves-geneseeqs-fandekang-ntrk-fusion-detection-kit-as-companion-diagnostic-for-vcare-pharmatechs-eratrectinib/2026-08-26T13:22:37+08:00https://flcube.com/astrazeneca-and-daiichi-sankyos-enhertu-wins-china-approval-for-first-line-her2-positive-metastatic-breast-cancer-in-combination-with-pertuzumab/2026-08-26T13:22:07+08:00https://flcube.com/iaso-biotherapeutics-completes-acquisition-of-medisix-therapeutics-adding-pebl-based-car-t-cell-therapy-platform-for-t-cell-malignancies/2026-08-26T13:21:33+08:00https://flcube.com/acrobiosystems-and-bailinke-pharmaceutical-form-strategic-partnership-to-build-ai-empowered-affinity-purification-solutions/2026-08-26T13:20:59+08:00https://flcube.com/astrazeneca-launches-tezspire-in-china-bringing-first-in-class-tslp-inhibitor-tezepelumab-to-severe-asthma-and-crswnp-patients/2026-08-26T13:20:28+08:00https://flcube.com/ledeinno-medical-valley-closes-over-200-million-rmb-in-series-b-and-b-rounds-shining-capital-leads-backing-for-wireless-scs-neuromodulation-platform/2026-08-26T13:20:05+08:00https://flcube.com/navi-therapeutics-completes-angel-and-series-a-rounds-totaling-several-hundred-million-rmb-legend-capital-co-leads-backing-for-next-generation-adc-platform/2026-08-26T13:19:31+08:00https://flcube.com/european-commission-revokes-eu-marketing-authorisation-for-csl-and-vfmcrps-tavneos-avacopan-withdrawn-across-eu-and-eea-markets/2026-08-26T13:19:06+08:00https://flcube.com/trump-picks-white-house-policy-advisor-heidi-overton-to-lead-fda-replacing-acting-commissioner-kyle-diamantas-after-makarys-resignation/2026-08-26T13:18:39+08:00https://flcube.com/jiangsu-hengrui-1h-2026-innovative-drug-sales-jump-16-4-to-rmb-8-8-billion-offset-generic-drag-as-rd-spending-climbs-19/2026-08-26T13:18:10+08:00https://flcube.com/ascentage-pharma-1h-2026-revenue-jumps-29-to-rmb-302-million-as-olverembatinib-and-lisaftoclax-power-commercial-growth/2026-08-26T13:17:32+08:00https://flcube.com/carsgen-1h-2026-satricabtagene-autoleucel-wins-nmpa-approval-as-worlds-first-car-t-for-solid-tumors-cash-runway-seen-into-2030/2026-08-26T13:17:01+08:00https://flcube.com/hengrui-wins-nmpa-approval-for-hrs-5965-complement-factor-b-inhibitor-for-complement-inhibitor-naive-pnh-patients/2026-08-26T13:16:38+08:00https://flcube.com/pharmaron-posts-17-9-first-half-revenue-growth-as-cro-demand-rebounds-cdmo-and-all-core-segments-expand/2026-08-26T13:15:56+08:00https://flcube.com/ultomiris-wins-nmpa-approval-for-pnh-in-china-bringing-long-acting-ravulizumab-c5-inhibitor-to-adult-and-pediatric-patients/2026-08-26T13:15:29+08:00https://flcube.com/henlius-h1-2026-earnings-trastuzumab-sales-surge-27-3-revenue-growth-as-overseas-profit-quadruples/2026-08-26T13:14:54+08:00https://flcube.com/simcere-h1-earnings-surge-as-neuroscience-revenue-jumps-60-9-and-profit-rises-37-9/2026-08-26T13:14:20+08:00https://flcube.com/innocare-pharma-swings-to-profit-as-h1-2026-revenue-jumps-55-5-on-orelabrutinib-growth/2026-08-26T13:13:46+08:00https://flcube.com/mirxes-signs-strategic-mou-with-gaia-health-to-expand-early-cancer-screening-in-the-philippines/2026-08-26T13:13:17+08:00https://flcube.com/wuxi-xdc-h1-revenue-surges-41-5-to-rmb-3-7-billion-as-adc-backlog-jumps-50-4/2026-08-26T13:12:50+08:00https://flcube.com/nmpa-approves-novartis-pluvicto-plus-arpi-for-psma-positive-mhspc-in-china-advancing-radioligand-therapy-to-earlier-prostate-cancer/2026-08-26T13:11:46+08:00https://flcube.com/fda-approves-jjs-imaavy-for-warm-autoimmune-hemolytic-anemia-marking-second-indication-for-nipocalimab/2026-08-26T13:07:01+08:00https://flcube.com/fda-approves-beones-tevimbra-plus-zanidatamab-and-chemotherapy-for-first-line-her2-positive-gastroesophageal-adenocarcinoma/2026-08-26T13:02:07+08:00https://flcube.com/mhlw-approves-takedas-first-in-class-orzeyful-oveporexton-for-narcolepsy-type-1-in-japan/2026-08-26T12:57:00+08:00https://flcube.com/wuxi-biologics-2026h1-revenue-climbs-18-4-to-rmb-11-8-billion-as-project-pipeline-hits-1064-integrated-programs/2026-08-26T12:51:27+08:00https://flcube.com/fosun-pharma-2026h1-revenue-rises-4-75-to-rmb-20-44-billion-as-innovative-drugs-and-globalization-power-growth/2026-08-26T12:45:24+08:00https://flcube.com/takeda-and-ant-group-form-digital-healthcare-partnership-to-advance-ai-driven-patient-care-in-china/2026-08-26T12:39:59+08:00https://flcube.com/ec-approves-gileads-trodelvy-plus-keytruda-for-first-line-pd-l1-positive-metastatic-tnbc-35-reduction-in-progression-risk/2026-08-26T12:34:41+08:00https://flcube.com/haisco-signs-exclusive-licensing-deal-with-sentivera-for-preclinical-autoimmune-asset-up-to-usd-1-46-billion-in-milestones/2026-08-26T12:27:11+08:00https://flcube.com/gsks-jemperli-wins-fda-priority-review-for-dmmr-msi-h-locally-advanced-rectal-cancer-pdufa-date-set-for-february-2027/2026-08-26T12:21:49+08:00https://flcube.com/merck-loses-third-circuit-appeal-as-court-upholds-medicare-drug-price-negotiations-under-ira/2026-08-25T16:20:06+08:00https://flcube.com/chinas-nhc-issues-notice-deepening-six-expansions-to-strengthen-family-doctor-contracted-services-with-ai-integration/2026-08-25T16:08:09+08:00https://flcube.com/hengruis-nmpa-accepts-nda-for-hrg2010-a-novel-levodopa-carbidopa-combination-for-parkinsons-disease/2026-08-25T12:16:37+08:00https://flcube.com/antengene-clears-australian-regulatory-hurdles-for-phase-i-attract-study-of-ucb-licensed-atg-201/2026-08-25T12:12:26+08:00https://flcube.com/nmpa-issues-108th-batch-catalog-of-reference-listed-drugs-for-generic-drugs-adding-17-new-specifications/2026-08-25T11:57:04+08:00https://flcube.com/hanmi-pharm-strikes-up-to-2-3-billion-licensing-deal-with-genentech-for-muscle-sparing-obesity-candidate-hm17321/2026-08-25T11:04:25+08:00https://flcube.com/leads-biolabs-files-nda-for-opamtistomig-in-ep-nec-worlds-first-4-1bb-bispecific-nears-potential-first-approval/2026-08-24T12:04:27+08:00https://flcube.com/yipinhong-wins-nmpa-clinical-trial-approval-for-category-1-urat1-inhibitor-aph03867-in-gout-and-hyperuricemia/2026-08-24T11:52:20+08:00https://flcube.com/immuneoncos-imm0306-wins-fda-ind-clearance-for-sle-worlds-first-cd47-cd20-bispecific-in-clinic-enters-u-s/2026-08-24T11:49:25+08:00https://flcube.com/north-china-pharma-wins-nmpa-clinical-trial-approval-for-world-first-hexavalent-norovirus-vaccine-candidate/2026-08-24T11:45:59+08:00https://flcube.com/hengrui-pharma-wins-nmpa-approval-for-three-clinical-trials-led-by-first-in-class-shr-7012-for-cutaneous-lupus/2026-08-24T11:36:16+08:00https://flcube.com/metis-and-westvac-biopharma-forge-ai-partnership-to-develop-personalized-mrna-cancer-vaccines/2026-08-21T14:46:57+08:00https://flcube.com/cstones-cs5007-ind-approved-by-nmpa-advancing-egfr-her3-bispecific-adc-for-egfr-resistant-tumors/2026-08-21T12:22:27+08:00https://flcube.com/longbio-pharmas-lp-003-bla-accepted-by-nmpa-for-seasonal-allergic-rhinitis-advancing-novel-anti-ige-antibody-toward-china-approval/2026-08-21T12:19:37+08:00https://flcube.com/china-nhc-mandates-priority-use-of-essential-medicines-as-2026-national-list-takes-effect/2026-08-21T12:16:44+08:00https://flcube.com/boehringer-ingelheim-upgrades-china-strategy-with-new-shanghai-rd-center-deepening-investment-in-pharma-and-animal-health/2026-08-21T12:14:35+08:00https://flcube.com/genentech-pledges-usd-750-million-for-oregon-device-fill-finish-plant-expanding-roches-u-s-manufacturing-footprint/2026-08-21T12:03:51+08:00https://flcube.com/simcere-secures-greater-china-rights-to-reyoung-bios-long-acting-rsv-antibody-rb0026-under-priority-review/2026-08-20T15:24:49+08:00https://flcube.com/chinas-cde-opens-public-comment-on-pioneer-program-for-cell-and-gene-therapy-products-capping-intake-at-15-drugs-per-year/2026-08-20T12:28:40+08:00https://flcube.com/abbisko-wins-nmpa-ind-clearance-for-pan-kras-inhibitor-absk211-in-advanced-solid-tumors-following-fda-green-light/2026-08-20T12:13:47+08:00https://flcube.com/vectorbuilder-and-lir-therapeutics-forge-ai-collaboration-to-optimize-aav-capsids-for-clinical-translation/2026-08-20T12:10:14+08:00https://flcube.com/leo-pharma-to-acquire-global-rights-to-dersimelagon-from-tanabe-late-stage-oral-therapy-for-rare-protoporphyrias-nears-fda-decision/2026-08-20T11:53:50+08:00https://flcube.com/haisco-pharmaceutical-wins-nmpa-clinical-approval-for-nav1-8-inhibitor-hsk51155-pain-drug-licensed-to-abbvie-in-usd-700-million-deal-advances-in-china/2026-08-19T17:32:15+08:00https://flcube.com/lepu-medicals-sirna-drug-mwn117-wins-nmpa-clinical-trial-approval-for-overweight-and-obesity-inhbe-targeting-therapy-shows-synergy-potential-with-glp-1-agonists/2026-08-19T17:23:16+08:00https://flcube.com/fda-issues-discussion-paper-on-genai-enabled-medical-devices-seeks-feedback-on-risk-framework-premarket-evaluation-and-postmarket-monitoring-by-october-19/2026-08-19T17:19:03+08:00https://flcube.com/johnson-johnson-wins-u-s-510k-clearance-for-monarch-quest-3-software-update-advancing-robotic-bronchoscopy-navigation-and-targeting/2026-08-19T16:49:16+08:00https://flcube.com/shanghai-yizhong-pharmaceuticals-yxc-002-wins-ind-approval-fourth-generation-brain-penetrant-egfr-tki-for-non-small-cell-lung-cancer-overcomes-c797s/2026-08-19T12:38:41+08:00https://flcube.com/genrix-bios-gr2302-bispecific-antibody-receives-nmpa-ind-approval-for-chronic-hepatitis-b-tcr-mimic-t-cell-engager-targets-hbv-infected-hepatocytes/2026-08-19T12:35:09+08:00https://flcube.com/novo-nordisk-china-launches-organizational-restructuring-merges-diabetes-and-insulin-divisions-into-hospital-business-division-creates-new-emerging-channels-division/2026-08-19T12:30:54+08:00https://flcube.com/nhwa-pharmaceutical-wins-nmpa-ind-approval-for-two-category-1-chemical-drugs-nh130-for-schizophrenia-alzheimers-psychosis-nh302-for-acute-pain/2026-08-19T12:27:46+08:00https://flcube.com/cspc-pharmaceuticals-anbenitamab-kn026-plus-hb1801-nda-accepted-by-nmpa-for-first-line-advanced-breast-cancer-her2-bispecific-combo-advances-in-china/2026-08-19T12:25:09+08:00https://flcube.com/bio-thera-solutions-expands-partnership-with-avalon-pharma-exclusive-mena-licensing-deal-for-dupixent-biosimilar-bat2406-second-collaboration-after-bat3306/2026-08-19T12:19:59+08:00https://flcube.com/betta-pharmaceuticals-partner-eyepoint-reports-eyp-1901-misses-primary-endpoint-in-first-pivotal-phase-iii-lugano-trial-for-wet-amd-duravyu-fails-non-inferiority-vs-afliberc/2026-08-19T12:17:42+08:00https://flcube.com/omniab-signs-global-collaboration-and-license-agreement-with-eli-lilly-for-ion-channel-program-up-to-370-million-in-milestones-plus-royalties/2026-08-18T12:30:35+08:00https://flcube.com/shanghai-yizhongs-first-in-class-tri-specific-biologic-yxc-001-wins-nmpa-clinical-trial-approval-for-advanced-solid-tumors/2026-08-18T12:14:08+08:00https://flcube.com/canbridge-pharmaceuticals-livmarli-granted-nhia-reimbursement-approval-in-taiwan-ibat-inhibitor-coverage-for-algs-and-pfic-takes-effect-september-1/2026-08-18T12:11:37+08:00https://flcube.com/enginprime-medical-closes-nearly-100-million-rmb-series-a-round-with-qiming-venture-partners-as-sole-investor-capital-earmarked-for-opusone-pvad-clinical-trials/2026-08-18T12:03:54+08:00https://flcube.com/guangdong-regulator-issues-recall-traceability-and-emergency-response-rules-for-imported-hong-kong-macao-pharmaceuticals-and-medical-devices-in-gba/2026-08-17T15:21:35+08:00https://flcube.com/fosun-pharma-launches-phase-2-trial-of-fxs7553-dpp-1-inhibitor-for-copd-in-china/2026-08-17T15:19:33+08:00https://flcube.com/asieris-pharmaceuticals-wins-fda-clearance-for-apl-2501-an-anti-cldn6-9-adc-in-advanced-solid-tumors/2026-08-17T15:16:14+08:00https://flcube.com/hengrui-pharmaceuticals-wins-nmpa-clearance-for-phase-ii-trial-of-hrs-4729-a-triple-agonist-peptide-drug-for-type-2-diabetes/2026-08-17T13:37:25+08:00https://flcube.com/cansino-biologics-files-nda-in-china-for-td5cp-a-first-in-nation-adolescent-and-adult-dtap-booster-vaccine/2026-08-17T13:33:39+08:00https://flcube.com/easton-pharmaceutical-doses-first-patient-in-phase-i-ii-trial-of-hp-002-a-brain-penetrant-btk-protac-for-b-cell-non-hodgkin-lymphoma/2026-08-17T13:29:05+08:00https://flcube.com/henlius-and-sandoz-strike-strategic-biosimilars-deal-covering-up-to-10-mab-and-adc-products-worth-usd-314-million-for-initial-assets/2026-08-17T13:24:39+08:00https://flcube.com/shanghai-ark-biopharmaceutical-wins-fda-clearance-for-ziresovir-phase-ii-trials-in-severe-pediatric-rsv/2026-08-17T13:21:26+08:00https://flcube.com/chongqing-pharscin-wins-china-clinical-trial-approval-for-oric-1327-in-glaucoma-and-ocular-hypertension/2026-08-17T13:06:55+08:00https://flcube.com/yiling-pharmaceutical-files-ind-in-china-for-lb220-d08-a-first-in-class-factor-b-inhibitor-for-ahus/2026-08-17T12:57:23+08:00https://flcube.com/pfizer-and-valneva-see-ema-validate-maa-for-pf-07307405-the-first-potential-blockbuster-lyme-disease-vaccine/2026-08-17T12:54:28+08:00https://flcube.com/sino-medical-sciences-wins-turkish-approval-for-ghunter-intracranial-thrombectomy-stent-broadening-global-footprint-in-ischemic-stroke-care/2026-08-17T12:38:54+08:00https://flcube.com/bristol-myers-squibb-secures-fda-approval-for-iberdomide-combination-in-multiple-myeloma-first-ever-nod-based-on-mrd-negative-response-data/2026-08-17T12:35:36+08:00https://flcube.com/xbiome-strikes-newco-style-technology-collaboration-with-biogent-therapeutics-for-ai-driven-bispecific-antibody-development/2026-08-14T12:21:59+08:00https://flcube.com/cde-adds-two-new-drugs-to-rare-disease-caring-program-extension-pilot-szj0107-and-jab-8263-included/2026-08-14T12:15:46+08:00https://flcube.com/celgenyx-secures-fda-ind-clearance-for-cg101-off-the-shelf-ipsc-derived-cell-therapy-in-acute-myeloid-leukemia-multicenter-phase-i-study-to-begin/2026-08-14T12:04:12+08:00https://flcube.com/nmpa-releases-draft-implementation-rules-for-the-national-key-rd-program-public-comment-open-through-12-sept-2026/2026-08-14T11:59:49+08:00https://flcube.com/tj-biopharma-and-biogen-win-nmpa-approval-for-felzartamab-jingfei-in-multiple-myeloma-first-commercial-milestone-under-greater-china-licensing-deal/2026-08-14T11:54:34+08:00https://flcube.com/hybio-pharmaceutical-grants-wansheng-pharmaceutical-exclusive-china-license-for-semaglutides-glycemic-control-indication-in-up-to-rmb-182-5-million-deal/2026-08-13T18:04:11+08:00https://flcube.com/insilico-medicine-and-thpharma-launch-ai-research-collaboration-to-build-reverse-translation-drug-discovery-strategy-around-phase-3-candidate-thp-001/2026-08-13T17:55:06+08:00https://flcube.com/ark-biopharmaceuticals-first-in-class-afc-ak0406-wins-nmpa-approval-for-influenza-prevention-clinical-trials/2026-08-13T17:43:11+08:00https://flcube.com/youcare-pharmaceuticals-ykyy033-sirna-injection-wins-us-fda-approval-to-conduct-clinical-trials-for-arterial-and-venous-thrombosis/2026-08-13T17:35:22+08:00https://flcube.com/hengrui-pharmas-shr-7590-injection-wins-nmpa-clinical-trial-approval-for-ulcerative-colitis-and-crohns-disease/2026-08-13T12:04:32+08:00https://flcube.com/zhaoke-ophthalmology-signs-exclusive-distribution-and-promotion-agreement-with-pengpai-bio-for-epinastine-hydrochloride-eye-drops-in-mainland-china/2026-08-13T12:01:21+08:00https://flcube.com/impact-therapeutics-nominates-kat6a-specific-protac-imp2794-as-preclinical-candidate-from-proprietary-tpd-platform/2026-08-13T11:57:49+08:00https://flcube.com/akesos-ivonescimab-wins-nmpa-approval-for-first-line-advanced-squamous-non-small-cell-lung-cancer-in-combination-with-chemotherapy/2026-08-13T11:54:51+08:00https://flcube.com/allist-pharmaceuticals-secures-exclusive-greater-china-license-for-arrivents-bispecific-adc-ast12608-arr-002/2026-08-13T11:52:08+08:00https://flcube.com/kintor-pharmaceutical-grants-wellrise-exclusive-distribution-rights-for-kt-939-raw-material-in-south-korea/2026-08-13T11:48:57+08:00https://flcube.com/cspc-pharmaceutical-receives-30-million-upfront-from-astrazeneca-under-sirna-drug-discovery-partnership/2026-08-13T11:42:15+08:00https://flcube.com/laeknas-nda-for-akt-inhibitor-afuresertib-accepted-by-cde-in-hr-her2-breast-cancer-after-qilu-licensing-deal/2026-08-12T17:51:08+08:00https://flcube.com/insilico-medicine-nominates-ism0900-ai-designed-oral-lpa-inhibitor-as-9th-preclinical-candidate-of-2026/2026-08-12T12:24:00+08:00https://flcube.com/haohai-wins-nmpa-approval-for-chinas-first-domestic-trifocal-toric-intraocular-lens-for-cataract-patients-with-astigmatism/2026-08-12T12:05:56+08:00https://flcube.com/wantais-9-valent-hpv-vaccine-wins-thailand-approval-chinas-first-and-worlds-second-9vhpv-vaccine-expands-into-southeast-asia/2026-08-12T12:03:12+08:00https://flcube.com/mabwell-signs-licensing-deals-with-southeast-asia-partners-for-aflibercept-biosimilar-9mw0813-in-philippines-vietnam-and-malaysia/2026-08-12T11:59:41+08:00https://flcube.com/essex-bio-technology-signs-strategic-framework-with-gunze-medical-to-expand-fgf-2-regenerative-medicine-access-across-asia/2026-08-12T11:38:12+08:00https://flcube.com/tempest-therapeutics-signs-strategic-partnership-with-senlang-to-advance-tpst-4003-in-vivo-car-t-candidate-in-china/2026-08-12T11:28:38+08:00https://flcube.com/zhaoke-ophthalmology-signs-strategic-mou-with-brazils-teuto-at-bio-2026-first-latin-america-eye-care-market-entry/2026-08-12T11:24:21+08:00https://flcube.com/sun-novo-and-gempharmatech-sign-long-term-strategic-cooperation-agreement-to-deepen-preclinical-collaboration-on-small-nucleic-acid-therapeutics-and-build-closed-loop-aoc-rd-syste/2026-08-11T13:30:19+08:00https://flcube.com/gan-lee-pharmaceuticals-signs-out-licensing-deal-with-menarini-on-bonfaglutide-a-twice-monthly-glp-1-ra-worth-up-to-eur-726-million-across-39-european-markets/2026-08-11T13:17:12+08:00https://flcube.com/zhifei-biological-submits-clinical-trial-application-in-china-for-nasal-spray-recombinant-rsv-vaccine-based-on-chimpanzee-adenovirus-vector/2026-08-11T13:02:15+08:00https://flcube.com/keymed-biosciences-bispecific-antibody-cm512-achieves-all-endpoints-in-phase-2-trial-for-chronic-rhinosinusitis-with-nasal-polyps/2026-08-11T12:58:32+08:00https://flcube.com/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-up-to-usd-1-32-billion-gaining-first-in-class-kcnt1-ion-channel-inhibitor-abs-1230-for-ultra-rare-epilepsy/2026-08-11T12:55:58+08:00https://flcube.com/cspc-pharmaceutical-groups-monkeypox-mrna-vaccine-sys6037-receives-fda-approval-to-conduct-clinical-trials-in-the-us/2026-08-11T12:52:54+08:00https://flcube.com/novo-nordisk-names-aws-preferred-cloud-provider-and-strategic-ai-partner-to-accelerate-drug-discovery-with-agentic-ai/2026-08-11T12:49:12+08:00https://flcube.com/xbiome-and-biomap-sign-strategic-cooperation-agreement-to-advance-ai-powered-microbiome-drug-and-probiotic-product-rd/2026-08-11T12:46:51+08:00https://flcube.com/beone-medicines-and-revolution-medicines-announce-clinical-collaboration-and-regional-licensing-deal-on-rason-inhibitors-across-select-asian-markets/2026-08-11T12:43:30+08:00https://flcube.com/hanx-biopharmaceuticals-partners-with-swiss-ai-biotech-twinedge-bioscience-to-advance-bispecific-antibody-candidate-hx009-for-dlbcl/2026-08-11T12:24:39+08:00https://flcube.com/astellas-submits-nda-in-japan-for-fezolinetant-a-first-in-class-nonhormonal-nk3-receptor-antagonist-for-menopausal-vasomotor-symptoms/2026-08-11T12:20:03+08:00https://flcube.com/crystalo-biopharma-signs-collaboration-and-licensing-deal-with-almirall-for-ai-driven-skin-disease-drug-discovery-worth-up-to-e254-5-million/2026-08-11T12:09:38+08:00https://flcube.com/tonghua-golden-horse-unit-signs-ma-intent-agreement-to-acquire-controlling-stake-in-8plus1-pharma/2026-08-11T12:06:08+08:00https://flcube.com/xinno-biotechnology-and-statia-biopharma-sign-exclusive-deal-to-develop-sta528-transdermal-therapy-for-autoimmune-diseases/2026-08-11T11:54:50+08:00https://flcube.com/chinas-12th-national-vbp-round-officially-confirmed-490-enterprises-selected-as-planned-procurement-value-shrinks-over-one-third-to-rmb-19-5-billion/2026-08-10T13:48:09+08:00https://flcube.com/sino-medical-sciences-neurovita-wins-eu-mdr-ce-certification-for-cometiu-worlds-first-intracranial-drug-eluting-stent-system/2026-08-10T13:45:45+08:00https://flcube.com/huadong-medicines-sinclair-secures-eu-mdr-ce-certification-for-kio015-chitosan-skin-booster-kytogen-defend/2026-08-10T13:38:08+08:00https://flcube.com/recursion-and-roche-genentech-reach-first-validated-target-milestone-in-usd-12-billion-ai-drug-discovery-alliance/2026-08-10T13:33:25+08:00https://flcube.com/genfleet-therapeutics-initiates-phase-3-trial-of-gfh375-for-kras-g12d-mutant-nsclc-in-china-first-patient-enrolled/2026-08-10T13:22:28+08:00https://flcube.com/braveheart-bio-hengrui-pharma-partner-debuts-on-nasdaq-with-usd-439-9-million-ipo-powered-by-hrs-1893-cardiac-myosin-inhibitor/2026-08-10T13:10:27+08:00https://flcube.com/salubriss-sal0195-sirna-drug-wins-nmpa-nod-for-lpa-clinical-trials/2026-08-10T12:50:12+08:00https://flcube.com/alebunds-ap301-nda-accepted-by-nmpa-for-hyperphosphatemia-in-ckd-dialysis-patients/2026-08-10T12:37:33+08:00https://flcube.com/sino-biopharmas-benmelstobart-anlotinib-combo-wins-nmpa-nod-for-first-line-sq-nsclc/2026-08-10T12:33:31+08:00https://flcube.com/hybio-files-first-tirzepatide-generic-anda-in-china-challenging-eli-lillys-glp-1-dominance/2026-08-10T12:29:33+08:00https://flcube.com/carsgen-therapeutics-secures-nmpa-clinical-trial-approval-for-allogeneic-car-t-therapy-ct1190b-in-relapsed-refractory-large-b-cell-lymphoma/2026-08-07T21:12:02+08:00https://flcube.com/transcenta-and-wuxi-biologics-forge-strategic-cdmo-partnership-with-rmb-190-million-manufacturing-facility-transaction/2026-08-07T21:03:23+08:00https://flcube.com/hengrui-pharmaceuticals-secures-fifth-nmpa-approval-for-ivarmacitinib-in-non-radiographic-axial-spondyloarthritis/2026-08-07T20:46:55+08:00https://flcube.com/hengrui-pharmaceuticals-secures-third-nmpa-approval-for-trastuzumab-rezetecan-in-her2-positive-colorectal-cancer/2026-08-07T20:38:15+08:00https://flcube.com/biogen-completes-1-billion-acquisition-of-raythera-to-bolster-immunology-portfolio-with-novel-small-molecule-pipeline/2026-08-07T20:32:53+08:00https://flcube.com/transthera-sciences-secures-nmpa-conditional-approval-for-tinengotinib-in-advanced-cholangiocarcinoma-with-fgfr2-alterations/2026-08-07T20:30:13+08:00https://flcube.com/syndax-terminates-entinostat-license-agreement-with-eoc-hk-ending-jingzhuda-commercial-rights-in-china/2026-08-06T14:57:31+08:00https://flcube.com/luye-pharmas-novel-vmat2-inhibitor-ly03015-completes-us-bridging-trial-with-enhanced-safety-profile-in-caucasian-subjects/2026-08-06T14:46:35+08:00https://flcube.com/remegen-forecasts-h1-2026-revenue-of-rmb-5-85b-net-profit-of-rmb-4-70b-on-telitacicept-and-abbvie-licensing-deal/2026-08-06T14:43:09+08:00https://flcube.com/shandong-boan-biotech-submits-bla-to-brazils-anvisa-for-aflibercept-biosimilar-ba9101-expanding-global-ophthalmic-footprint/2026-08-06T14:33:21+08:00https://flcube.com/chinas-cde-releases-109th-reference-listed-drug-catalog-adding-10-new-generic-drug-specifications/2026-08-06T14:28:42+08:00https://flcube.com/astrazeneca-and-cspc-pharmaceutical-establish-joint-venture-for-next-generation-biologics-manufacturing-base-in-shijiazhuang/2026-08-06T14:25:32+08:00https://flcube.com/insilico-medicine-nominates-ai-discovered-ism9077-as-32nd-preclinical-candidate-targeting-ophthalmic-and-inflammatory-diseases/2026-08-06T14:21:26+08:00https://flcube.com/eli-lillys-kras-g12c-inhibitor-olomorasib-receives-second-fda-breakthrough-therapy-designation-for-advanced-pancreatic-cancer/2026-08-06T00:37:35+08:00https://flcube.com/cspc-pharmaceuticals-nda-for-anbenitamab-hb1801-combination-accepted-by-china-nmpa-as-neoadjuvant-therapy-for-her2-breast-cancer/2026-08-06T00:31:00+08:00https://flcube.com/leads-biolabs-trispecific-t-cell-engager-lbl-051-enters-phase-ia-trial-for-refractory-autoimmune-diseases-through-oblenio-bio-partnership/2026-08-05T15:25:49+08:00https://flcube.com/curium-pharma-to-acquire-lantheus-holdings-in-8-billion-deal-expanding-radiopharmaceutical-market-dominance/2026-08-05T14:44:14+08:00https://flcube.com/sino-biopharmaceuticals-bcl-2-inhibitor-tqb3909-tablet-receives-cde-acceptance-for-cll-sll-treatment-in-relapsed-refractory-patients/2026-08-05T14:40:09+08:00https://flcube.com/haixi-pharmas-oral-namd-drug-candidate-hx9428-receives-fda-clearance-for-phase-2-trials-offering-alternative-to-intravitreal-injections/2026-08-05T14:19:58+08:00https://flcube.com/alphamab-oncologys-anbenitamab-nda-accepted-by-china-nmpa-for-her2-breast-cancer-neoadjuvant-treatment-granted-priority-review/2026-08-05T13:39:59+08:00https://flcube.com/alphamab-oncology-secures-2-2b-deal-with-pathos-ai-for-jskn016-global-licensing/2026-08-05T00:35:37+08:00https://flcube.com/hunan-zonsen-peplib-biotech-secures-over-rmb-300-million-in-series-c-financing/2026-08-05T00:28:01+08:00https://flcube.com/carsgen-therapeutics-ct0596-receives-nmpa-clinical-approval-for-relapsed-refractory-multiple-myeloma/2026-08-05T00:24:14+08:00https://flcube.com/innocare-pharmas-orelabrutinib-mesutoclax-combination-receives-breakthrough-therapy-designation-for-marginal-zone-lymphoma/2026-08-05T00:12:40+08:00https://flcube.com/adlai-nortyes-an4035-receives-australian-regulatory-approvals-for-first-in-class-pan-rason-adc/2026-08-05T00:08:47+08:00https://flcube.com/zai-labs-zocilurtatug-pelitecan-receives-fda-orphan-drug-designation-for-neuroendocrine-carcinoma/2026-08-04T16:02:58+08:00https://flcube.com/fda-grants-biologics-license-to-ezplaz-freeze-dried-plasma-first-fdp-approved-in-united-states/2026-08-04T15:58:17+08:00https://flcube.com/novartis-pluvicto-receives-fda-approval-for-metastatic-hormone-sensitive-prostate-cancer/2026-08-04T15:54:07+08:00https://flcube.com/siemens-healthineers-and-cleveland-clinic-announce-10-year-strategic-partnership/2026-08-04T15:44:08+08:00https://flcube.com/apeloa-pharmaceutical-and-metis-therapeutics-announce-strategic-cdmo-partnership/2026-08-04T12:41:16+08:00https://flcube.com/sansure-biotech-secures-eu-ivdr-ce-certification-for-five-nucleic-acid-diagnostic-kits/2026-08-04T12:37:40+08:00https://flcube.com/sino-biopharmaceuticals-tqb2102-receives-breakthrough-therapy-designation-from-nmpa-for-her2-low-breast-cancer/2026-08-04T12:33:44+08:00https://flcube.com/shaanxi-micot-pharmaceutical-announces-positive-phase-2-results-for-mt200605-in-acute-ischemic-stroke/2026-08-04T12:20:48+08:00https://flcube.com/cspc-pharmaceutical-launches-phase-ib-ii-trial-of-novel-sys6090-fusion-protein-for-colorectal-cancer/2026-08-04T12:16:52+08:00https://flcube.com/eli-radiopharma-and-united-imaging-research-institute-forge-strategic-alliance-to-advance-radiopharmaceutical-innovation/2026-08-04T12:04:38+08:00https://flcube.com/nmpa-proposes-framework-for-synchronized-development-of-anti-tumor-drugs-and-companion-diagnostics/2026-08-04T11:59:42+08:00https://flcube.com/cspc-pharmaceutical-launches-phase-ii-trial-of-novel-adc-sys6041-for-recurrent-ovarian-cancer-in-china/2026-08-04T11:57:01+08:00https://flcube.com/nmpa-releases-107th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation-adding-71-new-specifications/2026-08-04T11:54:01+08:00https://flcube.com/qyuns-therapeutics-secures-nmpa-approval-for-qx027n-clinical-trials-in-copd-and-crswnp-announces-global-partnership/2026-08-04T11:51:02+08:00https://flcube.com/jinling-pharmaceuticals-ferric-carboxymaltose-injection-receives-nmpa-acceptance-for-market-authorization/2026-08-04T11:47:49+08:00https://flcube.com/mabwell-shanghai-bioscience-secures-nmpa-approval-for-9mw5211-clinical-trials-in-primary-biliary-cholangitis/2026-08-04T11:43:44+08:00https://flcube.com/nanjing-leads-biolabs-secures-nmpa-approval-for-opamtistomig-lbl-024-in-metastatic-colorectal-cancer-clinical-trial/2026-08-04T11:40:18+08:00https://flcube.com/brightgenes-generic-tiotropium-bromide-inhalation-spray-gains-nmpa-approval-as-chinas-first-domestic-copd-treatment-alternative/2026-08-03T14:45:33+08:00https://flcube.com/insilico-medicines-nlrp3-inhibitor-ism8969-secures-nmpa-ind-approval-for-parkinsons-disease-with-global-clinical-trials-underway/2026-08-03T14:30:55+08:00https://flcube.com/chinas-12th-national-drug-volume-based-procurement-yields-preliminary-winners-with-originator-drugs-securing-key-positions/2026-08-03T14:26:44+08:00https://flcube.com/henlius-hlx43-pd-l1-adc-gains-nmpa-approval-for-advanced-solid-tumor-trials-with-bevacizumab/2026-08-03T14:16:39+08:00https://flcube.com/astrazeneca-and-bristol-myers-squibb-explore-400b-mega-merger-to-reshape-global-pharma-landscape/2026-08-03T14:06:54+08:00https://flcube.com/qyuns-therapeutics-partner-caldera-to-merge-with-synlogic-in-278m-backed-deal-advancing-tl1a-il-23p19-bispecific-antibody-for-inflammatory-bowel-disease/2026-07-30T20:58:00+08:00https://flcube.com/buchang-pharmaceuticals-withdraws-efperepoetin-alfa-registration-application-for-ckd-anemia-due-to-dossier-enhancement-requirements/2026-07-30T20:52:06+08:00https://flcube.com/hengrui-pharmaceuticals-her3-targeting-adc-ruzaltatug-rezetecan-receives-nmpa-marketing-application-acceptance-for-egfr-mutant-nsclc-post-tki-progression/2026-07-30T20:48:20+08:00https://flcube.com/huahai-pharmaceuticals-anti-il-36r-antibody-huayijing-receives-nmpa-priority-review-approval-for-generalized-pustular-psoriasis-flares/2026-07-30T20:44:59+08:00https://flcube.com/cspc-pharmaceuticals-nectin-4-targeting-adc-crb-701-receives-fda-approval-for-registrational-trial-in-second-line-oropharyngeal-squamous-cell-carcinoma/2026-07-30T20:41:51+08:00https://flcube.com/microport-neuroscientifics-artemis-dream-intracranial-drug-eluting-stent-enters-nmpa-green-channel-as-chinas-first-targeted-release-self-expanding-system/2026-07-30T20:38:08+08:00https://flcube.com/china-resources-pharmaceutical-to-acquire-lier-chemical-for-795m-in-strategic-move-into-agrochemical-sector/2026-07-30T20:33:42+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-approval-for-hrs5580-long-acting-nk-1-antagonist-in-combination-therapy-for-postoperative-nausea-and-vomiting-prevention/2026-07-30T20:29:59+08:00https://flcube.com/xgene-pharmaceutical-secures-35m-series-d-funding-to-advance-non-opioid-pain-therapy-xg005-into-phase-iii-trials-in-the-us/2026-07-30T18:44:44+08:00https://flcube.com/akeso-and-allink-biotherapeutics-launch-phase-ii-trial-of-pd-1-vegf-fgfr2b-adc-combination-for-squamous-nsclc-following-nmpa-ind-approval/2026-07-30T18:39:41+08:00https://flcube.com/guangzhou-innogens-ultra-long-acting-glp-1-agonist-efsubaglutide-alfa-advances-to-adolescent-obesity-phase-ib-trial-following-nmpa-approval-for-diabetes/2026-07-29T18:50:56+08:00https://flcube.com/gsk-commits-400-million-to-establish-major-cambridge-rd-center-consolidating-uk-research-operations/2026-07-29T18:46:20+08:00https://flcube.com/ribo-life-sciences-sirna-therapy-vortosiran-receives-ema-approval-for-stroke-prevention-trial-in-atrial-fibrillation-patients/2026-07-29T18:42:50+08:00https://flcube.com/hansoh-pharmaceuticals-b7-h3-adc-risvutatug-rezetecan-hits-primary-endpoint-in-osteosarcoma-phase-iii-trial-validating-gsk-partnership/2026-07-29T18:40:16+08:00https://flcube.com/insilico-medicines-ai-discovered-pan-tead-inhibitor-ism6331-receives-fda-fast-track-designation-for-malignant-pleural-mesothelioma/2026-07-29T18:33:08+08:00https://flcube.com/humanwell-healthcares-non-opioid-analgesic-hw243040-receives-nmpa-approval-for-peripheral-neuropathic-pain-clinical-trials/2026-07-29T18:30:21+08:00https://flcube.com/tpmeds-secures-tens-of-millions-in-rmb-angel-round-led-by-lotus-lake-ventures-to-advance-tpm004-ind-and-peptetris-platform/2026-07-29T18:27:16+08:00https://flcube.com/astrazenecas-ultomiris-fails-primary-endpoint-in-adult-hsct-tma-phase-iii-trial-despite-positive-pediatric-data/2026-07-29T18:20:12+08:00https://flcube.com/chinas-cde-tightens-drug-review-standards-with-new-no-supplemental-data-rule-for-major-deficiencies/2026-07-29T18:16:10+08:00https://flcube.com/changchun-high-tech-industries-subsidiary-gensci-advances-graves-disease-therapy-to-phase-ii-with-us-partner-yarrow-bioscience/2026-07-29T18:13:10+08:00https://flcube.com/chinas-nmpa-proposes-sweeping-reforms-to-medical-device-e-commerce-with-new-draft-regulations/2026-07-29T18:06:49+08:00https://flcube.com/chinas-12th-national-drug-procurement-round-attracts-500-companies-targets-7-34-billion-units/2026-07-29T18:04:37+08:00https://flcube.com/hbm-and-sinopharm-form-innovation-consortium-to-accelerate-fully-human-antibody-development-across-oncology-and-inflammatory-diseases/2026-07-28T19:01:43+08:00https://flcube.com/antengene-achieves-profitability-with-h1-2026-revenue-of-rmb-490-536m-driven-by-strategic-out-licensing-deals/2026-07-28T18:57:27+08:00https://flcube.com/china-medical-systems-rxilient-secures-exclusive-southeast-asia-rights-to-polichems-finjuve-and-ciclopoli-dermatology-portfolio/2026-07-28T18:53:48+08:00https://flcube.com/broncus-medicals-bronctru-dilation-catheter-secures-ce-mark-under-eu-mdr-for-comprehensive-lung-diagnostics-and-therapy/2026-07-28T18:49:36+08:00https://flcube.com/cspcs-albumin-bound-sirolimus-receives-nmpa-breakthrough-therapy-designation-for-rare-pecoma-tumor/2026-07-28T18:46:40+08:00https://flcube.com/hengruis-tissue-factor-targeting-adc-shr-4375-receives-fda-orphan-drug-designation-for-pancreatic-cancer/2026-07-28T18:43:29+08:00https://flcube.com/cspcs-novel-snri-ammuxetine-meets-primary-endpoint-in-phase-iii-depression-trial-poised-for-first-line-status/2026-07-28T18:40:23+08:00https://flcube.com/fosun-pharmas-dm1001-receives-nmpa-clearance-for-parkinsons-disease-clinical-trials/2026-07-28T18:37:27+08:00https://flcube.com/innocares-tyk2-inhibitor-fadeucravacitinib-hits-primary-endpoint-in-phase-iii-psoriasis-trial/2026-07-28T18:24:33+08:00https://flcube.com/hengruis-mineralocorticoid-receptor-antagonist-hrs-1780-advances-to-phase-2-3-for-resistant-hypertension-in-china/2026-07-28T18:21:42+08:00https://flcube.com/bio-sinceritys-first-in-class-epigenetic-inhibitor-bios0635-048-receives-nmpa-clearance-for-advanced-solid-tumor-trials/2026-07-28T18:18:03+08:00https://flcube.com/gsks-dovato-demonstrates-non-inferior-efficacy-to-biktarvy-in-phase-iiib-vogue-hiv-study/2026-07-28T18:15:07+08:00https://flcube.com/sichuan-keluns-dual-payload-adc-skb565-receives-nmpa-clearance-for-advanced-solid-tumor-clinical-trials/2026-07-28T18:10:40+08:00https://flcube.com/astrazeneca-reports-solid-q2-2026-results-with-5-revenue-growth-despite-farxiga-exclusivity-loss-and-china-vbp-headwinds/2026-07-28T18:07:58+08:00https://flcube.com/alexions-ultomiris-fails-to-meet-primary-endpoint-in-phase-iii-hsct-tma-trial-despite-showing-treatment-benefit-trend/2026-07-28T18:02:21+08:00https://flcube.com/sanofi-halts-amlitelimab-development-in-atopic-dermatitis-despite-positive-long-term-safety-data/2026-07-27T21:34:17+08:00https://flcube.com/roches-susvimo-receives-chmp-recommendation-for-neovascular-amd-with-contivue-implant-delivery-system/2026-07-27T21:20:39+08:00https://flcube.com/home-control-international-partners-with-articura-on-localized-healthcare-ai-infrastructure-in-indonesia/2026-07-27T21:15:26+08:00https://flcube.com/sino-biopharmaceutical-and-tempo-scan-form-jv-to-commercialize-innovative-drugs-in-indonesia/2026-07-27T21:10:56+08:00https://flcube.com/sichuan-biokins-her2-adc-t-bren-enters-phase-iii-trial-for-biliary-tract-cancer-after-platinum-failure/2026-07-27T21:01:36+08:00https://flcube.com/gileads-trodelvy-receives-positive-chmp-opinion-for-first-line-tnbc-treatment-in-combination-with-keytruda/2026-07-27T20:58:42+08:00https://flcube.com/walvax-biotechnologys-bivalent-hpv-vaccine-walrinvax-gains-tanzanian-approval-following-who-prequalification/2026-07-24T21:14:42+08:00https://flcube.com/kanghong-pharmaceutical-secures-nmpa-approval-for-khn921-gene-therapy-in-mybpc3-related-hypertrophic-cardiomyopathy-following-u-s-fda-clearance/2026-07-24T21:11:40+08:00https://flcube.com/changchun-high-tech-subsidiary-genescience-files-sle-clinical-application-for-novel-dual-target-baff-april-inhibitor-gensci136/2026-07-24T21:08:58+08:00https://flcube.com/lillys-retatrutide-delivers-up-to-22-6-weight-loss-in-phase-3-trials-establishing-triple-agonist-leadership-in-obesity-market/2026-07-24T21:04:25+08:00https://flcube.com/aidea-pharma-secures-nmpa-approval-for-darunavir-challenging-jjs-prezista-in-chinas-hiv-treatment-market/2026-07-24T21:02:06+08:00https://flcube.com/harbour-biomed-issues-profit-alert-h1-revenue-expected-at-120-125m-on-strong-platform-licensing-growth/2026-07-24T20:59:06+08:00https://flcube.com/genmab-abbvie-epcoritamab-phase-3-trial-misses-primary-os-endpoint-in-u-s-for-relapsed-refractory-dlbcl/2026-07-24T20:44:42+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-first-line-approval-for-camrelizumab-famitinib-combo-in-pd-l1-positive-cervical-cancer/2026-07-24T20:40:30+08:00https://flcube.com/roche-reports-6-h1-sales-growth-to-chf-30-4b-reaffirms-full-year-guidance-amid-strong-pharmaceutical-performance/2026-07-24T20:24:38+08:00https://flcube.com/nona-biosciences-partners-with-medical-university-of-vienna-on-infectious-disease-antibody-research-using-proprietary-h2l2-harbour-mice-platform/2026-07-24T18:39:19+08:00https://flcube.com/pakistan-china-pharma-pact-440m-in-agreements-positions-pakistan-as-regional-medicines-hub/2026-07-24T18:37:28+08:00https://flcube.com/astrazenecas-etcamah-wins-eu-approval-for-esr1-mutated-breast-cancer-next-gen-serd-shows-56-risk-reduction-in-pivotal-trial/2026-07-24T18:34:07+08:00https://flcube.com/microport-medbot-achieves-first-ever-semi-annual-profit-on-200-230-revenue-surge/2026-07-23T22:20:11+08:00https://flcube.com/cspc-pharmaceutical-launches-phase-2-trial-of-sys-6026-mrna-vaccine-for-hpv-related-cervical-precancer/2026-07-23T22:17:23+08:00https://flcube.com/pegbio-launches-commercial-prescriptions-for-paidakang-glp-1ra-in-china-triggers-milestone-payments/2026-07-23T22:13:43+08:00https://flcube.com/sino-biopharmaceutical-subsidiary-secures-nmpa-approval-for-im-101-therapeutic-vaccine-in-chronic-hepatitis-b/2026-07-23T22:08:41+08:00https://flcube.com/orbusneich-enrolls-first-patient-in-pivotal-japanese-trial-for-proprietary-drug-coated-balloon/2026-07-23T22:03:55+08:00https://flcube.com/summit-therapeutics-and-arcus-biosciences-launch-global-trial-of-ivonescimab-casdatifan-combination-for-renal-cell-carcinoma/2026-07-23T22:00:00+08:00https://flcube.com/trump-announces-phased-tariff-policy-on-generic-drug-imports-to-incentivize-u-s-manufacturing-reshoring/2026-07-23T21:56:17+08:00https://flcube.com/gsk-secures-early-fda-approval-for-jideytro-ros1-inhibitor-for-resistant-non-small-cell-lung-cancer/2026-07-23T21:54:01+08:00https://flcube.com/pfizer-secures-fda-priority-review-for-talzenna-xtandi-combination-in-earlier-stage-prostate-cancer/2026-07-23T21:42:03+08:00https://flcube.com/ribo-life-science-reports-positive-phase-2a-results-for-vortosiran-in-chronic-coronary-artery-disease/2026-07-23T21:36:04+08:00https://flcube.com/johnson-johnson-secures-fda-de-novo-authorization-for-ottava-worlds-first-table-integrated-robotic-surgical-system/2026-07-23T21:33:01+08:00https://flcube.com/guangdong-launches-greater-bay-area-cross-border-medical-import-framework-for-hong-kong-and-macau-pharmaceuticals/2026-07-23T21:25:23+08:00https://flcube.com/china-announces-12th-national-drug-volume-based-procurement-with-enhanced-pricing-mechanism-and-expanded-participation/2026-07-23T21:22:48+08:00https://flcube.com/haisco-pharma-secures-nmpa-approval-for-hsk39297-first-oral-cfb-inhibitor-for-paroxysmal-nocturnal-hemoglobinuria-in-china/2026-07-23T21:13:46+08:00https://flcube.com/takeda-secures-worlds-first-nmpa-approval-for-orexatone-novel-oral-ox2r-agonist-for-type-1-narcolepsy/2026-07-23T21:09:47+08:00https://flcube.com/shanghai-pharmaceuticals-commits-42m-to-siic-bio-med-fund-targeting-fic-bic-assets-from-ind-to-phase-ii/2026-07-22T13:53:12+08:00https://flcube.com/tyk-medicines-and-qilu-pharmaceutical-forge-strategic-partnership-for-egfr-tki-ty-9591-with-2-4b-deal/2026-07-22T13:47:00+08:00https://flcube.com/youcare-pharmaceutical-receives-nmpa-approval-for-ykyy033-clinical-trials-across-multiple-thrombotic-indications/2026-07-22T13:40:36+08:00https://flcube.com/trinomab-biotechnology-debuts-on-shanghai-star-market-with-first-in-class-anti-tetanus-monoclonal-antibody/2026-07-22T13:33:00+08:00https://flcube.com/novo-nordisk-sues-eli-lilly-over-alleged-false-advertising-of-zepbound-and-mounjaro-in-glp-1-market/2026-07-22T13:28:24+08:00https://flcube.com/junshi-biosciences-receives-nmpa-acceptance-for-toripalimab-expanded-indication-in-resectable-stage-ii-iii-nsclc/2026-07-22T13:22:32+08:00https://flcube.com/gilead-and-merck-to-present-phase-3-islend-trial-data-for-once-weekly-oral-hiv-regimen-at-aids-2026-conference/2026-07-22T11:27:01+08:00https://flcube.com/alebund-pharmaceuticals-initiates-global-phase-iib-trial-of-ap306-first-in-class-oral-pan-phosphate-transporter-inhibitor-for-hyperphosphatemia/2026-07-22T11:21:00+08:00https://flcube.com/nanjing-delova-biotech-completes-83m-series-c-financing-to-advance-late-stage-pain-management-pipeline/2026-07-22T11:12:05+08:00https://flcube.com/grand-pharma-partners-with-siemens-healthineers-to-commercialize-acunav-lumos-4d-ice-catheter-in-chinas-structural-heart-market/2026-07-21T19:26:06+08:00https://flcube.com/gsk-submits-bexsero-label-update-to-ema-for-single-dose-booster-in-adolescents-and-adults-previously-vaccinated-in-childhood/2026-07-21T19:22:05+08:00https://flcube.com/beijing-wantais-rsv-vaccine-receives-nmpa-clinical-trial-acceptance-for-lower-respiratory-tract-disease-prevention/2026-07-21T19:18:28+08:00https://flcube.com/insilico-medicine-forms-quantum-ai-alliance-with-byterna-and-duneq-to-accelerate-next-generation-rna-and-peptide-therapeutics/2026-07-21T19:14:52+08:00https://flcube.com/jacobio-pharmaceuticals-jab-8263-bet-inhibitor-proposed-for-nmpas-rare-disease-caring-program-for-myelofibrosis-treatment/2026-07-21T19:09:54+08:00https://flcube.com/eisai-and-biogen-secure-fda-approval-for-leqembi-subcutaneous-autoinjector-for-early-alzheimers-disease-initiation/2026-07-21T19:06:35+08:00https://flcube.com/samsung-biologics-bids-1-8-billion-for-polypeptide-group-to-enter-high-growth-peptide-therapeutics-market/2026-07-21T18:59:14+08:00https://flcube.com/akeso-biopharma-launches-greater-bay-area-charitable-program-to-provide-free-ivonescimab-to-hong-kong-lung-cancer-patients/2026-07-21T18:52:55+08:00https://flcube.com/china-launches-12th-batch-of-national-drug-procurement-with-vonoprazan-and-vitamin-b6-drawing-record-competition/2026-07-21T18:47:24+08:00https://flcube.com/hisun-pharmaceutical-secures-exclusive-rights-to-tisa-818-novel-multi-target-immunomodulator-for-ards-and-pulmonary-fibrosis/2026-07-21T18:45:43+08:00https://flcube.com/fujian-province-launches-comprehensive-biomedical-innovation-support-framework-with-accelerated-listing-premium-pricing-and-enhanced-insurance-coverage-mechanisms/2026-07-20T14:41:43+08:00https://flcube.com/chinas-nmpa-suspends-medochemies-tramadol-hydrochloride-capsules-following-non-compliant-overseas-inspection-and-documentation-failure/2026-07-20T14:39:12+08:00https://flcube.com/cansino-biologics-secures-nmpa-acceptance-for-menhycia-age-expansion-to-adolescents-extending-chinas-first-quadrivalent-meningococcal-conjugate-vaccine-coverage-to-ages-3-months-17-years/2026-07-20T14:26:56+08:00https://flcube.com/lees-pharmaceutical-enters-exclusive-global-licensing-agreement-with-ashlins-ocular-for-interferon-alpha-2b-outside-greater-china/2026-07-20T14:23:28+08:00https://flcube.com/easton-pharmaceutical-secures-nmpa-approval-for-chinas-first-generic-remimazolam-besylate-challenging-humanwells-ruima-monopoly-in-procedural-sedation-and-general-anesthesia/2026-07-20T14:13:14+08:00https://flcube.com/mabwell-secures-nmpa-ind-approval-for-9mw5211-injection-in-vitiligo-expanding-multi-indication-autoimmune-pipeline-with-highly-selective-depleting-antibody/2026-07-20T14:10:18+08:00https://flcube.com/chinas-health-authorities-issue-comprehensive-medical-equipment-centralized-procurement-framework-with-tiered-implementation-and-high-value-equipment-database/2026-07-20T14:03:23+08:00https://flcube.com/bio-sincerity-secures-nmpa-approval-for-levetiracetam-extended-release-granules-pediatric-friendly-epilepsy-treatment-for-patients-with-swallowing-difficulties/2026-07-20T13:52:48+08:00https://flcube.com/allergan-aesthetics-secures-european-commission-approval-for-boey-trenibotulinumtoxine-first-rapid-onset-short-duration-botulinum-neurotoxin-serotype-e-for-glabellar-lines/2026-07-20T12:16:39+08:00https://flcube.com/gsk-reports-mixed-phase-iii-results-for-camlipixant-in-refractory-chronic-cough-calm-1-trial-meets-primary-endpoint-while-calm-2-falls-short/2026-07-20T12:09:47+08:00https://flcube.com/wepon-medical-secures-fda-clinical-approval-for-wp107-huperzine-a-oral-solution-in-healthy-volunteers-following-nmpa-clearance-for-myasthenia-gravis/2026-07-20T12:06:56+08:00https://flcube.com/jacobio-launches-phase-ib-iii-trial-of-pan-kras-inhibitor-jab-23e73-for-kras-mutated-pancreatic-cancer-in-partnership-with-astrazeneca/2026-07-20T11:17:24+08:00https://flcube.com/cspc-pharmaceutical-launches-phase-iii-trial-of-b7-h3-targeting-adc-sys-6043-for-platinum-resistant-ovarian-cancer/2026-07-17T22:42:46+08:00https://flcube.com/cspc-pharmaceutical-launches-phase-ii-trial-of-albumin-bound-sirolimus-for-rare-vascular-tumor-epithelioid-hemangioendothelioma/2026-07-17T22:29:25+08:00https://flcube.com/immvira-bioscience-files-for-hong-kong-ipo-to-advance-novel-oncolytic-immunotherapy-and-engineered-exosome-pipeline/2026-07-17T22:23:14+08:00https://flcube.com/abbott-reports-strong-q2-2026-results-with-12-2-revenue-growth-driven-by-diagnostics-surge-and-medical-device-innovation/2026-07-17T22:13:49+08:00https://flcube.com/hengruis-hrs9531-dual-gipr-glp-1r-agonist-advances-to-phase-iii-for-obesity-with-knee-osteoarthritis-expanding-metabolic-disease-portfolio/2026-07-17T21:43:38+08:00https://flcube.com/sichuan-biokins-yizekang-receives-nmpa-approval-as-worlds-first-egfrxher3-bispecific-adc-for-esophageal-squamous-cell-carcinoma/2026-07-17T21:39:39+08:00https://flcube.com/eli-lilly-to-acquire-ataibeckley-for-3-8-billion-accelerating-psychedelic-therapeutics-development-for-treatment-resistant-depression/2026-07-17T21:30:39+08:00https://flcube.com/novartis-fabhalta-receives-fda-approval-as-first-oral-complement-factor-b-inhibitor-to-slow-renal-decline-in-primary-iga-nephropathy/2026-07-17T21:21:02+08:00https://flcube.com/shionogis-fetroja-receives-fda-acceptance-for-pediatric-snda-expanding-use-to-gram-negative-infections-in-hospital-acquired-pneumonia-and-complicated-utis/2026-07-17T19:32:18+08:00https://flcube.com/mercks-lipfendra-receives-fda-approval-as-first-oral-pcsk9-inhibitor-for-ldl-cholesterol-reduction-in-hypercholesterolemia-patients/2026-07-17T19:26:47+08:00https://flcube.com/jasper-therapeutics-completes-acquisition-of-kira-pharmaceuticals-in-all-stock-transaction-secures-132m-private-placement-for-complement-therapies-pipeline/2026-07-17T19:02:19+08:00https://flcube.com/dp-technology-excalipoint-therapeutics-launch-ai-antibody-discovery-platform-through-strategic-partnership-focused-on-t-cell-engagers/2026-07-17T18:57:27+08:00https://flcube.com/innocare-pharmas-soficitinib-meets-primary-endpoint-in-phase-iii-atopic-dermatitis-trial-as-highly-selective-tyk2-inhibitor/2026-07-16T18:44:30+08:00https://flcube.com/amoytop-biotech-secures-nmpa-clinical-trial-approval-for-act201-novel-aso-therapy-for-chronic-hepatitis-b/2026-07-16T18:40:41+08:00https://flcube.com/boehringer-ingelheim-reports-16-2-h1-2026-sales-growth-driven-by-jardiance-and-new-oncology-launches/2026-07-16T18:37:06+08:00https://flcube.com/china-resources-pharmaceutical-to-acquire-23-5-stake-in-lier-chemical-to-advance-synthetic-biology-pipeline/2026-07-16T18:27:03+08:00https://flcube.com/harbour-biomed-and-kelun-biotech-secure-nmpa-ind-approval-for-hbm7575-skb575-long-acting-bispecific-antibody-for-asthma/2026-07-16T16:40:11+08:00https://flcube.com/hengrui-pharmaceuticals-secures-dual-nmpa-approvals-for-hrs-8797-atopic-dermatitis-drug-and-hrs-8829-stroke-therapy/2026-07-16T16:34:22+08:00https://flcube.com/ascletis-pharma-selects-asc30_48-fdc-as-first-in-class-oral-dual-gipr-glp-1r-agonist-for-obesity/2026-07-16T16:28:18+08:00https://flcube.com/fosun-pharma-secures-nmpa-approval-for-fxr0906-liver-targeted-sirna-therapy-for-hypertriglyceridemia/2026-07-16T16:25:28+08:00https://flcube.com/china-medical-system-secures-nmpa-approval-for-cms-d017-novel-complement-factor-b-inhibitor-for-amd/2026-07-16T16:21:35+08:00https://flcube.com/roche-secures-fda-priority-review-for-gazyva-in-primary-membranous-nephropathy-based-on-phase-iii-majesty-data/2026-07-16T16:18:17+08:00https://flcube.com/novo-nordisk-secures-eu-approval-for-wegovy-pill-first-oral-semaglutide-25mg-for-obesity-treatment/2026-07-16T16:13:26+08:00https://flcube.com/lepu-medical-secures-nmpa-clinical-trial-approval-for-mwn110-novel-actriia-b-antibody-for-weight-management/2026-07-16T16:02:16+08:00https://flcube.com/merck-kgaas-enpatoran-receives-fda-breakthrough-therapy-designation-for-cutaneous-lupus/2026-07-16T15:58:56+08:00https://flcube.com/braveheart-bio-files-ipo-prospectus-with-nasdaq-for-1-8b-cardiac-myosin-inhibitor-asset/2026-07-16T15:55:50+08:00https://flcube.com/wuxi-biologics-enters-cdrmo-partnership-with-canbridge-through-2028/2026-07-16T15:52:24+08:00https://flcube.com/chinas-cde-releases-draft-guideline-for-real-world-evidence-based-pediatric-indication-expansion-of-marketed-drugs/2026-07-16T15:49:24+08:00https://flcube.com/johnson-johnson-reports-q2-2026-results-with-6-6-sales-growth-raises-full-year-guidance/2026-07-16T15:47:43+08:00https://flcube.com/innovent-biologics-secures-1-1b-global-cd40l-antibody-deal-with-spero-therapeutics/2026-07-15T12:53:34+08:00https://flcube.com/hansoh-pharmaceutical-secures-2-3b-il-23-deal-and-strategic-stake-in-avere-nextcure-merger/2026-07-15T12:40:37+08:00https://flcube.com/everest-medicines-and-jd-healthcare-forge-strategic-digital-healthcare-alliance-to-accelerate-innovative-drug-access/2026-07-15T12:32:21+08:00https://flcube.com/innovent-biologics-secures-macau-approval-for-dual-immunotherapy-neoadjuvant-regimen-in-msi-h-dmmr-colon-cancer/2026-07-15T12:28:15+08:00https://flcube.com/kelun-biotechs-sacituzumab-tirumotecan-achieves-worlds-first-adc-immunotherapy-phase-iii-success-in-pd-l1-negative-nsclc/2026-07-15T12:23:06+08:00https://flcube.com/cspc-pharmaceutical-secures-dual-nmpa-breakthrough-therapy-designations-for-her2-positive-breast-cancer-combination/2026-07-15T12:18:49+08:00https://flcube.com/biogen-advances-diranersen-into-phase-3-development-following-positive-alzheimers-phase-2-data/2026-07-15T12:12:55+08:00https://flcube.com/sino-biopharmaceuticals-trd205-secures-nmpa-breakthrough-therapy-designation-for-chronic-post-surgical-neuropathic-pain/2026-07-15T12:08:00+08:00https://flcube.com/insilico-medicine-and-bora-pharmaceuticals-forge-2-5b-strategic-alliance-to-pioneer-ai-driven-drug-rd/2026-07-15T12:02:51+08:00https://flcube.com/lynk-pharmaceuticals-completes-phase-3-enrollment-for-zemprocitinib-in-ankylosing-spondylitis-trial/2026-07-15T11:56:55+08:00https://flcube.com/cr-pharmaceutical-commercial-and-innovent-biologics-forge-strategic-partnership-to-build-integrated-health-management-ecosystem/2026-07-14T15:16:39+08:00https://flcube.com/chinas-state-council-unveils-15th-five-year-national-health-plan-with-strong-support-for-innovative-therapeutics-and-ai-integration/2026-07-14T15:10:49+08:00https://flcube.com/haisco-pharmaceutical-secures-nmpa-ind-acceptance-for-hsk60002-tablets-in-inflammatory-diseases/2026-07-14T15:07:43+08:00https://flcube.com/chinas-nhsa-completes-preliminary-review-of-2026-medical-insurance-catalog-with-91-pass-rate-for-basic-medicines/2026-07-14T15:04:56+08:00https://flcube.com/bk-corporation-completes-patient-enrollment-in-phase-ii-diabetic-foot-ulcer-trial-for-pro-101-2-rhpdgf-bb-therapy/2026-07-14T15:02:19+08:00https://flcube.com/huadong-medicines-subsidiary-secures-nmpa-approval-for-first-in-class-trispecific-agonist-dr10624-in-heart-failure-treatment/2026-07-14T14:55:33+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-clinical-trial-approval-for-shr-3079-in-systemic-lupus-erythematosus-and-rheumatoid-arthritis/2026-07-14T14:51:22+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-breakthrough-therapy-designation-for-hrs-7058-in-kras-g12c-mutant-pancreatic-cancer/2026-07-14T14:45:00+08:00https://flcube.com/dizal-pharmaceutical-secures-1-5-billion-global-licensing-deal-with-astrazeneca-for-sunvozertinib-in-egfr-exon20ins-nsclc/2026-07-14T14:40:31+08:00https://flcube.com/gsk-terminates-2-2-billion-neurodegenerative-disease-partnership-with-alector-following-dual-clinical-failures/2026-07-14T14:36:25+08:00https://flcube.com/fosun-pharma-secures-nmpa-approval-for-phase-1-trial-of-hlx37-bispecific-antibody-in-combination-therapies-for-advanced-solid-tumors/2026-07-14T14:26:39+08:00https://flcube.com/zhaoke-ophthalmology-acquires-global-rights-to-nvk002-for-myopia-control-licenses-u-s-rights-to-nevakar/2026-07-14T14:19:06+08:00https://flcube.com/haisco-submits-nmpa-marketing-application-for-crisugabalins-new-indication-in-neuropathic-pain-treatment/2026-07-14T13:54:49+08:00https://flcube.com/shenyang-xingqi-pharmaceutical-secures-nmpa-approval-for-sq-23101-injection-novel-bispecific-antibody-therapy-for-thyroid-eye-disease/2026-07-14T13:44:45+08:00https://flcube.com/sisram-medical-restructures-daxibotulinumtoxina-partnership-with-fosun-wanbang-through-new-sublicense-and-promotion-services-agreements/2026-07-13T16:44:05+08:00https://flcube.com/teva-secures-global-rights-to-polpharma-biologics-ocrelizumab-biosimilar-expanding-multiple-sclerosis-portfolio/2026-07-13T16:39:41+08:00https://flcube.com/ema-chmp-recommends-revocation-of-tavneos-marketing-authorization-following-data-integrity-concerns-in-advocate-trial/2026-07-13T16:35:58+08:00https://flcube.com/chinas-national-health-commission-launches-comprehensive-continuous-medication-management-framework-to-enhance-patient-safety-and-healthcare-quality/2026-07-13T16:33:55+08:00https://flcube.com/drug-farm-closes-first-tranche-of-55-million-series-d-financing-to-advance-first-in-class-pipeline-across-multiple-therapeutic-areas/2026-07-13T16:31:43+08:00https://flcube.com/shionogi-nagasaki-university-and-mmv-secure-jpy-910-million-ghit-fund-support-for-novel-malaria-prevention-drug-development/2026-07-13T16:26:43+08:00https://flcube.com/triastek-secures-strategic-financing-to-advance-3d-printed-oral-peptide-pipeline-and-build-shanghai-international-rd-center/2026-07-13T16:23:23+08:00https://flcube.com/abbisko-therapeutics-secures-fda-ind-clearance-for-pan-kras-inhibitor-absk211-targeting-broad-spectrum-of-kras-alterations-in-solid-tumors/2026-07-13T16:19:27+08:00https://flcube.com/longbio-pharma-secures-fda-ind-approval-for-novel-anti-ige-antibody-lp-003-in-peanut-allergy-expanding-global-allergic-disease-pipeline/2026-07-13T16:16:25+08:00https://flcube.com/pfizer-and-astellas-secure-fda-approval-for-padcev-keytruda-combination-as-first-platinum-free-neoadjuvant-adjuvant-therapy-for-muscle-invasive-bladder-cancer/2026-07-13T16:12:36+08:00https://flcube.com/takeda-and-indonesian-government-launch-30-million-plasma-ecosystem-initiative-to-expand-access-to-lifesaving-therapies/2026-07-13T16:04:49+08:00https://flcube.com/sanofi-secures-fda-approval-for-sarclisa-escena-subcutaneous-formulation-first-dual-administration-anti-cancer-therapy-for-multiple-myeloma/2026-07-13T16:01:54+08:00https://flcube.com/hansoh-pharmas-b7-h3-adc-risvutatug-rezetecan-meets-primary-endpoint-in-phase-iii-sclc-trial-showing-significant-survival-benefit-over-topotecan/2026-07-13T15:55:30+08:00https://flcube.com/roche-secures-ce-mark-for-elecsys-igra-tb-test-delivering-automated-solution-for-tuberculosis-infection-detection/2026-07-13T15:52:45+08:00https://flcube.com/insilico-medicine-announces-strategic-cns-drug-discovery-collaboration-with-china-medical-system-eligible-for-rmb-1-2-billion-in-milestone-payments/2026-07-13T15:47:58+08:00https://flcube.com/transthera-secures-nmpa-approval-for-phase-2-trial-of-tt-00973-in-combination-with-firmonertinib-for-egfr-mutant-nsclc/2026-07-13T15:43:53+08:00https://flcube.com/pegbio-partners-with-rani-therapeutics-on-oral-biologic-delivery-platform-targeting-obesity-and-metabolic-disease-candidates/2026-07-10T15:49:06+08:00https://flcube.com/salubris-pharmaceuticals-secures-nmpa-ind-clearance-for-sal0167-proprietary-cyclic-peptide-targeting-hyperlipidemia/2026-07-10T15:44:37+08:00https://flcube.com/simcere-pharmaceuticals-forges-global-drug-discovery-alliance-with-schrodinger-combining-computational-platform-with-therapeutic-expertise/2026-07-10T14:11:14+08:00https://flcube.com/conba-pharmaceutical-secures-greater-china-rights-to-cebranopadol-first-in-class-dual-target-analgesic-from-adneuris-therapeutics/2026-07-10T14:05:46+08:00https://flcube.com/jacobio-pharmas-incubator-secures-nmpa-ind-clearance-for-jar-2203-injection-novel-therapy-targeting-hyperlipoproteinemiaa/2026-07-10T13:58:36+08:00https://flcube.com/haixi-pharma-launches-phase-iii-trial-of-c019199-first-in-class-multi-targeted-immunomodulator-for-refractory-osteosarcoma/2026-07-10T13:55:00+08:00https://flcube.com/astellas-pharma-submits-bla-to-china-nmpa-for-padcev-keytruda-combination-in-muscle-invasive-bladder-cancer-showing-60-reduction-in-recurrence-risk-for-cisplatin-ineligible-patients/2026-07-09T21:27:38+08:00https://flcube.com/jiangsu-aidea-pharmaceutical-receives-nmpa-clinical-trial-approval-for-adc119-chinas-first-domestic-complete-hiv-regimen-combining-novel-nnrti-with-established-nrtis/2026-07-09T21:22:34+08:00https://flcube.com/shenyang-xingqi-pharmaceutical-reports-positive-phase-2-results-for-sq-22031-eye-drops-in-neurotrophic-keratitis-advances-to-pivotal-phase-3-trial/2026-07-09T21:13:25+08:00https://flcube.com/sino-biopharmaceutical-secures-exclusive-global-rights-to-yikexin-trace-treatment-series-through-cttq-partnership-with-beijing-cist/2026-07-09T21:10:11+08:00https://flcube.com/changchun-high-new-technologys-subsidiary-gensci-secures-nmpa-ind-acceptance-for-gensci148-first-in-class-vegf-multi-blocker-for-retinal-vascular-diseases/2026-07-09T21:03:44+08:00https://flcube.com/johnson-johnson-secures-fda-approval-for-dual-energy-thermocool-smarttouch-sf-platform-first-single-catheter-solution-combining-radiofrequency-and-pulsed-field-ablation/2026-07-09T20:59:27+08:00https://flcube.com/abbvie-secures-european-commission-approval-for-tepkinly-combination-therapy-in-relapsed-refractory-follicular-lymphoma-with-79-reduction-in-disease-progression-risk/2026-07-09T20:54:53+08:00https://flcube.com/xenovector-and-jilin-university-launch-strategic-partnership-to-advance-gene-edited-pig-organ-transplantation-from-breakthrough-to-affordable-healthcare/2026-07-09T20:49:39+08:00https://flcube.com/zhejiang-hisun-pharmaceutical-and-tigermed-forge-strategic-alliance-to-create-end-to-end-innovative-drug-development-pipeline/2026-07-09T20:46:42+08:00https://flcube.com/chinas-national-health-commission-unveils-2026-essential-medicines-list-adding-116-new-drugs-with-full-insurance-coverage/2026-07-09T20:41:52+08:00https://flcube.com/jenscares-lux-valve-plus-secures-ce-mark-as-worlds-second-transcatheter-tricuspid-valve-replacement/2026-07-08T15:08:00+08:00https://flcube.com/sino-biopharmaceutical-secures-2-1b-astrazeneca-deal-for-inhaled-dual-pde3-4-inhibitor-tqc3721/2026-07-08T15:05:18+08:00https://flcube.com/mabwell-bioscience-secures-nmpa-approval-for-9mw5211-antibody-in-type-1-diabetes-expanding-autoimmune-pipeline/2026-07-08T15:00:01+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-clinical-approval-for-first-in-class-shr-4685-in-advanced-solid-tumors/2026-07-08T14:45:48+08:00https://flcube.com/astrazeneca-and-ionis-launch-wainua-eplontersen-in-china-for-hereditary-attr-amyloidosis-with-polyneuropathy/2026-07-08T14:40:54+08:00https://flcube.com/otr-therapeutics-partners-with-lg-chem-to-accelerate-early-stage-oncology-programs-with-china-global-development-model/2026-07-08T14:33:45+08:00https://flcube.com/qihan-biotech-secures-nmpa-approval-for-dual-target-allogeneic-car-t-therapy-qt-019c-in-refractory-lupus/2026-07-08T14:29:10+08:00https://flcube.com/insilico-medicine-launches-phase-3-trial-for-ai-discovered-rentosertib-in-idiopathic-pulmonary-fibrosis/2026-07-08T14:20:09+08:00https://flcube.com/transcenta-returns-select-lilly-assets-in-portfolio-restructuring-retains-blosozumab-rights/2026-07-08T14:15:15+08:00https://flcube.com/hanx-biopharmaceuticals-partners-with-hust-cityu-macau-institute-to-establish-ai-driven-drug-discovery-joint-laboratory/2026-07-08T14:11:11+08:00https://flcube.com/nanjing-pharmaceutical-acquires-majority-stakes-in-datsing-bio-tech-and-kejian-technology-for-rmb-750-million/2026-07-08T14:08:10+08:00https://flcube.com/ltz-therapeutics-secures-fda-ind-approval-for-ltz-232-first-in-class-myeloid-engager-targeting-epcam-high-solid-tumors/2026-07-08T14:04:15+08:00https://flcube.com/peking-university-third-hospital-introduces-worlds-first-pth-replacement-therapy-palopegteriparatide-through-beijing-rare-disease-pilot-zone/2026-07-08T14:01:12+08:00https://flcube.com/mindrank-secures-52-million-series-b-to-advance-ai-drug-discovery-platform-and-phase-iii-glp-1ra-candidate-mdr-001/2026-07-08T13:57:28+08:00https://flcube.com/shanghai-stexo-biotechnology-secures-nmpa-clinical-approval-for-stx11101-extracellular-vesicle-therapy-in-acute-liver-failure/2026-07-08T13:54:38+08:00https://flcube.com/biocytogen-and-whitehawk-forge-global-bsadc-partnership-to-accelerate-next-generation-cancer-therapies/2026-07-08T13:46:50+08:00https://flcube.com/sino-biopharmaceutical-expands-gsk-partnership-to-commercialize-trelegy-and-anoro-ellipta-in-china/2026-07-08T13:40:07+08:00https://flcube.com/china-adds-methoxyethyl-etomidate-loretomidate-and-solriamfetol-to-controlled-psychotropic-substances-list/2026-07-08T13:35:46+08:00https://flcube.com/china-nmpa-launches-pioneer-program-to-accelerate-nams-adoption-in-drug-development/2026-07-07T21:08:32+08:00https://flcube.com/immunocon-mabgalaxy-forge-full-chain-ai-antibody-rd-network-for-bispecific-drug-development/2026-07-07T21:05:51+08:00https://flcube.com/vertex-pharmaceuticals-to-acquire-crinetics-for-10b-adding-palsonify-and-atumelnant-to-endocrine-portfolio/2026-07-07T21:02:12+08:00https://flcube.com/hainan-shuangcheng-pharmaceutical-secures-10m-us-licensing-deal-for-sc-c141-rd-project/2026-07-07T20:56:00+08:00https://flcube.com/cstone-pharmaceuticals-partners-with-arrotex-for-sugemalimab-commercialization-across-australia-and-new-zealand/2026-07-07T20:50:39+08:00https://flcube.com/serapha-bio-secures-2b-base-editing-therapy-deal-for-aatd-with-yoltech-and-completes-230m-merger/2026-07-07T20:47:34+08:00https://flcube.com/alphamab-oncology-nanolek-partner-on-armocibart-hemophilia-prophylaxis-for-russian-and-eaeu-markets/2026-07-07T19:05:49+08:00https://flcube.com/truelab-biopharmaceutical-bionyra-pharma-forge-985m-tl1a-antibody-deal-with-dual-ibd-candidates/2026-07-07T18:57:18+08:00https://flcube.com/shanghai-zj-bio-tech-ebola-detection-kit-receives-who-emergency-use-listing-for-bundibugyo-strain/2026-07-07T18:49:42+08:00https://flcube.com/campfield-therapeutics-launches-with-180m-series-a-to-advance-prifemilast-pde4-inhibitor-for-ibd/2026-07-07T14:28:36+08:00https://flcube.com/bristar-immunotech-secures-28m-series-c-to-advance-star-t-platform-and-in-vivo-technology/2026-07-07T14:21:22+08:00https://flcube.com/formosa-pharmaceuticals-samil-pharma-expand-partnership-with-app13007-vietnam-licensing-deal/2026-07-07T14:17:19+08:00https://flcube.com/carephar-pharmaceutical-silk-road-medical-forge-central-asia-deal-for-keverprazan-p-cab-innovation/2026-07-07T14:13:16+08:00https://flcube.com/guangdong-launches-spring-rain-action-to-accelerate-medical-device-innovation-transformation-with-900-clinical-achievements-target/2026-07-07T14:01:28+08:00https://flcube.com/astex-pharmaceuticals-genentech-forge-515m-breast-cancer-small-molecule-drug-collaboration/2026-07-07T13:55:46+08:00https://flcube.com/novartis-to-acquire-myricx-bio-for-1-1-billion-to-strengthen-adc-pipeline-with-novel-n-myristoyltransferase-inhibitor-payload-technology/2026-07-06T14:55:00+08:00https://flcube.com/pyrotech-therapeutics-secures-hundreds-of-millions-in-pre-b-financing-to-advance-pyroptosis-targeted-immunomodulator-platforms-for-cancer-and-inflammatory-diseases/2026-07-06T14:49:40+08:00https://flcube.com/iregene-therapeutics-secures-rmb-260-million-series-c-financing-to-advance-ipsc-derived-parkinsons-disease-therapy-with-fda-fast-track-and-rmat-designations/2026-07-06T14:44:26+08:00https://flcube.com/sino-biopharmaceutical-submits-china-marketing-application-for-worlds-first-intra-incisional-long-acting-ropivacaine-analgesic/2026-07-06T11:42:30+08:00https://flcube.com/shaanxi-micot-enrolls-first-patient-in-phase-ib-ii-clinical-trial-of-mt1002-for-acute-ischemic-stroke-treatment/2026-07-06T11:32:33+08:00https://flcube.com/chinas-nmpa-unveils-comprehensive-regulatory-framework-for-cell-and-gene-therapy-products-with-streamlined-review-pathways/2026-07-06T11:29:34+08:00https://flcube.com/changchun-high-new-tech-secures-nmpa-clinical-approval-for-gensci164-pth1r-agonist-in-hypoparathyroidism-treatment/2026-07-06T11:27:17+08:00https://flcube.com/hua-medicine-partners-with-gemvcare-on-real-world-clinical-study-for-dorzagliatin-in-precision-diabetes-management/2026-07-06T11:23:13+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-priority-review-for-trastuzumab-rezetecan-in-her2-low-breast-cancer-expanding-third-indication-in-china-2/2026-07-03T15:10:51+08:00https://flcube.com/edding-genors-trispecific-antibody-gb268-secures-nmpa-ind-approval-for-phase-ib-ii-breast-cancer-trial-targeting-tnbc-and-hr-her2-subtypes/2026-07-03T15:07:39+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-priority-review-for-trastuzumab-rezetecan-in-her2-low-breast-cancer-expanding-third-indication-in-china/2026-07-03T15:03:05+08:00https://flcube.com/shandong-boan-biotechnology-secures-nmpa-approval-for-phase-ii-trial-of-ba1106-ba1104-combination-in-nsclc-chinas-first-non-il-2-blocking-anti-cd25-antibody/2026-07-03T14:51:18+08:00https://flcube.com/cspc-pharmaceuticals-megalith-subsidiary-enters-1-77-billion-sirna-collaboration-with-astrazeneca-for-novel-rnai-therapeutics/2026-07-03T14:46:49+08:00https://flcube.com/bio-sincerity-secures-nmpa-clinical-trial-approval-for-bios0629-109-novel-xpo1-inhibitor-for-advanced-malignant-tumors/2026-07-03T13:24:10+08:00https://flcube.com/novartis-secures-eu-approval-for-itvisma-first-gene-replacement-therapy-for-broad-sma-population-including-patients-two-years-and-older/2026-07-03T13:04:05+08:00https://flcube.com/ocumension-therapeutics-secures-nmpa-approval-for-ot-502-chinas-first-single-dose-sustained-release-intraocular-steroid-for-postoperative-inflammation/2026-07-03T12:57:57+08:00https://flcube.com/hotgen-biotech-launches-ai-subsidiary-to-transform-small-nucleic-acid-drug-discovery/2026-07-03T12:43:10+08:00https://flcube.com/hangzhou-adamercks-aom0498-receives-nmpa-approval-as-chinas-first-homegrown-neuromuscular-blockade-reversal-agent-completing-decade-long-national-innovation-program/2026-07-02T15:30:26+08:00https://flcube.com/junshi-biosciences-licenses-anti-il-17a-antibody-roconkibart-to-fosun-wanbang-for-greater-china-1-34b-deal-secures-commercialization-of-phase-iii-ready-psoriasis-therapy/2026-07-02T15:25:58+08:00https://flcube.com/jingxin-pharmaceutical-secures-nmpa-approval-for-chinas-first-generic-cariprazine-in-schizophrenia-capturing-market-opportunity-as-reference-product-remains-unlaunched/2026-07-02T15:19:21+08:00https://flcube.com/transthera-completes-patient-enrollment-in-global-phase-iii-trial-of-tinengotinib-for-advanced-cholangiocarcinoma-multi-kinase-inhibitor-backed-by-multiple-regulatory-designations/2026-07-02T15:15:52+08:00https://flcube.com/transthera-advances-phase-ii-trial-of-selective-btk-inhibitor-tt-01488-with-anti-cd20-antibodies-for-mantle-cell-lymphoma-novel-non-covalent-approach-shows-enhanced-safety-profile/2026-07-02T15:10:18+08:00https://flcube.com/insilico-medicine-and-takeda-launch-600m-strategic-ai-drug-discovery-collaboration-pharma-ai-platform-to-drive-candidate-identification-for-high-potential-therapeutic-targets/2026-07-02T15:06:26+08:00https://flcube.com/nona-biosciences-and-lonza-forge-strategic-alliance-to-develop-best-in-class-blood-brain-barrier-penetration-technology-for-cns-therapeutics/2026-07-02T15:01:46+08:00https://flcube.com/juventas-cell-therapys-car-t-therapy-yuanruida-receives-hsa-filing-acceptance-for-r-r-b-all-expanding-global-regulatory-footprint-following-nmpa-approval/2026-07-02T14:50:33+08:00https://flcube.com/ipsen-to-acquire-memo-therapeutics-for-e200m-plus-milestones-gaining-phase-ii-bk-virus-antibody-potravitug-for-transplant-nephropathy/2026-07-02T14:45:51+08:00https://flcube.com/beijing-sinotau-secures-nmpa-approval-for-xtr021-radiodrug-clinical-trial-in-mcrpc-next-generation-psma-targeted-therapy-shows-enhanced-efficacy-profile/2026-07-02T14:40:32+08:00https://flcube.com/ribo-life-science-achieves-first-milestone-in-sirna-collaboration-with-madrigal-for-mash-therapeutics/2026-07-02T14:37:43+08:00https://flcube.com/abbisko-therapeutics-and-astrazeneca-launch-strategic-collaboration-on-novel-targeted-immuno-combination-therapy-for-egfr-mutated-nsclc/2026-07-02T14:34:52+08:00https://flcube.com/bio-heart-secures-nmpa-approval-for-bioheart-biodegradable-drug-eluting-stent-first-fully-absorbable-coronary-stent-in-china/2026-07-02T14:29:50+08:00https://flcube.com/hybio-pharmas-generic-tirzepatide-anda-accepted-by-fda-first-to-file-challenger-targets-20b-dual-glp-1-gip-agonist-franchise-with-paragraph-iv-certification/2026-07-01T14:12:55+08:00https://flcube.com/roche-receives-fda-priority-review-for-enspryng-in-thyroid-eye-disease-il-6-inhibitor-leverages-novel-recycling-technology-for-second-indication/2026-07-01T14:01:11+08:00https://flcube.com/huiyu-pharma-receives-nmpa-clinical-trial-approval-for-hy-1016-extended-release-dienogest-injection-novel-formulation-aims-to-transform-endometriosis-treatment-adherence/2026-07-01T13:56:00+08:00https://flcube.com/raysightmed-secures-nearly-rmb-100-million-in-strategic-financing-led-by-state-owned-capital-accelerates-cardiovascular-diagnostics-scale-up-and-ai-surgical-robotics-development/2026-07-01T12:08:39+08:00https://flcube.com/cspc-innovation-launches-phase-iii-trial-of-sys6010-adc-pd-1-combo-in-resected-nsclc-novel-egfr-targeted-antibody-drug-conjugate-enters-adjuvant-setting/2026-07-01T12:03:46+08:00https://flcube.com/sanofi-reports-positive-phase-3-baby-comet-results-for-nexviazyme-in-infantile-onset-pompe-disease-ert-shows-100-survival-and-ventilation-free-outcomes-at-52-weeks/2026-07-01T12:00:17+08:00https://flcube.com/beone-medicines-reports-43-reduction-in-disease-progression-with-brukinsa-rituximab-combo-in-phase-iii-mcl-study-chemotherapy-free-regimen-shows-significant-pfs-benefit/2026-07-01T11:55:34+08:00https://flcube.com/ribo-life-science-acquires-additional-25-93-stake-in-azemidite-for-rmb-70-million-strengthens-sirna-therapeutics-supply-chain/2026-07-01T11:49:57+08:00https://flcube.com/metis-techbio-signs-record-1-62b-global-licensing-deal-for-ai-designed-tri-specific-tce-mts-128-largest-preclinical-tce-out-licensing-by-chinese-pharma-company/2026-06-30T15:18:49+08:00https://flcube.com/eli-lilly-partners-with-innovent-biologics-on-verzenio-cdk4-6-inhibitor-chinese-biotech-secures-exclusive-commercialization-rights-in-mainland-china/2026-06-30T15:11:38+08:00https://flcube.com/qyuns-therapeutics-to-acquire-remaining-34-stake-in-cmc-subsidiary-cellularforce-for-rmb-86m-full-ownership-secures-nda-pathway-for-il-17a-and-il-4r%ce%b1-antibody-pipeline/2026-06-30T14:55:31+08:00https://flcube.com/shanghai-bao-pharmaceuticals-secures-nmpa-ind-approval-for-bj044-recombinant-ulinastatin-first-synthetic-biology-derived-therapy-for-critical-care-indications/2026-06-30T12:08:02+08:00https://flcube.com/anhui-wanbang-pharmaceutical-to-acquire-75-52-stake-in-cro-ctsmed-for-rmb-302m-expands-clinical-research-capabilities-through-strategic-vertical-integration/2026-06-30T12:05:08+08:00https://flcube.com/abbvie-and-genmabs-epcoritamab-lenalidomide-combination-achieves-primary-endpoint-in-phase-3-dlbcl-trial-60-reduction-in-progression-death-risk-vs-standard-r-gemox/2026-06-30T12:01:01+08:00https://flcube.com/roche-launches-axelios-1-next-generation-sequencing-platform-powered-by-proprietary-sbx-technology-single-molecule-system-promises-same-day-whole-genome-results/2026-06-30T11:58:00+08:00https://flcube.com/merck-partners-with-adap-crisis-task-force-to-expand-access-to-idvynso-hiv-treatment-two-drug-regimen-targets-virologically-suppressed-patients/2026-06-30T11:53:03+08:00https://flcube.com/ipsen-to-acquire-kartos-therapeutics-for-450m-upfront-adding-investigational-mdm2-inhibitor-navtemadlin-to-myelofibrosis-pipeline/2026-06-30T11:47:09+08:00https://flcube.com/biocytogen-prevails-in-shanghai-ip-court-as-harbour-biomed-patent-infringement-claims-dismissed-rennano-platform-cleared-of-antibody-technology-violations/2026-06-30T11:35:59+08:00https://flcube.com/innovative-medical-management-subsidiary-cereblink-secures-registration-for-am5-upper-limb-rehabilitation-exoskeleton-emg-driven-system-targets-cns-injury-recovery/2026-06-30T11:31:58+08:00https://flcube.com/hua-medicine-completes-greater-china-rollout-as-dorzagliatin-gains-macau-approval-first-in-class-glucokinase-activator-now-available-across-all-chinese-territories/2026-06-30T11:21:45+08:00https://flcube.com/abbvies-skyrizi-wins-fda-approval-for-pediatric-psoriasis-expanding-il-23-blocker-to-children-six-and-older/2026-06-29T21:59:56+08:00https://flcube.com/akeso-biopharma-ships-first-batch-of-gumokimab-for-psoriasis-following-nmpa-approval/2026-06-29T21:54:40+08:00https://flcube.com/eli-lillys-jaypirca-wins-chmp-recommendation-for-all-line-cll-treatment-regardless-of-prior-btk-inhibitor-use/2026-06-29T21:23:37+08:00https://flcube.com/fosun-pharmaceutical-approves-hong-kong-ipo-spin-off-of-vaccine-subsidiary-fosun-adgenvax/2026-06-29T20:58:54+08:00https://flcube.com/jjs-tecvayli-daratumumab-combo-receives-chmp-recommendation-for-earlier-multiple-myeloma-treatment-line/2026-06-29T20:51:30+08:00https://flcube.com/chinas-cde-unveils-108th-batch-of-reference-preparations-for-generic-drug-evaluation-adds-28-new-drugs/2026-06-29T15:05:32+08:00https://flcube.com/nhsa-advances-record-674-drugs-in-2026-insurance-catalog-review-with-92-preliminary-pass-rate/2026-06-29T15:03:22+08:00https://flcube.com/mabwell-bioscience-secures-nmpa-approval-for-9mw5211-clinical-trial-in-multiple-sclerosis-expanding-autoimmune-pipeline/2026-06-25T23:58:54+08:00https://flcube.com/abu-dhabi-health-department-partners-with-sanofi-to-establish-vaccine-innovation-center-in-helm-cluster/2026-06-25T23:21:03+08:00https://flcube.com/takeda-secures-nmpa-approval-for-adzynma-chinas-first-recombinant-adamts13-therapy-for-congenital-ttp/2026-06-25T23:12:10+08:00https://flcube.com/gileads-trodelvy-sacituzumab-govitecan-secures-european-commission-approval-for-first-line-metastatic-tnbc-expanding-adc-access-to-treatment-naive-patients/2026-06-25T00:08:10+08:00https://flcube.com/henlius-and-organon-canada-launch-denosumab-biosimilars-bildyos-and-tuzemty-expanding-access-to-bone-targeted-therapies-across-all-canadian-indications/2026-06-25T00:05:00+08:00https://flcube.com/abbvies-skyrizi-risankizumab-secures-european-commission-approval-for-pediatric-plaque-psoriasis-first-il-23-inhibitor-authorized-for-children-as-young-as-six/2026-06-25T00:01:59+08:00https://flcube.com/yhlo-biotech-and-jingyi-bio-forge-strategic-alliance-to-advance-neuroimmunology-diagnostics-expanding-autoimmune-testing-into-neurological-disorders/2026-06-24T23:57:57+08:00https://flcube.com/sanofis-wayrilz-rilzabrutinib-secures-japanese-approval-for-immune-thrombocytopenia-expanding-global-footprint-across-six-major-markets/2026-06-24T23:51:27+08:00https://flcube.com/mabwell-secures-nmpa-clinical-trial-approval-for-6mw5311-bispecific-antibody-dual-us-china-authorization-for-hematological-malignancies/2026-06-24T23:45:52+08:00https://flcube.com/abb-bio-tech-secures-nmpa-clinical-trial-approval-for-mrna-mpox-vaccine-first-dual-approved-candidate-globally/2026-06-24T23:42:34+08:00https://flcube.com/china-medical-systems-silvemimab-becomes-worlds-first-dual-epitope-fully-human-rabies-antibody-approved-in-china/2026-06-24T00:35:14+08:00https://flcube.com/fusen-pharmaceutical-secures-rmb-300m-strategic-investment-for-henan-subsidiary-debt-restructuring-and-working-capital/2026-06-24T00:32:04+08:00https://flcube.com/biokin-secures-worlds-first-egfrxher3-bispecific-adc-approval-with-loncomystatug-deruxtecan-for-nasopharyngeal-carcinoma/2026-06-24T00:27:30+08:00https://flcube.com/china-launches-12th-national-drug-volume-based-procurement-batch-with-65-products-patent-disputes-highlighted/2026-06-24T00:24:53+08:00https://flcube.com/pierre-fabre-secures-european-commission-approval-for-braftovi-combination-in-braf-mutant-colorectal-cancer/2026-06-24T00:23:06+08:00https://flcube.com/hengruis-rezvilutamide-receives-ema-acceptance-for-metastatic-prostate-cancer-treatment/2026-06-24T00:19:46+08:00https://flcube.com/abbvie-to-acquire-apogee-therapeutics-for-10-9b-to-expand-inflammatory-disease-pipeline/2026-06-24T00:15:13+08:00https://flcube.com/bioarctic-partners-with-eli-lilly-on-novel-neurodegenerative-disease-therapy-using-braintransporter-platform/2026-06-23T23:57:14+08:00https://flcube.com/carsgen-therapeutics-secures-worlds-first-solid-tumor-car-t-approval-with-kylimei-for-gastric-cancer/2026-06-23T23:51:09+08:00https://flcube.com/haisco-pharmaceutical-secures-1-46b-global-licensing-deal-with-nuvectis-for-braf-and-cfb-inhibitor-programs/2026-06-23T23:48:28+08:00https://flcube.com/macrogenics-secures-24-5m-milestone-from-sanofi-following-fda-approval-expansion-for-tzield-in-type-1-diabetes/2026-06-23T23:45:15+08:00https://flcube.com/pfizer-reports-mixed-phase-3-results-for-sigvotatug-vedotin-in-non-small-cell-lung-cancer/2026-06-23T23:42:20+08:00https://flcube.com/anhui-province-launches-national-alliance-for-monoclonal-antibody-biologics-volume-based-procurement/2026-06-23T23:38:45+08:00https://flcube.com/antengene-corporation-secures-980m-global-licensing-deal-with-k2-therapeutics-for-cdh6xcd3-bispecific-t-cell-engager/2026-06-22T22:12:32+08:00https://flcube.com/cspc-innovation-pharmaceutical-files-hong-kong-ipo-prospectus-following-strategic-evolution-from-caffeine-producer-to-biopharmaceutical-player/2026-06-22T22:06:45+08:00https://flcube.com/zhiyi-biotechnology-files-hong-kong-ipo-prospectus-as-chinas-leading-live-biotherapeutic-products-developer/2026-06-22T22:00:11+08:00https://flcube.com/gan-lee-pharmaceuticals-secures-uae-approval-for-insulin-glargine-prefilled-pen-expanding-global-diabetes-portfolio/2026-06-22T21:54:25+08:00https://flcube.com/mabwell-bioscience-presents-promising-phase-i-ii-data-for-nectin-4-adc-bulumtatug-fuvedotin-in-cervical-cancer-at-esmo-gc/2026-06-22T21:50:54+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-pivotal-phase-iii-trial-for-ibi3003-trispecific-antibody-in-relapsed-refractory-multiple-myeloma/2026-06-22T21:46:33+08:00https://flcube.com/curegene-pharmaceutical-initiates-pivotal-us-clinical-trial-for-evategrel-worlds-first-dual-formulation-p2y12-inhibitor-addressing-clopidogrel-resistance/2026-06-22T21:43:23+08:00https://flcube.com/microport-medbots-toumai-remote-surgical-robot-achieves-worlds-first-ce-certification-for-multi-specialty-robotic-surgery/2026-06-22T21:40:50+08:00https://flcube.com/jenscares-ken-valve-tavr-system-gains-hong-kong-approval-for-aortic-regurgitation-following-mainland-china-launch/2026-06-22T20:40:42+08:00https://flcube.com/iaso-biotherapeutics-fucaso-becomes-first-bcma-car-t-therapy-approved-in-singapore-for-relapsed-refractory-multiple-myeloma/2026-06-22T20:37:43+08:00https://flcube.com/sanofis-sarclisa-subcutaneous-formulation-approved-in-japan-for-multiple-myeloma-across-treatment-settings/2026-06-22T20:23:14+08:00https://flcube.com/dawnrays-pharmaceutical-launches-rmb-200-million-biopharma-venture-fund-with-shanghai-jianxin-partners/2026-06-22T20:16:34+08:00https://flcube.com/roches-lunsumio-polatuzumab-combination-accepted-for-fda-review-in-relapsed-refractory-large-b-cell-lymphoma/2026-06-22T20:12:21+08:00https://flcube.com/sunshine-lake-pharma-advances-novel-ly6g6d-4-1bb-bispecific-antibody-hec-921-toward-phase-i-clinical-trials-in-china/2026-06-22T20:07:04+08:00https://flcube.com/mercks-capvaxive-pneumococcal-vaccine-expands-to-pediatric-population-with-fda-approval-for-ages-2-17/2026-06-22T19:49:38+08:00https://flcube.com/cspc-pharmaceuticals-efmedaglutide-alfa-glp-1-therapy-accepted-for-nmpa-review-in-type-2-diabetes-indication/2026-06-22T19:44:16+08:00https://flcube.com/cspc-pharmaceuticals-cosentyx-biosimilar-accepted-for-nmpa-review-in-chinas-competitive-il-17a-market/2026-06-22T18:08:46+08:00https://flcube.com/cspc-pharmaceutical-secures-fda-clearance-for-syhx2008-octreotide-biosimilar-clinical-trials-in-us-market/2026-06-22T18:06:26+08:00https://flcube.com/samsung-biologics-and-organon-expand-biosimilars-partnership-with-canadian-rights-for-pyzchiva-ustekinumab/2026-06-22T14:33:38+08:00https://flcube.com/johnson-johnson-secures-second-nmpa-approval-for-akeega-in-brca2-mutated-metastatic-prostate-cancer-following-amplitude-trial-success/2026-06-22T14:22:07+08:00https://flcube.com/insilico-medicine-and-sk-biopharmaceuticals-launch-2-5b-ai-drug-discovery-collaboration-targeting-neuroimmune-diseases/2026-06-22T14:07:29+08:00https://flcube.com/ucb-completes-2-2b-acquisition-of-candid-therapeutics-to-advance-bcma-t-cell-engager-for-autoimmune-diseases/2026-06-18T23:18:03+08:00https://flcube.com/eli-lilly-acquires-4e-therapeutics-to-advance-next-generation-chronic-pain-pipeline/2026-06-18T23:10:09+08:00https://flcube.com/xunfei-healthcare-partners-with-sinar-mas-group-to-deploy-ai-medical-solutions-across-indonesia/2026-06-18T23:05:45+08:00https://flcube.com/hotgen-biotech-secures-nmpa-approval-for-sgt003-bispecific-antibody-targeting-tumor-microenvironment/2026-06-18T23:01:06+08:00https://flcube.com/gsk-and-spero-therapeutics-secure-fda-approval-for-utebzi-first-oral-carbapenem-antibiotic-for-complicated-utis/2026-06-18T22:57:50+08:00https://flcube.com/alebund-pharmaceuticals-raises-163m-in-hong-kong-ipo-to-advance-kidney-disease-pipeline/2026-06-18T22:51:38+08:00https://flcube.com/shanghai-henlius-biotech-secures-nmpa-approval-for-phase-i-trial-of-hlx3902-trispecific-antibody-in-advanced-solid-tumors/2026-06-18T22:45:16+08:00https://flcube.com/biogen-to-acquire-immunology-specialist-raythera-in-1-billion-deal-targeting-anti-inflammatory-pipeline/2026-06-18T22:33:03+08:00https://flcube.com/hopstem-biotechnology-secures-fda-clearance-for-hnpc01-neural-progenitor-cell-therapy-in-hemorrhagic-stroke-motor-dysfunction/2026-06-18T14:06:18+08:00https://flcube.com/wuxi-xdc-partners-with-biodlink-international-for-monoclonal-antibody-intermediate-manufacturing-in-rmb-190-million-crdmo-agreement/2026-06-18T13:58:01+08:00https://flcube.com/bayer-ag-completes-2-45-billion-acquisition-of-perfuse-therapeutics-for-per-001-glaucoma-implant/2026-06-18T13:51:05+08:00https://flcube.com/walvax-biotechnologys-13-valent-pneumococcal-vaccine-weuphoria-meets-all-endpoints-in-indonesian-phase-iii-trial/2026-06-17T22:46:49+08:00https://flcube.com/insilico-medicines-nlrp3-inhibitor-ism8969-achieves-first-in-human-milestone-in-phase-i-trial-for-cns-disorders/2026-06-17T22:42:09+08:00https://flcube.com/hengrui-pharmaceuticals-expands-dalpiciclib-label-with-nmpa-approval-for-early-breast-cancer-adjuvant-therapy/2026-06-17T22:33:24+08:00https://flcube.com/hengrui-pharmaceuticals-receives-nmpa-clinical-approvals-for-two-novel-anti-tumor-candidates-shr-6914-and-hrs-7525-addressing-unmet-needs-in-prostate-cancer-and-solid-tumors/2026-06-17T22:19:30+08:00https://flcube.com/zai-labs-dll3-targeting-adc-zocilurtatug-pelitecan-receives-ema-orphan-drug-designation-for-pulmonary-neuroendocrine-carcinomas/2026-06-17T22:16:15+08:00https://flcube.com/luye-pharmas-dual-target-candidate-ly03015-achieves-breakthrough-phase-ii-results-in-tardive-dyskinesia-with-76-5-response-rate/2026-06-17T22:09:28+08:00https://flcube.com/gsks-momelotinib-receives-orphan-drug-designation-from-fda-and-ema-for-vexas-syndrome-addressing-critical-unmet-need-in-rare-myeloid-disorder/2026-06-17T21:51:35+08:00https://flcube.com/regent-pacifics-senstend-receives-nmpa-approval-with-four-year-data-protection-triggering-5m-milestone-payment-from-wanbang/2026-06-17T21:48:16+08:00https://flcube.com/bayer-ag-inaugurates-second-consumer-health-innovation-center-in-china-expanding-skin-and-digestive-health-partnerships/2026-06-17T21:33:06+08:00https://flcube.com/shanghai-henlius-biotech-receives-australian-clearance-for-phase-ii-study-of-pd-l1-adc-hlx43-combined-with-hansizhuang-in-nsclc-neoadjuvant-therapy/2026-06-17T21:01:13+08:00https://flcube.com/shanghai-henlius-biotechs-hlx04-o-meets-primary-endpoints-in-phase-iii-trial-for-wet-amd-demonstrating-non-inferiority-to-ranibizumab/2026-06-17T20:57:41+08:00https://flcube.com/nmpa-releases-106th-batch-of-reference-drugs-for-generic-quality-consistency-evaluation-including-beone-medicines-brukinsa-zanubrutinib/2026-06-17T15:26:58+08:00https://flcube.com/chinas-cde-proposes-framework-for-reference-listed-drug-selection-following-marketing-authorization-holder-changes-for-foreign-originator-drugs-manufactured-locally/2026-06-17T15:21:17+08:00https://flcube.com/chinas-national-health-commission-revises-physician-practice-regulations-to-align-with-physicians-law-and-enhance-multi-site-practice-framework/2026-06-17T15:19:49+08:00https://flcube.com/servier-group-partners-with-n-lorem-foundation-to-develop-aso-therapies-for-rare-neurodevelopmental-disorders/2026-06-17T15:18:12+08:00https://flcube.com/shanghai-juncell-therapeutics-files-for-hkex-listing-with-breakthrough-til-therapy-gc101-for-solid-tumors/2026-06-17T15:15:31+08:00https://flcube.com/everest-medicines-licenses-dmx-200-from-dimerix-ccr2-inhibitor-for-fsgs-targets-asia-pacific-markets/2026-06-16T22:59:03+08:00https://flcube.com/zelgen-biopharmaceuticals-secures-nmpa-approval-for-zepuping-in-severe-alopecia-areata-first-immuno-inflammatory-indication-for-pan-jak-inhibitor/2026-06-16T22:50:22+08:00https://flcube.com/hinova-pharmaceuticals-reports-positive-phase-iia-data-for-hp515-in-mash-thr-%ce%b2-agonist-achieves-50-liver-fat-reduction/2026-06-16T22:44:35+08:00https://flcube.com/chia-tai-tianqing-presents-positive-phase-ii-data-for-tqc2938-in-allergic-rhinitis-novel-st2-targeting-mab-shows-efficacy-across-inflammatory-pathways/2026-06-16T22:16:26+08:00https://flcube.com/harbour-biomed-and-biomap-launch-megastream-techbio-next-generation-ai-drug-discovery-company-targeting-global-markets/2026-06-16T20:52:21+08:00https://flcube.com/bms-secures-nmpa-approval-for-sotyktu-in-psoriatic-arthritis-first-selective-tyk2-inhibitor-expands-china-indications/2026-06-16T14:59:25+08:00https://flcube.com/lonza-and-antharis-therapeutics-forge-exclusive-adc-partnership-dual-payload-platform-targets-gastrointestinal-cancers/2026-06-16T14:52:55+08:00https://flcube.com/astrazeneca-joins-zero-prostate-cancers-blitz-the-barriers-initiative-ambitious-program-aims-to-save-100000-lives-by-2035/2026-06-16T14:44:23+08:00https://flcube.com/gilead-sciences-submits-snda-for-once-weekly-oral-yeztugo-prep-potential-first-long-acting-oral-hiv-prevention-option/2026-06-16T14:34:08+08:00https://flcube.com/johnson-johnson-invests-1-billion-in-jacksonville-vision-facility-expands-acuvue-manufacturing-and-distribution/2026-06-16T14:25:17+08:00https://flcube.com/lynk-pharmaceuticals-files-for-hong-kong-ipo-autoimmune-pipeline-led-by-jak-inhibitors-and-novel-protein-degraders/2026-06-16T14:19:49+08:00https://flcube.com/bayer-secures-fda-approval-for-ambelvist-novel-high-relaxivity-mri-contrast-agent-with-lower-gadolinium-dose/2026-06-16T14:13:29+08:00https://flcube.com/shanghai-leadingtac-secures-nmpa-approval-for-lt-010391-chinas-first-clinical-stage-oral-kras-g12d-degrader/2026-06-16T14:03:19+08:00https://flcube.com/fosun-pharma-secures-nmpa-approval-for-fumaining-in-pediatric-langerhans-cell-histiocytosis-expands-mek-inhibitor-franchise/2026-06-16T13:55:48+08:00https://flcube.com/triapex-laboratories-files-for-hong-kong-ipo-next-generation-cro-with-240-nmpa-approvals/2026-06-16T13:49:45+08:00https://flcube.com/ningbo-sanxing-medical-electric-files-hkex-prospectus-with-dual-business-model-in-power-equipment-and-rehabilitation-services/2026-06-15T22:38:22+08:00https://flcube.com/gritpharma-secures-nmpa-approval-for-doxylamine-as-chinas-first-novel-short-term-insomnia-treatment/2026-06-15T22:29:54+08:00https://flcube.com/baheal-pharma-partners-with-jinan-junxin-hospital-to-launch-zap-x-precision-radiosurgery-center/2026-06-15T22:26:46+08:00https://flcube.com/lannacheng-biotechnology-files-hkex-prospectus-with-13-candidate-radiopharmaceutical-pipeline/2026-06-15T22:22:37+08:00https://flcube.com/harbour-biomed-wins-20-2-million-patent-verdict-against-amgen-in-delaware-court/2026-06-15T21:56:53+08:00https://flcube.com/sichuan-biokins-iza-bren-becomes-worlds-first-egfrxher3-bispecific-adc-with-nda-accepted-by-chinas-nmpa/2026-06-15T21:53:13+08:00https://flcube.com/ssy-group-secures-exclusive-china-license-for-opt101-novel-peritoneal-dialysis-therapy-from-opterion-health/2026-06-15T21:49:12+08:00https://flcube.com/simcere-pharmaceutical-partners-with-stanford-university-to-develop-first-in-class-ipf-therapy/2026-06-15T21:43:57+08:00https://flcube.com/novo-nordisk-to-fully-launch-sogroya-in-china-this-summer-for-pediatric-growth-hormone-deficiency/2026-06-15T21:40:38+08:00https://flcube.com/medtronic-completes-550-million-acquisition-of-scientia-vascular-to-strengthen-neurovascular-portfolio/2026-06-15T21:35:42+08:00https://flcube.com/sanofis-tzield-receives-fda-approval-to-preserve-insulin-production-in-recently-diagnosed-type-1-diabetes/2026-06-15T21:32:16+08:00https://flcube.com/roches-ventana-pten-assay-receives-fda-approval-as-first-companion-diagnostic-for-astrazenecas-truqap-in-prostate-cancer/2026-06-15T21:25:28+08:00https://flcube.com/jazz-pharmaceuticals-reports-phase-3-lagoon-trial-misses-primary-endpoint-for-zepzelca-in-relapsed-small-cell-lung-cancer/2026-06-15T21:02:36+08:00https://flcube.com/astrazenecas-truqap-receives-fda-approval-as-first-targeted-therapy-for-pten-deficient-prostate-cancer/2026-06-15T20:56:47+08:00https://flcube.com/micot-pharmaceutical-successfully-lists-on-hong-kong-stock-exchange-with-hk1-22-billion-ipo/2026-06-15T20:48:48+08:00https://flcube.com/merck-secures-fda-approval-for-keytruda-welireg-combination-as-adjuvant-therapy-in-high-risk-kidney-cancer/2026-06-15T20:43:06+08:00https://flcube.com/chinas-nhsa-receives-record-818-drug-applications-for-2026-national-reimbursement-drug-list-adjustment/2026-06-15T20:37:19+08:00https://flcube.com/simcere-pharmaceutical-secures-nmpa-approval-for-sim0689-bispecific-antibody-targeting-pd-1-and-vegf-in-solid-tumors/2026-06-15T20:35:04+08:00https://flcube.com/mabwell-bioscience-secures-fda-approval-for-6mw5311-bispecific-antibody-trial-in-hematologic-malignancies/2026-06-15T20:30:37+08:00https://flcube.com/qingfeng-pharmaceutical-group-partners-with-tasco-pharma-to-commercialize-anti-tumor-and-cns-medicines-in-vietnam/2026-06-15T20:25:07+08:00https://flcube.com/merck-secures-nmpa-approval-for-enflonsia-clesrovimab-first-single-dose-rsv-monoclonal-antibody-in-china/2026-06-15T20:12:14+08:00https://flcube.com/junshi-biosciences-secures-global-exclusive-rights-to-cass-tetravalent-recombinant-dengue-vaccine-in-landmark-licensing-deal/2026-06-12T20:42:05+08:00https://flcube.com/shouyao-holdings-secures-nmpa-approval-for-second-generation-alk-inhibitor-ct-707-as-first-line-treatment-for-alk-positive-nsclc/2026-06-12T20:26:44+08:00https://flcube.com/creaternas-my008211a-becomes-chinas-first-home-grown-oral-cfb-inhibitor-approved-for-paroxysmal-nocturnal-hemoglobinuria/2026-06-12T20:20:18+08:00https://flcube.com/chinas-cde-releases-107th-batch-of-reference-preparations-for-generic-drug-consistency-evaluation-with-17-new-drugs-added/2026-06-12T20:15:55+08:00https://flcube.com/takedas-zasocitinib-demonstrates-superior-efficacy-over-deucravacitinib-in-phase-iii-psoriasis-trial-with-35-pasi-100-response-rate/2026-06-12T15:08:27+08:00https://flcube.com/kelun-biotech-receives-usd-89-million-settlement-payment-from-medilink-therapeutics-over-adc-pipeline-out-licensing-dispute/2026-06-12T15:00:39+08:00https://flcube.com/wuxi-apptec-files-federal-lawsuit-against-u-s-department-of-defense-over-erroneous-inclusion-on-chinese-military-companies-list/2026-06-12T14:40:13+08:00https://flcube.com/hj-science-launches-hk1-11-billion-ipo-on-hong-kong-exchange-to-advance-clinical-stage-pipeline-in-autoimmune-metabolic-and-oncology-therapies/2026-06-12T14:34:28+08:00https://flcube.com/longbio-pharmas-anti-ige-antibody-lp-003-meets-primary-endpoint-in-phase-iii-seasonal-allergic-rhinitis-trial/2026-06-12T14:13:54+08:00https://flcube.com/cascade-pharmaceuticals-secures-rmb-318-million-series-d-financing-to-advance-bile-acid-metabolism-pipeline/2026-06-12T14:07:44+08:00https://flcube.com/novartis-del-brax-meets-primary-endpoints-in-fshd-biomarker-study-potential-first-disease-modifying-therapy-for-rare-muscular-dystrophy/2026-06-12T13:58:13+08:00https://flcube.com/quantumpharm-xtalpi-secures-400-million-ai-driven-partnership-for-best-in-class-gpcr-targeting-oral-small-molecule-drug/2026-06-11T21:15:17+08:00https://flcube.com/novartis-secures-fourth-china-approval-for-tafinlar-mekinist-combo-in-braf-v600e-mutated-radioactive-iodine-refractory-differentiated-thyroid-cancer/2026-06-11T21:06:00+08:00https://flcube.com/yipinhong-pharmacy-receives-nmpa-clearance-for-aph03571-dual-mechanism-therapy-in-flt3-mutated-relapsed-refractory-aml/2026-06-11T20:58:56+08:00https://flcube.com/cspc-pharmaceuticals-phase-iii-trial-of-anbenitamab-docetaxel-combination-meets-primary-endpoint-in-first-line-her2-positive-advanced-breast-cancer/2026-06-11T20:55:20+08:00https://flcube.com/harbour-biomeds-ind-for-hbm7004-bispecific-antibody-accepted-by-nmpa-for-advanced-solid-tumors-following-u-s-clearance/2026-06-11T20:50:37+08:00https://flcube.com/qingsong-health-and-basel-medical-forge-three-year-strategic-alliance-to-deploy-ai-driven-healthcare-solutions-across-southeast-asia/2026-06-11T20:45:23+08:00https://flcube.com/imviva-biotech-receives-fda-clearance-for-phase-1b-basket-trial-of-cta313-allogeneic-car-t-therapy-in-b-cell-mediated-autoimmune-diseases/2026-06-11T20:36:12+08:00https://flcube.com/akeso-biopharma-secures-nmpa-approval-for-gumokimab-il-17a-monoclonal-antibody-for-moderate-to-severe-plaque-psoriasis/2026-06-11T20:28:41+08:00https://flcube.com/hansoh-pharmaceuticals-nda-for-hs-10568-calcium-sensing-receptor-modulator-accepted-by-chinas-nmpa-for-secondary-hyperparathyroidism-in-dialysis-patients/2026-06-11T15:08:55+08:00https://flcube.com/orionis-biosciences-secures-1-44-billion-novartis-partnership-for-molecular-glue-drug-discovery-using-ai-powered-allo-glue-platform/2026-06-11T15:04:20+08:00https://flcube.com/bio-thera-solutions-secures-singapore-approval-for-bat2206-biosimilar-to-jjs-stelara-expanding-access-across-multiple-autoimmune-indications/2026-06-11T14:49:47+08:00https://flcube.com/pku-hi-tech-huatai-pharmaceuticals-blacklisted-from-chinas-volume-based-procurement-following-quality-compliance-failures/2026-06-11T14:44:48+08:00https://flcube.com/sanofi-halts-phase-3-mobilize-trial-for-riliprubart-in-refractory-cidp-patients-following-interim-analysis/2026-06-11T14:09:38+08:00https://flcube.com/neurogen-pharma-secures-nmpa-approval-for-ajovy-fremanezumab-in-china-launching-first-quarterly-cgrp-migraine-prevention-therapy/2026-06-10T22:05:41+08:00https://flcube.com/harbour-biomeds-tslp-inhibitor-hbm9378-win378-doses-first-patient-in-phase-ii-copd-study-with-windward-bio-supporting-twice-yearly-dosing-regimen/2026-06-10T21:42:34+08:00https://flcube.com/haisco-pharmaceutical-files-nav1-8-inhibitor-hsk51155-with-nmpa-following-700m-abbvie-licensing-deal-for-novel-pain-therapeutic/2026-06-10T21:38:12+08:00https://flcube.com/huadong-medicines-ellanse-s-dermal-filler-receives-nmpa-acceptance-for-forehead-contouring-indication-expanding-chinas-premium-aesthetic-portfolio/2026-06-10T21:32:37+08:00https://flcube.com/henlius-biotechs-serplulimab-becomes-worlds-first-pd-1-inhibitor-approved-for-perioperative-gastric-cancer-treatment-following-landmark-phase-iii-results/2026-06-10T21:28:54+08:00https://flcube.com/hengrui-pharmaceuticals-advances-triple-asset-breast-cancer-strategy-with-nmpa-approval-for-hrs-6209-combination-study-leveraging-selective-cdk4-inhibitor-and-novel-serd/2026-06-10T21:22:43+08:00https://flcube.com/westgene-biopharma-and-cartesian-therapeutics-forge-500m-mrna-partnership-for-in-vivo-car-t-and-t-cell-engager-autoimmune-therapies/2026-06-10T21:18:12+08:00https://flcube.com/takedas-entyvio-receives-fda-acceptance-for-pediatric-sbla-in-ulcerative-colitis-and-crohns-disease-expanding-gut-selective-biologic-to-patients-aged-2/2026-06-10T21:01:21+08:00https://flcube.com/chinas-four-health-regulators-issue-revised-good-clinical-practice-guidelines-effective-september-2026-strengthening-trial-oversight-and-ethical-standards/2026-06-10T20:40:25+08:00https://flcube.com/burning-rock-reports-q1-2026-revenue-of-16m-accelerates-strategic-shift-to-in-hospital-testing-with-49-revenue-share/2026-06-10T15:05:58+08:00https://flcube.com/chinas-national-health-commission-launches-anti-corruption-campaign-targeting-pharmaceutical-sales-and-healthcare-services-misconduct/2026-06-10T14:54:48+08:00https://flcube.com/lynk-pharmaceuticals-and-formation-bio-dose-first-patient-in-phase-i-blkr201-study-for-cns-penetrant-tyk201-inhibitor-backed-by-605m-partnership/2026-06-10T14:52:47+08:00https://flcube.com/zai-lab-launches-commercial-rollout-of-cobenfy-in-china-following-first-nationwide-prescription-for-schizophrenia-treatment/2026-06-10T14:44:10+08:00https://flcube.com/eli-lilly-secures-fda-approval-for-every-eight-week-ebglyss-regimen-in-atopic-dermatitis-offering-just-six-annual-injections/2026-06-10T14:31:46+08:00https://flcube.com/laekna-therapeutics-secures-527m-global-licensing-deal-with-vasque-bio-for-pi3k%ce%b1-inhibitor-lae118-retaining-china-rights/2026-06-10T14:25:05+08:00https://flcube.com/antengene-launches-phase-i-attract-study-for-atg-201-bispecific-antibody-in-autoimmune-diseases-following-1-18b-ucb-licensing-deal/2026-06-10T14:17:11+08:00https://flcube.com/shanghai-bio-heart-secures-israeli-registration-for-iberis-rdn-system-worlds-only-dual-access-renal-denervation-platform/2026-06-10T14:04:36+08:00https://flcube.com/jikeshu-sebaloxavir-marboxil-receives-nmpa-approval-for-adolescent-influenza-treatment-expanding-single-dose-category-1-antiviral-franchise/2026-06-09T23:39:04+08:00https://flcube.com/cspc-pharmaceutical-receives-fda-clearance-for-once-monthly-semaglutide-syh9017-in-weight-management-challenging-weekly-glp-1-standard/2026-06-09T23:33:14+08:00https://flcube.com/lepu-medical-receives-tga-approval-for-phase-i-trial-of-dual-targeting-sirna-mwx205-against-pcsk9-and-angptl3-in-australia/2026-06-09T23:30:52+08:00https://flcube.com/everest-medicines-secures-asia-pacific-rights-to-vcare-pharmas-next-generation-p2y12-inhibitor-sumecigrel-in-3m-licensing-deal/2026-06-09T23:28:15+08:00https://flcube.com/shandong-buchang-pharmaceuticals-partners-with-vietnamese-mkt-for-exclusive-adalimumab-biosimilar-distribution-in-vietnam/2026-06-09T23:25:53+08:00https://flcube.com/european-commission-approves-sanofis-subcutaneous-sarclisa-isatuximab-across-all-multiple-myeloma-indications-based-on-phase-iii-iraklia-data/2026-06-09T23:22:04+08:00https://flcube.com/sichuan-biokin-receives-fda-go-ahead-for-phase-iii-trial-of-dll3-targeting-adc-bl-m14d1-in-first-line-extensive-stage-small-cell-lung-cancer/2026-06-09T23:15:48+08:00https://flcube.com/bayer-announces-consumer-health-leadership-restructuring-with-new-global-and-u-s-appointments/2026-06-09T23:13:12+08:00https://flcube.com/remegen-secures-dual-nmpa-approvals-for-taiai-telitacicept-in-sjogrens-syndrome-and-iga-nephropathy-expanding-first-in-class-blys-april-inhibitor-franchise/2026-06-09T23:10:45+08:00https://flcube.com/konruns-pharmaceutical-to-acquire-30-stake-in-huamao-pharma-for-28-2-million-achieving-vertical-integration-from-api-to-finished-formulation/2026-06-09T23:04:02+08:00https://flcube.com/adcentrx-therapeutics-receives-nmpa-ind-clearance-for-steap1-targeting-adc-adrx-0405-in-advanced-solid-tumors/2026-06-09T22:54:05+08:00https://flcube.com/zai-lab-secures-nmpa-approval-for-tivdak-tisotumab-vedotin-in-recurrent-or-metastatic-cervical-cancer-based-on-phase-iii-innovatv-301-data/2026-06-09T22:41:13+08:00https://flcube.com/otsuka-pharmaceutical-secures-nmpa-approval-for-voyxact-sibeprenlimab-in-iga-nephropathy-based-on-pivotal-phase-iii-visionary-data/2026-06-09T22:27:30+08:00https://flcube.com/hangzhou-highlightll-pharmaceutical-files-for-hong-kong-ipo-with-seven-candidate-pipeline-targeting-autoimmune-and-neurodegenerative-diseases/2026-06-09T22:24:58+08:00https://flcube.com/boji-medical-raises-66-million-through-private-placement-to-expand-integrated-cro-and-tcm-innovation-platform/2026-06-09T22:00:33+08:00https://flcube.com/pfizer-secures-fda-approval-for-marstacimab-expanded-indication-in-hemophilia-a-and-b-across-pediatric-and-adult-populations/2026-06-09T21:57:37+08:00https://flcube.com/msd-and-gilead-discontinue-phase-3-keynote-d46-evoke-03-study-of-trodelvy-keytruda-combination-in-first-line-nsclc/2026-06-09T21:46:49+08:00https://flcube.com/jj-to-acquire-firefly-bio-for-1-billion-adding-proprietary-dac-platform-targeting-kras-driven-tumors/2026-06-09T21:37:19+08:00https://flcube.com/nurix-and-roche-forge-2-3-billion-global-collaboration-for-btk-degrader-bexobrutideg-across-oncology-immunology-and-neurology/2026-06-09T21:32:48+08:00https://flcube.com/gsk-to-acquire-nuvalent-for-10-6-billion-adding-breakthrough-lung-cancer-therapies-to-oncology-portfolio/2026-06-09T21:25:49+08:00https://flcube.com/pegbio-receives-7-8m-milestone-payment-from-tenry-pharma-for-paidakang-glp-1-agonist-chinese-biotech-secures-first-commercial-revenue-from-type-2-diabetes-asset/2026-06-08T22:07:34+08:00https://flcube.com/sino-medical-sciences-secures-colombian-approval-for-ht-supreme-drug-eluting-stent-advanced-dual-polymer-technology-expands-latin-american-presence/2026-06-08T22:03:08+08:00https://flcube.com/henlius-biotech-doses-first-us-patient-in-global-phase-i-trial-of-hlx17-pembrolizumab-biosimilar-dual-fda-nmpa-approval-enables-simultaneous-development-in-china-and-united-states/2026-06-08T21:59:13+08:00https://flcube.com/novo-nordisks-cagrisema-fixed-dose-combination-delivers-superior-hba1c-and-weight-loss-in-phase-3-reimagine-trials-amylin-glp-1-dual-therapy-outperforms-semaglutide-monotherapy/2026-06-08T21:55:41+08:00https://flcube.com/bayers-kerendia-finerenone-demonstrates-significant-kidney-protection-in-non-diabetic-ckd-phase-iii-trial-first-mineralocorticoid-receptor-antagonist-to-show-efficacy-beyond-diabetes-pop/2026-06-08T15:11:15+08:00https://flcube.com/novo-nordisks-zenagamtide-amycretin-delivers-1-71-a1c-reduction-and-14-6-weight-loss-in-phase-2-type-2-diabetes-trial-dual-glp-1-amylin-agonist-advances-to-phase-3/2026-06-08T15:07:02+08:00https://flcube.com/oricell-therapeutics-receives-nmpa-clearance-for-worlds-first-gpc3-targeted-car-t-therapy-in-advanced-liver-cancer-ori-c101-enters-confirmatory-phase-ii/2026-06-08T15:03:12+08:00https://flcube.com/boehringer-ingelheims-survodutide-dual-agonist-achieves-34-visceral-fat-reduction-and-60-masld-resolution-in-phase-iii-ada-2026-data/2026-06-08T14:59:33+08:00https://flcube.com/eli-lillys-retatrutide-delivers-unprecedented-28-3-weight-loss-and-resolves-multiple-obesity-comorbidities-in-phase-iii-triumph-1-and-transcend-t2d-1-trials/2026-06-08T14:56:29+08:00https://flcube.com/eli-lillys-foundayo-orforglipron-demonstrates-significant-weight-loss-across-all-menopausal-stages-addresses-critical-gap-in-womens-metabolic-health/2026-06-08T14:53:38+08:00https://flcube.com/antengene-unveils-atg-207-bispecific-fusion-protein-data-at-eular-2026-novel-%ce%b1cd3xtgf-%ce%b2-molecule-shows-potent-immunomodulatory-activity-in-autoimmune-models/2026-06-08T14:48:13+08:00https://flcube.com/sciwind-biosciences-unveils-superior-weight-loss-data-for-ecnoglutide-vs-semaglutide-at-ada-2026-first-camp-biased-glp-1-agonist-shows-35-greater-efficacy/2026-06-08T14:44:45+08:00https://flcube.com/msd-launches-winrevair-sotatercept-in-china-first-activin-signaling-inhibitor-for-pulmonary-arterial-hypertension/2026-06-08T14:32:58+08:00https://flcube.com/junshi-biosciences-forms-strategic-jv-with-zhiyu-biomedicine-contributing-oncology-antibody-ip-and-adc-platform-for-multispecific-development/2026-06-08T14:08:46+08:00https://flcube.com/everest-medicines-licenses-lnz100-presbyopia-treatment-from-corxel-for-greater-china-aceclidine-based-eye-drop-offers-novel-miotic-mechanism/2026-06-08T14:00:10+08:00https://flcube.com/guangzhou-lupengs-rocbrutinib-receives-nmpa-priority-approval-for-relapsed-refractory-mantle-cell-lymphoma-fourth-generation-btk-inhibitor-shows-63-9-response-rate/2026-06-05T14:21:49+08:00https://flcube.com/chinas-nhc-releases-sixth-pediatric-drug-priority-list-27-varieties-including-emicizumab-pembrolizumab-and-omalizumab-targeted-for-development/2026-06-05T14:17:56+08:00https://flcube.com/sichuan-biokin-receives-nmpa-go-ahead-for-bl-m08d1-bispecific-antibody-in-dlbcl-combination-therapy-adc-leverages-proven-bl-b01d1-platform/2026-06-05T14:13:35+08:00https://flcube.com/mabwell-bioscience-secures-nmpa-clinical-approval-for-9mw5211-in-inflammatory-bowel-disease-highly-specific-depleting-antibody-targets-pathogenic-immune-cells/2026-06-05T14:10:15+08:00https://flcube.com/ssy-group-secures-global-rights-to-pediatric-antispasmodic-and-copd-drugs-from-xinzheng-heying-full-ip-transfer-in-category-2-2-and-2-3-assets/2026-06-05T14:06:37+08:00https://flcube.com/shanghai-bao-pharmaceuticals-kj103-nda-accepted-by-nmpa-first-in-class-igg-degrading-enzyme-for-highly-sensitized-kidney-transplant-patients/2026-06-05T14:01:22+08:00https://flcube.com/sichuan-biokin-enrolls-first-patient-in-phase-iii-trial-of-bl-m05d1-adc-for-claudin18-2-positive-gastric-cancer/2026-06-05T13:57:46+08:00https://flcube.com/lonza-and-stipple-bio-forge-strategic-adc-partnership-combining-epitope-discovery-with-glyco-connect-platform-for-next-generation-oncology-therapies/2026-06-05T13:53:35+08:00https://flcube.com/gilead-and-lakefront-complete-1-675b-acquisition-of-ouro-medicines-securing-bcmaxcd3-t-cell-engager-for-autoimmune-diseases/2026-06-05T13:49:45+08:00https://flcube.com/teva-launches-ahzantive-biosimilar-to-bayers-eylea-across-europe-expanding-access-to-retinal-disease-treatments/2026-06-05T13:44:56+08:00https://flcube.com/pfizer-licenses-chai-discoverys-ai-platform-for-drug-discovery-gains-early-access-to-breakthrough-chai-3-model-for-antibody-design/2026-06-05T13:38:44+08:00https://flcube.com/biogen-secures-fda-breakthrough-therapy-designation-for-salanersen-in-spinal-muscular-atrophy-once-yearly-aso-with-novel-chemical-structure/2026-06-05T13:18:28+08:00https://flcube.com/innovent-biologics-reports-positive-phase-iii-results-for-ibi343-in-advanced-gastric-cancer-cldn18-2-targeting-adc-files-nda-with-nmpa/2026-06-05T13:15:45+08:00https://flcube.com/everest-medicines-secures-asia-pacific-rights-to-mabworks-obexelimab-%ce%b2-in-30-9m-deal-first-in-class-cd20-antibody-for-nmosd/2026-06-05T13:12:41+08:00https://flcube.com/jiangsu-vcare-pharmatech-secures-nmpa-approval-for-eratrectinib-next-generation-trk-inhibitor-with-enhanced-brain-penetration-and-circular-molecular-structure/2026-06-05T13:09:08+08:00https://flcube.com/ge-healthcare-secures-fda-510k-clearance-for-mim-contour-protegeai-2-0-ai-auto-contouring-platform-with-predetermined-change-control-plan/2026-06-05T13:01:06+08:00https://flcube.com/hansoh-pharmaceuticals-olatorepatide-glp-1-gip-dual-agonist-accepted-for-nmpa-review-for-weight-management-indication/2026-06-04T21:33:32+08:00https://flcube.com/johnson-johnsons-nipocalimab-imaavy-demonstrates-efficacy-in-phase-ii-jasmine-study-for-systemic-lupus-erythematosus-first-fcrn-blocker-to-show-success-in-sle/2026-06-04T21:28:30+08:00https://flcube.com/lundbeck-partners-with-cradle-to-deploy-ai-guided-protein-engineering-for-cns-antibody-discovery/2026-06-04T21:21:36+08:00https://flcube.com/novo-nordisk-launches-wegovy-oral-tablets-in-uae-first-international-market-outside-us-for-semaglutide-weight-management-therapy/2026-06-04T21:09:57+08:00https://flcube.com/medtronic-makes-strategic-ice-catheter-investments-to-strengthen-cardiac-ablation-leadership-and-affera-ecosystem-integration/2026-06-04T20:53:34+08:00https://flcube.com/regeneron-expands-cytomx-partnership-to-4-billion-in-potential-milestones-for-conditionally-activated-bispecific-cancer-therapies/2026-06-04T20:23:50+08:00https://flcube.com/ascidian-therapeutics-partners-with-eli-lilly-in-1-9-billion-rna-exon-editing-deal-for-monogenic-kidney-diseases/2026-06-04T20:07:52+08:00https://flcube.com/medtronic-submits-fda-510k-filings-to-expand-hugo-ras-system-into-general-and-gynecologic-surgery-adds-ligasure-maryland-instrument/2026-06-04T20:01:15+08:00https://flcube.com/yunnan-baiyao-secures-fda-clinical-approval-for-inb301-in-tumor-cachexia-first-chinese-tcm-company-to-advance-novel-therapy-in-us-oncology-market/2026-06-04T19:58:12+08:00https://flcube.com/changchun-high-new-tech-secures-nmpa-clinical-trial-approval-for-gensci155-in-dual-indications-bronchopulmonary-dysplasia-and-acute-ischemic-stroke/2026-06-04T14:59:58+08:00https://flcube.com/medtronic-reports-strong-q4-and-fy26-results-with-6-6-organic-growth-cardiac-ablation-solutions-surge-78/2026-06-04T14:44:52+08:00https://flcube.com/fda-issues-draft-guidance-to-accelerate-gene-therapy-development-through-platform-knowledge-sharing/2026-06-04T14:37:34+08:00https://flcube.com/chinas-national-health-commission-unveils-ambitious-plan-for-community-health-service-expansion-by-2030/2026-06-04T14:35:40+08:00https://flcube.com/shandong-boan-biotech-licenses-ba5101-dulaglutide-biosimilar-for-us-market-first-global-copycat-of-trulicity/2026-06-04T13:17:53+08:00https://flcube.com/kadwise-biotech-and-epiprobe-forge-strategic-partnership-to-advance-pediatric-cancer-diagnostics-in-china/2026-06-03T19:49:30+08:00https://flcube.com/huahai-pharmaceutical-receives-nmpa-approval-for-dual-target-ipf-therapy-hb0056-adding-to-global-clinical-trial-authorizations/2026-06-03T19:39:55+08:00https://flcube.com/genesis-medtech-secures-ce-mark-for-worlds-first-integrated-scissor-type-ultrasonic-scalpel-following-2025-china-approval/2026-06-03T19:36:50+08:00https://flcube.com/everest-medicines-secures-1-14-billion-deal-with-travere-therapeutics-for-next-gen-btk-inhibitor-civorebrutinib-in-global-kidney-disease-market/2026-06-03T19:34:19+08:00https://flcube.com/xtalpi-backed-signet-therapeutics-secures-fda-ind-approval-for-worlds-first-pan-tead-inhibitor-sigx2649-ahead-of-schedule/2026-06-03T19:25:56+08:00https://flcube.com/legend-biotechs-in-vivo-car-t-therapy-lb2501-shows-100-response-rate-in-relapsed-refractory-b-cell-lymphoma-with-no-serious-safety-events/2026-06-03T19:20:56+08:00https://flcube.com/kelun-biotechs-novel-b7-h3-adc-skb500-shows-42-7-response-rate-across-multiple-solid-tumors-in-first-in-human-asco-2026-presentation/2026-06-03T19:04:24+08:00https://flcube.com/abbvies-aquipta-atogepant-receives-european-commission-approval-for-acute-migraine-treatment-expanding-beyond-preventive-use/2026-06-03T14:33:14+08:00https://flcube.com/xtalpis-ai-biology-spin-off-infevo-secures-tens-of-millions-in-angel-funding-to-build-virtual-cell-system-for-drug-discovery/2026-06-03T14:03:34+08:00https://flcube.com/roches-oral-serd-giredestrant-receives-fda-priority-review-for-early-breast-cancer-adjuvant-treatment/2026-06-03T13:53:38+08:00https://flcube.com/cspc-pharmaceutical-receives-nmpa-approval-for-first-in-class-mrna-lnp-dual-target-car-t-therapy-sys-6063-in-systemic-lupus-erythematosus/2026-06-03T13:47:53+08:00https://flcube.com/astrazenecas-next-gen-serd-camizestrant-shows-55-reduction-in-progression-risk-and-superior-ctdna-clearance-in-phase-iii-serena-6-trial/2026-06-03T13:36:00+08:00https://flcube.com/daiichi-sankyo-astrazeneca-secure-fda-approval-for-datroway-in-triple-negative-breast-cancer-after-phase-iii-tropion-breast02-success/2026-06-03T13:22:26+08:00https://flcube.com/astrazenecas-fasenra-becomes-first-biologic-approved-in-china-for-hypereosinophilic-syndrome/2026-06-03T13:21:48+08:00https://flcube.com/astrazenecas-imfinzi-bcg-combination-approved-for-high-risk-non-muscle-invasive-bladder-cancer-in-us/2026-06-03T13:21:09+08:00https://flcube.com/systimmune-and-bristol-myers-squibbs-dual-targeted-adc-izalontamabbrengitecan-shows-significant-survival-benefit-in-two-phase-iii-trials/2026-06-03T13:15:04+08:00https://flcube.com/cspc-pharmaceuticals-b7-h3-adc-sys-6043-shows-41-8-response-rate-in-phase-i-solid-tumor-study/2026-06-03T13:04:18+08:00https://flcube.com/chinas-nmpa-introduces-comprehensive-medical-device-classification-reforms-with-2-5-year-transitional-periods/2026-06-02T20:09:07+08:00https://flcube.com/rallybio-to-merge-with-avenzo-therapeutics-in-215-million-deal-creating-pipeline-rich-entity-focused-on-chinese-origin-oncology-assets/2026-06-02T20:07:31+08:00https://flcube.com/simcere-pharmaceutical-secures-exclusive-rights-to-primegenxs-pumecitinib-gel-for-atopic-dermatitis-in-greater-china/2026-06-02T14:42:23+08:00https://flcube.com/amgens-tarlatamab-receives-ec-approval-for-extensive-stage-sclc-with-40-mortality-reduction-in-phase-iii-trial/2026-06-02T14:37:24+08:00https://flcube.com/servier-group-acquires-edgewise-therapeutics-muscular-dystrophy-business-for-up-to-2-65-billion/2026-06-02T14:34:25+08:00https://flcube.com/alphamab-oncologys-her3xtrop2-bispecific-adc-jskn016-shows-64-5-response-rate-in-triple-negative-breast-cancer-at-asco-2026/2026-06-02T14:29:01+08:00https://flcube.com/sino-biopharmaceuticals-saitanxin-shows-32-4-response-rate-in-cdk4-6-inhibitor-resistant-breast-cancer-at-asco-2026/2026-06-02T14:26:21+08:00https://flcube.com/hemacell-therapeutics-secures-44-million-series-b-to-advance-worlds-first-megakaryocyte-injection-for-platelet-regeneration/2026-06-02T14:19:34+08:00https://flcube.com/haisco-pharmaceutical-secures-fda-approval-for-cypsedo-as-first-chinese-developed-intravenous-anesthetic-in-us-market/2026-06-02T14:04:52+08:00https://flcube.com/shionogis-xocova-becomes-first-oral-covid-19-post-exposure-prophylaxis-approved-by-fda/2026-06-02T13:55:12+08:00https://flcube.com/bms-camzyos-receives-fda-priority-review-for-adolescent-obstructive-hcm-treatment/2026-06-02T13:47:53+08:00https://flcube.com/livzon-pharmaceutical-secures-nmpa-approval-for-lzm012-xkh004-chinas-first-il-17a-f-dual-inhibitor-for-ankylosing-spondylitis/2026-06-02T13:29:01+08:00https://flcube.com/changchun-high-new-tech-secures-fda-approval-for-gensci145-mutation-selective-pi3k%ce%b1-inhibitor-for-pik3ca-mutant-solid-tumors/2026-06-02T13:24:48+08:00https://flcube.com/changchun-high-new-tech-secures-fda-clearance-for-gensci136-clinical-study-in-generalized-myasthenia-gravis/2026-06-02T13:20:49+08:00https://flcube.com/legend-biotech-unveils-first-in-human-data-for-dll3-targeted-car-t-therapy-lb2102-in-relapsed-small-cell-lung-cancer-at-asco-2026/2026-06-02T13:17:06+08:00https://flcube.com/zelgen-biopharma-unveils-breakthrough-data-for-bispecific-and-trispecific-antibodies-at-asco-2026/2026-06-02T13:08:18+08:00https://flcube.com/novartis-scemblix-demonstrates-sustained-superiority-over-standard-tkis-in-chronic-myeloid-leukemia-with-144-week-asc4first-data/2026-06-02T13:00:40+08:00https://flcube.com/haisco-pharmaceutical-and-eli-lilly-forge-3-billion-drug-discovery-alliance-spanning-multiple-therapeutic-areas/2026-06-02T12:56:44+08:00https://flcube.com/bms-secures-ec-approval-for-opdivo-avd-combination-in-advanced-classical-hodgkin-lymphoma/2026-06-02T11:30:56+08:00https://flcube.com/d3-bios-next-gen-kras-g12c-inhibitor-elisrasib-shows-81-response-rate-in-first-line-nsclc-at-asco-2026/2026-06-01T20:27:06+08:00https://flcube.com/impact-therapeutics-selective-parp1-inhibitor-imp1734-shows-29-6-response-rate-in-ovarian-cancer-at-asco-2026/2026-06-01T20:23:42+08:00https://flcube.com/cttqs-egfr-c-met-bispecific-adc-tqb6411-shows-44-response-rate-in-heavily-pretreated-solid-tumors-at-asco-2026/2026-06-01T20:19:48+08:00https://flcube.com/genfleets-gfs202a-becomes-worlds-first-cachexia-bispecific-antibody-to-show-clinical-activity-at-asco-2026/2026-06-01T20:15:52+08:00https://flcube.com/lanovas-cldn18-2-adc-lm-302-shows-15-month-pfs-in-gastric-cancer-phase-ii-data-at-asco-2026/2026-06-01T20:13:01+08:00https://flcube.com/alphamab-cspcs-her2-bispecific-antibody-anbenitamab-wins-nmpa-approval-for-refractory-gastric-cancer-with-75-pfs-benefit/2026-06-01T15:09:55+08:00https://flcube.com/lynk-pharmaceuticals-advances-pan-jak-inhibitor-lnk01004-into-phase-ii-for-vitiligo-and-hand-eczema-with-skin-restricted-design/2026-06-01T15:05:51+08:00https://flcube.com/cf-pharmtechs-inhaled-sirna-therapy-icf004-receives-nmpa-clinical-approval-for-interstitial-lung-disease/2026-06-01T15:03:39+08:00https://flcube.com/peijia-medical-secures-exclusive-china-distribution-rights-for-b-brauns-sequent-please-cis-intracranial-drug-coated-balloon/2026-06-01T15:00:28+08:00https://flcube.com/basecare-medical-secures-nmpa-category-iii-approval-for-gems-oocyte-retrieval-solution-in-chinas-ivf-market/2026-06-01T14:57:52+08:00https://flcube.com/shandong-boan-submits-dual-denosumab-biosimilar-blas-to-fda-for-osteoporosis-and-oncology-indications/2026-06-01T14:54:32+08:00https://flcube.com/hanmi-pharm-secures-1-26-billion-deal-with-eli-lilly-for-glp-2-analog-sonefpeglutide-in-global-licensing-agreement/2026-06-01T14:51:33+08:00https://flcube.com/henlius-biotechs-perjeta-biosimilar-hlx11-poherdy-secures-nmpa-approval-for-her2-positive-breast-cancer-in-china/2026-06-01T14:47:02+08:00https://flcube.com/true-health-medical-files-hong-kong-ipo-for-percutaneous-surgery-robot-portfolio-with-multiple-china-first-innovations/2026-06-01T14:43:34+08:00https://flcube.com/chengdu-kanghua-initiates-phase-ii-trial-for-rsv-mrna-vaccine-through-nanoribo-acquisition-in-chinas-untapped-market/2026-06-01T14:32:10+08:00https://flcube.com/abbvies-venclyxto-receives-european-commission-approval-for-two-novel-fixed-duration-combinations-in-first-line-cll-treatment/2026-06-01T14:28:00+08:00https://flcube.com/beijing-wantais-9-valent-hpv-vaccine-achieves-nationwide-distribution-across-13000-vaccination-sites-in-china/2026-06-01T14:23:02+08:00https://flcube.com/bristol-myers-squibbs-mezigdomide-kd-combination-shows-52-risk-reduction-in-relapsed-multiple-myeloma-in-phase-3-successor-2-trial/2026-06-01T14:18:28+08:00https://flcube.com/mercks-calderasib-pembrolizumab-combination-receives-fda-breakthrough-therapy-designation-for-first-line-kras-g12c-mutant-nsclc/2026-06-01T14:00:06+08:00https://flcube.com/eli-lillys-retevmo-shows-83-risk-reduction-in-disease-recurrence-for-early-stage-ret-fusion-positive-nsclc-in-phase-3-libretto-432-trial/2026-06-01T13:42:35+08:00https://flcube.com/nmpa-opens-2026-national-reimbursement-drug-list-application-window-with-revised-eligibility-criteria-and-price-controls/2026-06-01T13:39:51+08:00https://flcube.com/teligenes-tl118-enters-nmpas-spark-initiative-for-pediatric-cancer-treatment-development/2026-06-01T13:37:19+08:00https://flcube.com/fda-proposes-streamlined-animal-testing-requirements-for-oncology-drugs-to-accelerate-development-timeline/2026-06-01T13:33:36+08:00https://flcube.com/sanofis-venglustat-receives-fda-priority-review-and-breakthrough-therapy-designation-for-type-3-gaucher-disease/2026-05-29T22:20:08+08:00https://flcube.com/beone-medicines-and-amgens-tarlatamab-receives-nmpa-conditional-approval-for-second-line-es-sclc-in-china/2026-05-29T22:17:20+08:00https://flcube.com/northland-biotechs-engensis-gene-therapy-receives-nmpa-approval-for-severe-lower-limb-ischemia-ulcers/2026-05-29T22:09:32+08:00https://flcube.com/shionogis-symproic-naldemedine-receives-nmpa-approval-for-opioid-induced-constipation-in-china/2026-05-29T21:50:00+08:00https://flcube.com/sino-biopharmaceuticals-idh1-inhibitor-tqb3454-receives-nmpa-priority-review-for-biliary-tract-cancer/2026-05-29T21:43:58+08:00https://flcube.com/sihuan-pharmaceutical-and-dprotein-biotechnology-form-ai-powered-medical-aesthetics-joint-venture/2026-05-29T21:37:26+08:00https://flcube.com/innocare-pharmas-btk-inhibitor-orelabrutinib-gains-nmpa-review-acceptance-for-primary-immune-thrombocytopenia-indication/2026-05-29T21:17:10+08:00https://flcube.com/salvectors-receives-nmpa-clinical-approval-for-yb1-x7-worlds-first-oncolytic-salmonella-therapy-for-advanced-solid-tumors/2026-05-29T21:12:31+08:00https://flcube.com/kexing-pharmaceutical-and-sinotherapeutics-partner-to-commercialize-tofacitinib-extended-release-tablets-in-kuwait-and-mexico/2026-05-29T21:05:59+08:00https://flcube.com/genrix-bio-licenses-bcmaxcd3-bispecific-velinotamig-to-fosuns-yaopharma-for-greater-china-in-268m-deal/2026-05-29T15:07:30+08:00https://flcube.com/henlius-biotech-initiates-china-dosing-in-phase-ii-iii-trial-of-novel-pd-l1-adc-hlx43-for-squamous-nsclc/2026-05-29T14:55:14+08:00https://flcube.com/hengrui-pharmaceuticals-receives-nmpa-approval-to-study-shr-1819-in-pediatric-atopic-dermatitis-challenging-sanofis-dupilumab/2026-05-29T14:50:28+08:00https://flcube.com/sino-biopharmaceutical-and-gsk-report-19-functional-cure-rate-with-bepirovirsen-in-phase-iii-hepatitis-b-studies-at-easl-2026/2026-05-29T14:46:05+08:00https://flcube.com/konruns-pharmaceutical-to-present-promising-phase-ii-kc1036-data-in-advanced-thymic-tumors-at-asco-2026/2026-05-29T14:39:09+08:00https://flcube.com/innovent-biologics-and-pfizer-forge-10-5b-global-oncology-partnership-spanning-12-first-in-class-programs/2026-05-29T14:29:50+08:00https://flcube.com/yoltech-therapeutics-secures-500m-series-c-financing-to-advance-in-vivo-gene-editing-pipeline-including-chinas-first-lnp-based-therapy/2026-05-29T14:25:03+08:00https://flcube.com/chinas-nhsa-proposes-first-national-basic-medical-insurance-medical-service-items-list-to-standardize-reimbursement-framework/2026-05-29T13:51:22+08:00https://flcube.com/jj-secures-fda-approval-for-tremfya-label-expansion-to-include-structural-joint-damage-inhibition-in-psoriatic-arthritis/2026-05-29T13:30:45+08:00https://flcube.com/suzhou-ribo-life-science-files-phase-ii-ema-application-for-rbd1119-novel-sirna-antithrombotic-for-coronary-artery-disease/2026-05-29T13:24:57+08:00https://flcube.com/longbio-pharma-raises-hkd-1-25-billion-in-hong-kong-ipo-clinical-stage-biotech-advances-anti-ige-and-bifunctional-complement-inhibitors-for-allergic-and-autoimmune-diseases/2026-05-28T22:35:18+08:00https://flcube.com/antengene-receives-nmpa-approval-for-phase-iii-clinch-3-trial-of-atg-022-cldn18-2-targeted-adc-advances-in-gastric-cancer-with-multi-region-clinical-strategy/2026-05-28T22:29:54+08:00https://flcube.com/jj-appoints-han-ting-as-shanghai-based-immunology-head-while-novartis-china-announces-major-restructuring-dual-leadership-shifts-signal-strategic-repositioning-in-china-market/2026-05-28T22:23:02+08:00https://flcube.com/sino-biopharmaceutical-presents-promising-phase-i-data-for-kylo-0603-at-easl-2026-thr-%ce%b2-agonist-shows-28-5-ldl-c-reduction-with-favorable-safety-profile/2026-05-28T22:11:13+08:00https://flcube.com/dizal-pharmaceuticals-zegfrovy-receives-priority-review-for-first-line-egfr-exon20ins-nsclc-phase-iii-wu-kong28-data-shows-significant-pfs-benefit-over-chemotherapy/2026-05-28T22:05:49+08:00https://flcube.com/lantheus-holdings-receives-7-billion-buyout-offer-from-curium-pharma-radiopharmaceutical-leaders-alzheimers-portfolio-attracts-strategic-interest/2026-05-28T21:59:25+08:00https://flcube.com/vectorbuilder-commits-50-million-to-chicago-biomanufacturing-hub-integrated-rd-and-gmp-facility-to-streamline-gene-delivery-product-development/2026-05-28T21:54:40+08:00https://flcube.com/sciclone-pharmaceuticals-launches-vibativ-in-china-dual-mechanism-glycopeptide-antibiotic-offers-enhanced-mrsa-treatment-with-once-daily-dosing/2026-05-28T21:49:08+08:00https://flcube.com/roche-launches-liver-disease-panel-digital-algorithms-combine-biomarker-diagnostics-with-ce-certified-liverpro-to-transform-chronic-liver-disease-management/2026-05-28T21:35:44+08:00https://flcube.com/abbvie-secures-fda-approval-for-decnupaz-in-blastic-plasmacytoid-dendritic-cell-neoplasm-first-cd123-targeting-adc-addresses-ultra-rare-hematologic-malignancy/2026-05-28T21:27:30+08:00https://flcube.com/innocare-pharma-secures-australian-tga-approval-for-hibruka-in-relapsed-refractory-mantle-cell-lymphoma-highly-selective-btk-inhibitor-expands-international-footprint/2026-05-28T21:24:35+08:00https://flcube.com/shanghai-yizhong-pharmas-trifunctional-antibody-fusion-protein-yxc-001-receives-ind-acceptance-in-china-novel-approach-targets-advanced-solid-tumors-with-precision-il-2-delivery/2026-05-28T21:20:26+08:00https://flcube.com/viridian-therapeutics-secures-commercial-manufacturing-agreement-with-wuxi-biologics-for-veligrotug-anti-igf-1r-antibody-advances-toward-thyroid-eye-disease-treatment/2026-05-28T21:14:33+08:00https://flcube.com/shanghai-pharma-and-trinomab-partner-to-commercialize-xintituo-in-philippines-worlds-first-recombinant-anti-tetanus-toxin-monoclonal-antibody-expands-overseas/2026-05-28T21:07:10+08:00https://flcube.com/shanghai-pharma-partners-with-beone-medicines-on-imdelltra-distribution-expanding-access-to-dll3-cd3-bispecific-t-cell-engager-in-china/2026-05-28T20:51:56+08:00https://flcube.com/shanghai-pharma-to-divest-30-stake-in-sino-american-squibb-for-147m/2026-05-28T20:43:18+08:00https://flcube.com/junshi-biosciences-completes-phase-iii-neotorch-study-of-toripalimab-in-perioperative-nsclc-plans-regulatory-filing/2026-05-27T21:33:00+08:00https://flcube.com/transthera-sciences-and-allist-pharmaceuticals-launch-phase-ii-combination-study-of-tt-00973-and-furmonertinib-in-egfr-mutant-nsclc/2026-05-27T21:28:56+08:00https://flcube.com/fosun-pharma-invests-rmb-220-million-in-hepa-thera-becomes-second-largest-shareholder-in-liver-disease-biotech/2026-05-27T21:19:13+08:00https://flcube.com/changchun-high-new-technology-industries-subsidiary-secures-nmpa-approval-for-gensci144-novel-oral-pku-treatment-targeting-slc6a19-transporter/2026-05-27T21:10:59+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-clinical-approvals-for-two-novel-anti-tumor-drug-candidates-shr-5421-and-hrs-1635/2026-05-27T21:05:26+08:00https://flcube.com/astellas-pharma-unveils-csp2026-strategic-plan-targeting-pipeline-driven-growth-and-strategic-brand-expansion/2026-05-27T20:56:14+08:00https://flcube.com/boston-scientific-danaher-and-siemens-healthineers-launch-a3-international-medical-technology-innovation-center-at-shanghai-eastern-hub/2026-05-27T20:50:36+08:00https://flcube.com/shanghai-henlius-biotech-initiates-phase-ii-iii-study-of-pimurutamab-hlx07-combination-therapy-in-first-line-advanced-squamous-nsclc/2026-05-27T20:38:59+08:00https://flcube.com/hengrui-pharmaceuticals-and-kailera-therapeutics-report-strong-phase-iii-results-for-oral-glp-1-agonist-hrs-7535-in-type-2-diabetes/2026-05-27T15:01:23+08:00https://flcube.com/insilico-medicine-and-human-longevity-spin-off-hlfm-launch-multi-million-dollar-ai-foundation-model-for-human-longevity-research/2026-05-27T14:53:20+08:00https://flcube.com/shanghai-henlius-biotech-doses-first-patient-in-china-for-global-phase-i-study-of-daratumumab-biosimilar-hlx15-sc-in-multiple-myeloma/2026-05-27T13:49:37+08:00https://flcube.com/eli-lilly-to-acquire-three-infectious-disease-companies-for-up-to-3-83-billion-expanding-vaccine-portfolio-beyond-traditional-therapeutics/2026-05-27T12:59:47+08:00https://flcube.com/shanghai-simpletouch-robot-files-for-hong-kong-ipo-advancing-percutaneous-puncture-surgical-robotics-platform/2026-05-27T12:57:11+08:00https://flcube.com/qingfeng-pharmaceutical-secures-greater-china-rights-to-merzs-inbrija-levodopa-inhalation-powder-for-parkinsons-disease-off-episodes/2026-05-26T22:10:51+08:00https://flcube.com/peak-pharmaceutical-partners-with-shanghai-pharma-subsidiary-to-optimize-neffy-supply-chain-and-channel-development-in-china/2026-05-26T15:08:34+08:00https://flcube.com/hotgen-biotech-secures-nmpa-clinical-filing-acceptance-for-sgc001-monoclonal-antibody-in-severe-acute-pancreatitis/2026-05-26T14:59:39+08:00https://flcube.com/nmpa-issues-comprehensive-guidelines-for-online-prescription-drug-retail-mandating-human-pharmacist-review-and-ai-prescription-blocking/2026-05-26T14:54:20+08:00https://flcube.com/changchun-high-new-technology-secures-nmpa-clinical-filing-acceptance-for-gensci144-slc6a19-inhibitor-in-chronic-kidney-disease/2026-05-26T14:51:32+08:00https://flcube.com/cansino-biologics-initiates-phase-i-ii-trial-for-pcv24-pneumococcal-conjugate-vaccine-with-enhanced-serotype-coverage/2026-05-26T14:44:58+08:00https://flcube.com/china-medical-system-secures-nmpa-approval-for-cms-d001-tyk2-inhibitor-in-ulcerative-colitis-and-crohns-disease/2026-05-26T14:35:25+08:00https://flcube.com/microport-neurotech-secures-fda-approval-for-numen-helia-spring-coil-system-advanced-solution-for-complex-neurovascular-lesions/2026-05-26T14:28:39+08:00https://flcube.com/eli-lilly-reports-positive-phase-1b-results-for-verve-102-base-editing-therapy-with-sustained-ldl-c-reductions-up-to-18-months/2026-05-26T14:22:05+08:00https://flcube.com/insilico-medicine-and-eterna-therapeutics-expand-ai-driven-partnership-into-skin-anti-aging-and-scientific-skincare/2026-05-26T14:19:12+08:00https://flcube.com/zbd-pharmaceutical-secures-marketing-rights-for-teruisis-cd20-targeted-adc-trs005-in-relapsed-refractory-non-hodgkin-lymphoma/2026-05-26T14:10:05+08:00https://flcube.com/pierre-fabre-secures-eu-recommendation-for-braftovi-combo-in-first-line-braf-v600e-mutant-metastatic-colorectal-cancer/2026-05-26T14:01:20+08:00https://flcube.com/otr-therapeutics-secures-nmpa-approval-for-phase-ib-ii-trial-of-otr-8100-best-in-class-small-molecule-inhibitor-for-malignant-tumors/2026-05-26T13:52:10+08:00https://flcube.com/d3-bio-secures-breakthrough-therapy-designation-for-elisrasib-next-generation-kras-g12c-inhibitor-for-first-line-nsclc/2026-05-26T13:44:22+08:00https://flcube.com/sinocelltech-files-for-hong-kong-secondary-listing-to-expand-global-capital-access-and-therapeutic-portfolio/2026-05-25T23:40:04+08:00https://flcube.com/lifetech-scientific-to-acquire-starway-medical-technology-in-276-million-deal-to-expand-structural-heart-portfolio/2026-05-25T23:34:39+08:00https://flcube.com/biocytogen-launches-rensuper-workstation-ai-driven-antibody-discovery-platform-to-transform-therapeutic-development/2026-05-25T23:31:43+08:00https://flcube.com/johnson-johnson-medtech-partners-with-beijing-shijitan-hospital-to-establish-chinas-first-split-type-surgical-robot-training-base/2026-05-25T23:28:01+08:00https://flcube.com/cloudbreak-pharma-submits-fda-ind-for-cbt-358-novel-sfa-technology-based-dry-eye-treatment/2026-05-25T23:24:42+08:00https://flcube.com/henlius-biotechs-pd-1-inhibitor-hetronifly-receives-chmp-recommendation-for-squamous-nsclc-in-eu/2026-05-25T23:20:51+08:00https://flcube.com/boehringer-ingelheims-ofev-receives-chmp-endorsement-for-idiopathic-and-progressive-pulmonary-fibrosis/2026-05-25T23:10:58+08:00https://flcube.com/regenerons-otarmeni-gene-therapy-accepted-for-ema-accelerated-review-as-first-potential-treatment-for-otof-related-hearing-loss/2026-05-25T23:04:19+08:00https://flcube.com/everest-medicines-secures-south-korean-approval-for-velsipity-in-ulcerative-colitis-following-pfizer-arena-legacy/2026-05-25T22:55:27+08:00https://flcube.com/jiangsu-chia-tai-tianqing-secures-nmpa-priority-review-for-lm-302-adc-in-cldn18-2-positive-gastric-cancer/2026-05-25T22:14:57+08:00https://flcube.com/lupin-secures-nmpa-approval-for-oseltamivir-phosphate-in-china-through-yabao-pharmaceuticals-partnership/2026-05-25T22:07:05+08:00https://flcube.com/gilead-sciences-secures-fda-accelerated-approval-for-hepcludex-as-first-us-treatment-for-hepatitis-delta-virus/2026-05-25T22:01:45+08:00https://flcube.com/abbvie-secures-chmp-positive-opinion-for-maviret-in-acute-hepatitis-c-treatment-across-all-age-groups/2026-05-25T21:56:14+08:00https://flcube.com/novo-nordisk-secures-chmp-positive-opinion-for-wegovy-7-2-mg-single-dose-pen-and-oral-semaglutide-in-eu-obesity-treatment/2026-05-25T21:36:53+08:00https://flcube.com/hangzhou-diagens-secures-nmpa-category-iii-approval-for-ai-autovision-chromosome-karyotyping-system/2026-05-25T21:26:41+08:00https://flcube.com/biogen-denali-terminate-parkinsons-drug-biib122-after-phase-iib-luma-study-failure/2026-05-25T21:18:37+08:00https://flcube.com/junshi-biosciences-secures-nmpa-approval-for-loqtorzi-combination-therapy-in-her2-expressing-urothelial-carcinoma/2026-05-24T11:32:47+08:00https://flcube.com/junshi-biosciences-partners-with-antengene-on-cancer-combination-js207-pd-1-vegf-bispecific-plus-atg-037-cd73-inhibitor/2026-05-24T11:29:03+08:00https://flcube.com/shanghai-henlius-biotech-secures-australian-tga-approval-for-phase-i-trial-of-hlx3902-trispecific-t-cell-engager-in-prostate-cancer/2026-05-24T11:25:40+08:00https://flcube.com/shanghai-henlius-biotech-secures-nmpa-approval-for-phase-i-trial-of-hlx48-bispecific-adc-in-advanced-solid-tumors/2026-05-24T11:22:24+08:00https://flcube.com/sino-biopharmaceutical-presents-positive-phase-iii-and-ii-data-for-m701-bispecific-antibody-at-asco-2026/2026-05-24T11:18:47+08:00https://flcube.com/qyuns-therapeutics-and-huadong-medicine-secure-nmpa-approval-for-stelara-biosimilar-hdm3001-2-qx001s-in-crohns-disease/2026-05-24T11:15:21+08:00https://flcube.com/3d-medicines-enrolls-first-patient-in-pivotal-phase-iii-trial-of-envafolimab-for-resectable-nsclc/2026-05-24T11:11:30+08:00https://flcube.com/zai-lab-announces-executive-leadership-reshuffle-as-coo-josh-smiley-steps-down-after-nearly-four-years/2026-05-23T22:28:18+08:00https://flcube.com/allergan-aesthetics-secures-chmp-positive-opinion-for-boey-trenibotulinumtoxine-in-glabellar-lines-treatment-across-european-economic-area/2026-05-23T22:11:19+08:00https://flcube.com/lupeng-pharma-enrolls-first-patient-in-global-phase-3-rocket-cll-trial-of-fourth-gen-btk-inhibitor-rocbrutinib-vs-pirtobrutinib/2026-05-23T22:08:49+08:00https://flcube.com/eli-lillys-retatrutide-delivers-breakthrough-weight-loss-results-in-phase-3-triumph-1-trial-for-obesity-treatment/2026-05-22T22:51:48+08:00https://flcube.com/merck-kgaa-launches-phase-iii-proceade-crc-03-trial-for-first-in-class-ceacam5-adc-precemtabart-tocentecan-in-metastatic-colorectal-cancer/2026-05-22T22:14:54+08:00https://flcube.com/astellas-and-msds-padcev-keytruda-combination-receives-positive-chmp-opinion-for-muscle-invasive-bladder-cancer-in-eu/2026-05-22T21:35:48+08:00https://flcube.com/hansoh-pharmas-hs-10504-receives-nmpa-breakthrough-therapy-designation-for-fourth-generation-egfr-inhibitor-in-resistant-nsclc/2026-05-22T21:29:39+08:00https://flcube.com/bayers-kerendia-receives-fda-priority-review-for-expanded-indication-in-type-1-diabetes-associated-chronic-kidney-disease/2026-05-22T21:26:31+08:00https://flcube.com/gilead-sciences-launches-five-year-who-partnership-to-accelerate-elimination-of-visceral-leishmaniasis-in-high-burden-regions/2026-05-22T21:21:05+08:00https://flcube.com/johnson-johnson-partners-with-abu-dhabi-doh-to-launch-global-surgical-intelligence-network-powered-by-polyphonic-platform/2026-05-22T21:15:28+08:00https://flcube.com/eli-lilly-acquires-engage-biologics-for-202m-to-bolster-genetic-medicines-portfolio-with-tethosome-platform/2026-05-22T21:11:13+08:00https://flcube.com/yangtze-river-pharma-secures-nmpa-approval-for-fazamorexant-next-generation-dora-for-insomnia-treatment/2026-05-22T21:06:27+08:00https://flcube.com/boehringer-ingelheim-and-sino-biopharmaceutical-secure-nmpa-conditional-approval-for-hernexeos-in-first-line-her2-mutant-nsclc-with-76-response-rate/2026-05-21T20:55:03+08:00https://flcube.com/jenscares-lux-valve-plus-demonstrates-97-8-efficacy-in-tricuspid-regurgitation-reduction-in-global-eu-trinity-study-12-month-follow-up/2026-05-21T14:38:40+08:00https://flcube.com/bayzed-health-group-partners-with-microport-subsidiaries-to-establish-specialized-cardiovascular-and-surgical-robot-centers-across-hospital-network/2026-05-21T14:29:41+08:00https://flcube.com/transcenta-and-inhibrx-report-20-response-rate-for-ozekibart-in-heavily-pretreated-colorectal-cancer-following-recent-fda-filing-for-chondrosarcoma/2026-05-21T14:20:37+08:00https://flcube.com/sino-medical-sciences-secures-eu-label-update-for-ht-supreme-stent-enabling-one-month-dual-antiplatelet-therapy/2026-05-21T14:13:34+08:00https://flcube.com/mabwell-bioscience-secures-second-nmpa-approval-for-denosu-biosimilar-expanding-indication-to-bone-metastases-and-multiple-myeloma/2026-05-21T14:08:44+08:00https://flcube.com/pfizers-25-valent-pneumococcal-vaccine-candidate-shows-superior-serotype-3-response-in-phase-ii-infant-study/2026-05-21T13:51:34+08:00https://flcube.com/medtronic-to-acquire-spr-therapeutics-for-650-million-expanding-chronic-pain-management-portfolio/2026-05-21T13:42:51+08:00https://flcube.com/beone-medicines-launches-one-save-changes-everything-global-cancer-care-initiative-partnering-with-soccer-legend-tim-howard/2026-05-21T13:35:27+08:00https://flcube.com/bristol-myers-squibb-partners-with-anthropic-to-deploy-claude-ai-across-enterprise-signaling-strategic-shift-to-agentic-workflows/2026-05-21T13:28:44+08:00https://flcube.com/cbc-group-and-global-healthcare-opportunities-merge-to-create-21-billion-healthcare-investment-colossus/2026-05-20T17:42:57+08:00https://flcube.com/sanofis-efdoralprin-alfa-demonstrates-superior-faat-normalization-in-alpha-1-antitrypsin-deficiency-phase-ii-elevaate-study/2026-05-20T17:39:59+08:00https://flcube.com/takeda-faces-885m-antitrust-verdict-in-amitiza-pay-for-delay-litigation-damages-to-be-trebled-under-u-s-law/2026-05-20T14:06:12+08:00https://flcube.com/novartis-pluvicto-demonstrates-significant-psa-response-improvement-in-psma-positive-mhspc-patients-in-psmaddition-study/2026-05-20T13:57:45+08:00https://flcube.com/china-population-welfare-foundation-and-lilly-china-launch-tuohu-changan-patient-assistance-program-for-inflammatory-bowel-disease/2026-05-20T13:50:45+08:00https://flcube.com/hybio-pharmaceutical-partners-with-undisclosed-chinese-firms-for-glp-1-api-commercialization-in-americas-markets/2026-05-20T13:44:52+08:00https://flcube.com/shanghai-zj-bio-tech-secures-international-approvals-for-molecular-diagnostic-platforms-in-netherlands-and-mexico/2026-05-20T13:38:10+08:00https://flcube.com/shandong-buchang-pharmaceuticals-secures-exclusive-license-for-kyn003-broad-spectrum-influenza-vaccine-through-strategic-partnership-with-hefei-keyinuo/2026-05-20T12:34:22+08:00https://flcube.com/bayers-asundexian-receives-fda-priority-review-for-secondary-stroke-prevention-following-positive-phase-iii-oceanic-stroke-trial/2026-05-20T12:29:45+08:00https://flcube.com/ucbs-bimzelx-demonstrates-superior-joint-outcomes-vs-skyrizi-in-phase-iii-be-bold-trial-for-psoriatic-arthritis/2026-05-20T12:26:14+08:00https://flcube.com/united-laboratories-secures-nmpa-tacit-approval-for-tul108-clinical-study-in-china-following-us-trial-authorization/2026-05-20T12:20:41+08:00https://flcube.com/immuneonco-doses-first-patient-in-phase-ii-trial-of-imm0306-for-systemic-lupus-erythematosus/2026-05-20T12:17:10+08:00https://flcube.com/bio-thera-solutions-secures-fda-approval-for-golimumab-biosimilars-immgolis-and-immgolis-intri/2026-05-19T23:54:12+08:00https://flcube.com/gsk-restructures-china-vaccine-business-with-dedicated-shingrix-and-engerix-b-teams/2026-05-19T23:51:10+08:00https://flcube.com/boston-scientific-invests-1-5b-for-34-stake-in-mirus-secures-option-to-acquire-siegel-tavr-business-for-additional-3b/2026-05-19T23:47:51+08:00https://flcube.com/henlius-biotech-secures-exclusive-china-rights-to-ctfhs-third-generation-egfr-tki-fhnd9041-for-nsclc/2026-05-19T23:43:48+08:00https://flcube.com/lundbecks-asedebart-receives-japanese-orphan-drug-designation-for-congenital-adrenal-hyperplasia-and-cushings-disease/2026-05-19T23:20:40+08:00https://flcube.com/leads-biolabs-opamtistomig-becomes-worlds-first-4-1bb-bispecific-antibody-to-enter-pivotal-phase-iii-for-ep-nec/2026-05-19T23:16:44+08:00https://flcube.com/cspc-pharmaceutical-receives-nmpa-clinical-trial-approval-for-syh2095-worlds-first-kat6-inhibitor/2026-05-19T23:12:23+08:00https://flcube.com/regeneron-partners-with-parabilis-medicines-on-2-2b-helicon-peptide-platform-deal-targeting-undruggable-proteins/2026-05-19T23:08:33+08:00https://flcube.com/boehringer-ingelheims-jascayd-nerandomilast-approved-in-japan-for-ipf-and-progressive-pulmonary-fibrosis/2026-05-19T23:05:07+08:00https://flcube.com/bayers-hyrnuo-receives-fda-priority-review-for-first-line-her2-mutated-nsclc-treatment/2026-05-19T23:00:18+08:00https://flcube.com/shimai-pharmaceutical-files-hong-kong-ipo-prospectus-with-advanced-t-cell-engager-pipeline/2026-05-19T22:44:42+08:00https://flcube.com/sanegene-bios-c3-targeted-sirna-sgb-9768-expands-to-hematological-disorders-following-nmpa-clinical-trial-approval/2026-05-19T22:31:07+08:00https://flcube.com/youcare-pharmaceutical-commits-147m-to-build-nucleic-acid-drug-manufacturing-base-in-hangzhou-biopharma-town/2026-05-19T22:22:37+08:00https://flcube.com/hengruis-her3-targeting-adc-shr-a2009-achieves-phase-iii-success-in-egfr-mutated-nsclc-after-tki-failure/2026-05-19T21:57:10+08:00https://flcube.com/brightgene-pursues-hong-kong-secondary-listing-as-global-api-and-intermediates-leader/2026-05-19T21:46:07+08:00https://flcube.com/china-tightens-medical-insurance-personal-account-oversight-with-mandatory-white-list-for-retail-pharmacy-purchases/2026-05-19T20:24:25+08:00https://flcube.com/mercks-sacituzumab-tirumotecan-demonstrates-first-ever-os-and-pfs-benefit-in-phase-3-endometrial-cancer-trial/2026-05-19T20:09:01+08:00https://flcube.com/bayzed-health-and-meinian-onehealth-forge-strategic-partnership-to-build-integrated-full-cycle-health-management-ecosystem/2026-05-19T20:01:02+08:00https://flcube.com/ande-healthcare-files-hong-kong-ipo-prospectus-as-leading-chinese-medical-consumables-innovator/2026-05-19T19:55:37+08:00https://flcube.com/gsks-arexvy-rsv-vaccine-receives-expanded-japanese-approval-for-adults-18-49-at-increased-risk/2026-05-19T19:44:18+08:00https://flcube.com/taiji-industry-secures-nmpa-clinical-trial-approval-for-dsc158a-next-generation-influenza-rna-polymerase-inhibitor/2026-05-19T19:38:10+08:00https://flcube.com/accro-bioscience-secures-50m-series-c-to-advance-ripk2-inhibitor-ac-101-into-phase-iib-ulcerative-colitis-trial/2026-05-19T19:34:45+08:00https://flcube.com/full-life-technologies-secures-150m-financing-to-advance-radiopharmaceutical-pipeline-and-establish-independent-actinium-225-production/2026-05-19T19:05:33+08:00https://flcube.com/viatris-submits-fast-acting-meloxicam-nda-to-fda-for-moderate-to-severe-acute-pain-decision-expected-december-2026/2026-05-19T18:57:33+08:00https://flcube.com/bms-partners-with-tigerlily-foundation-to-address-racial-disparities-in-breast-cancer-clinical-trial-access-pharma-giant-commits-to-improving-representation-of-young-women-of-color/2026-05-18T23:24:54+08:00https://flcube.com/regenerons-fianlimab-cemiplimab-combination-fails-to-meet-primary-endpoint-in-phase-iii-melanoma-trial-lag-3-pd-1-dual-therapy-shows-no-pfs-benefit-over-pembrolizumab-monotherapy/2026-05-18T23:19:36+08:00https://flcube.com/astrazenecas-baxfendy-secures-fda-approval-for-uncontrolled-hypertension-first-in-class-aldosterone-synthase-inhibitor-with-selective-cyp11b2-targeting/2026-05-18T22:52:50+08:00https://flcube.com/harbour-biomed-unveils-preclinical-data-for-let003-ai-discovered-acvr2a-2b-antibody-shows-best-in-class-potential-in-obesity-combination-therapy-with-glp-1-drugs/2026-05-18T14:56:42+08:00https://flcube.com/allogene-therapeutics-terminates-asian-car-t-joint-venture-with-overland-pharmaceuticals-strategic-retreat-from-allogeneic-cell-therapy-market-in-asia/2026-05-18T14:50:35+08:00https://flcube.com/astrazeneca-and-daiichi-sankyos-enhertu-secures-dual-fda-approval-for-her2-positive-early-breast-cancer-neoadjuvant-and-adjuvant-indications-supported-by-landmark-phase-3-data/2026-05-18T14:43:18+08:00https://flcube.com/roches-tecentriq-secures-fda-approval-for-ctdna-guided-adjuvant-treatment-in-muscle-invasive-bladder-cancer-first-mrd-directed-immunotherapy-with-41-mortality-reduction/2026-05-18T13:32:08+08:00https://flcube.com/biogens-zorevunersen-receives-china-breakthrough-therapy-designation-for-dravet-syndrome-first-aso-targeting-scn1a-gene-in-rare-epileptic-encephalopathy/2026-05-18T13:22:05+08:00https://flcube.com/shanghai-curegenes-cg-0255-receives-nmpa-clearance-for-ischemic-stroke-clinical-trial-first-thiol-based-p2y12-inhibitor-overcoming-clopidogrel-resistance/2026-05-18T13:17:10+08:00https://flcube.com/shenzhen-salubris-secures-chinese-approval-for-xinfutai-plus-first-once-weekly-teriparatide-for-high-risk-postmenopausal-osteoporosis/2026-05-18T13:11:04+08:00https://flcube.com/changchun-genesciences-gensci161-receives-fda-clearance-for-hidradenitis-suppurativa-clinical-trial-novel-bispecific-antibody-targeting-il-1%ce%b1-il-1%ce%b2/2026-05-18T12:48:38+08:00https://flcube.com/alibaba-health-reports-strong-fy2026-results-with-35-2-profit-growth-and-launches-medical-llm-h/2026-05-15T14:12:24+08:00https://flcube.com/amgens-izervay-nda-accepted-by-nmpa-for-geographic-atrophy-secondary-to-age-related-macular-degeneration/2026-05-15T13:57:43+08:00https://flcube.com/china-issues-national-guidelines-for-home-hospital-bed-services-to-address-healthcare-access-for-vulnerable-populations/2026-05-15T13:47:35+08:00https://flcube.com/chongqing-genrix-bio-receives-nmpa-clinical-approval-for-gr1803-bispecific-antibody-in-relapsed-refractory-multiple-myeloma/2026-05-15T13:43:48+08:00https://flcube.com/astrazeneca-reports-positive-phase-iii-volga-interim-results-for-imfinzi-based-combinations-in-muscle-invasive-bladder-cancer/2026-05-15T13:38:56+08:00https://flcube.com/chipscreen-biosciences-secures-macao-market-approval-for-bilessglu-chiglitazar-novel-ppar-pan-agonist-for-type-2-diabetes/2026-05-15T13:25:59+08:00https://flcube.com/biogen-reports-positive-phase-ii-celia-results-for-diranersen-first-in-class-tau-targeting-aso-therapy-in-early-alzheimers-disease/2026-05-15T13:16:00+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-clinical-approval-for-rss0393-latex-in-atopic-dermatitis-treatment/2026-05-15T13:09:53+08:00https://flcube.com/eli-lilly-commits-50m-to-unicef-usa-alliance-targeting-non-communicable-disease-prevention-in-children-across-21-lmics/2026-05-15T12:49:41+08:00https://flcube.com/sichuan-biokin-receives-nmpa-go-ahead-for-si-b036-bispecific-antibody-clinical-study-in-advanced-solid-tumors/2026-05-15T12:28:41+08:00https://flcube.com/hansoh-pharma-receives-nmpa-approval-for-hs-10541-phase-i-trial-category-1-kras-g12c-inhibitor-targets-advanced-solid-tumors/2026-05-14T20:41:33+08:00https://flcube.com/basecare-medical-device-secures-nmpa-approval-for-gems-embryo-culture-medium-chinese-ivf-specialist-completes-global-regulatory-triad/2026-05-14T20:35:22+08:00https://flcube.com/pfizers-hympavzi-gains-european-approval-for-hemophilia-with-inhibitors-novel-tfpi-targeting-therapy-offers-weekly-subcutaneous-alternative-to-factor-replacement/2026-05-14T20:18:34+08:00https://flcube.com/henlius-biotech-secures-australian-tga-approval-for-hlx48-phase-i-trial-novel-egfr-c-met-bispecific-adc-targets-advanced-solid-tumors/2026-05-14T20:06:17+08:00https://flcube.com/takeda-reports-28-5b-revenue-in-fy2025-despite-vyvanse-patent-cliff-78-net-profit-surge-amid-1-26b-restructuring-plan/2026-05-14T19:56:19+08:00https://flcube.com/takeda-q3-revenue-drops-3-3-on-vyvanse-generics-raises-full-year-forecast/2026-05-14T19:54:55+08:00https://flcube.com/takeda-ends-128m-kyoto-university-ipsc-project-after-decade-of-research/2026-05-14T19:54:54+08:00https://flcube.com/takeda-enters-1-7-billion-ai-drug-discovery-partnership-with-iambic-therapeutics/2026-05-14T19:54:53+08:00https://flcube.com/takedas-oveporexton-wins-fda-priority-review-for-narcolepsy-type-1-potential-first-orexin-agonist/2026-05-14T19:54:52+08:00https://flcube.com/chinas-cde-reports-record-drug-review-activity-in-2025-breakthrough-therapy-designations-surge-11-as-regulatory-filings-hit-20149/2026-05-14T19:42:41+08:00https://flcube.com/shanghai-implements-fixed-amount-reimbursement-model-for-11th-nvbp-drugs-patients-bear-excess-costs-above-winning-prices/2026-05-14T19:33:14+08:00https://flcube.com/novo-nordisks-wegovy-shows-21-6-weight-loss-in-early-responders-oasis-4-subgroup-analysis-reveals-clinically-meaningful-benefits-across-patient-populations/2026-05-14T15:05:02+08:00https://flcube.com/abb-bio-tech-launches-phase-i-ii-trial-of-recombinant-rsv-vaccine-cho-cell-derived-adjuvanted-candidate-shows-enhanced-pre-f-protein-expression-and-stability/2026-05-14T14:36:05+08:00https://flcube.com/tennor-therapeutics-raises-71m-in-hong-kong-ipo-antimicrobial-pipeline-targets-h-pylori-and-implant-associated-infections/2026-05-14T14:28:43+08:00https://flcube.com/kanghong-pharmas-gene-therapy-khn921-receives-fda-approval-for-hypertrophic-cardiomyopathy-trial-aav9-vector-targets-mybpc3-mutations-with-potential-one-time-treatment/2026-05-14T14:19:52+08:00https://flcube.com/innocare-pharma-doses-first-patient-in-icp-054-zb021-trial-novel-oral-il-17aa-af-inhibitor-shows-promise-for-autoimmune-diseases/2026-05-14T14:05:11+08:00https://flcube.com/hengrui-pharma-launches-phase-ib-ii-trial-of-novel-triple-combination-therapy-shr-3821-with-adebrelimab-and-reltirafusp-alfa-targets-advanced-solid-tumors/2026-05-14T13:57:40+08:00https://flcube.com/beone-medicines-bcl2-inhibitor-beqalzi-sonrotoclax-receives-fda-fast-track-for-relapsed-mantle-cell-lymphoma-52-response-rate-in-phase-i-ii-study/2026-05-14T13:48:03+08:00https://flcube.com/chinas-nhsa-unveils-five-year-medical-insurance-fund-supervision-plan-2026-2030-ai-powered-oversight-to-combat-fraud-across-healthcare-ecosystem/2026-05-14T13:33:11+08:00https://flcube.com/zhongsheng-pharmas-onradivir-anruiwei-receives-nmpa-review-acceptance-for-pediatric-influenza-a-indication-phase-iii-data-shows-favorable-efficacy-vs-tamiflu/2026-05-14T13:27:29+08:00https://flcube.com/huadong-medicine-receives-nmpa-approval-for-hdm2017-adc-trial-in-colorectal-cancer-cadherin-17-targeting-therapy-shows-broad-solid-tumor-potential/2026-05-14T13:21:59+08:00https://flcube.com/fosun-pharma-secures-global-rights-to-aribios-alzheimers-drug-ar1001-in-240m-deal-pde-5-inhibitor-shows-promise-in-phase-iii/2026-05-14T13:15:54+08:00https://flcube.com/shanghai-henlius-biotech-doses-first-patient-in-phase-i-trial-of-hlx97-novel-kat6a-b-inhibitor-for-advanced-solid-tumors/2026-05-14T13:04:37+08:00https://flcube.com/merck-co-forges-four-strategic-partnerships-with-chinese-biotechs-to-advance-autoimmune-and-oncology-pipeline-through-mcicc-platform/2026-05-14T00:07:54+08:00https://flcube.com/eli-lilly-reports-long-term-weight-loss-maintenance-with-foundayo-and-lower-dose-zepbound-in-phase-3-trials/2026-05-13T23:53:27+08:00https://flcube.com/legend-biotech-reports-56-q1-revenue-growth-to-305m-driven-by-carvykti-sales-surge-and-jj-milestone-payment/2026-05-13T23:48:53+08:00https://flcube.com/shanghai-immunocan-biotech-secures-rmb-250m-series-a-led-by-vivo-capital-to-advance-gene-edited-antibody-discovery-platforms/2026-05-13T23:39:08+08:00https://flcube.com/sichuan-kelun-biotech-receives-nmpa-approval-for-itgb6-targeted-adc-skb105-in-advanced-solid-tumors-following-crescent-biopharma-licensing-deal/2026-05-13T23:37:18+08:00https://flcube.com/shenzhen-weiguang-biological-to-raise-rmb-1-5b-in-private-placement-to-fund-smart-industrial-base-expansion/2026-05-13T23:32:03+08:00https://flcube.com/cellular-intelligence-acquires-global-rights-to-novo-nordisks-parkinsons-cell-therapy-program-plans-ai-driven-acceleration/2026-05-13T23:27:27+08:00https://flcube.com/porton-advanced-solutions-and-dark-horse-consulting-forge-strategic-alliance-to-accelerate-global-cell-and-gene-therapy-development/2026-05-13T23:21:25+08:00https://flcube.com/serviers-b7-h4-adc-emiltatug-ledadotin-receives-fda-breakthrough-therapy-designation-for-advanced-adenoid-cystic-carcinoma/2026-05-13T23:00:23+08:00https://flcube.com/immuneonco-receives-nmpa-approval-for-imm0306-clinical-study-in-primary-sjogrens-syndrome-expanding-dual-target-bispecific-platform/2026-05-13T22:49:39+08:00https://flcube.com/bayer-reports-4-1-q1-sales-growth-to-e13-4b-with-mixed-pharmaceutical-performance-amid-ira-impact-and-generic-competition/2026-05-13T22:35:51+08:00https://flcube.com/boehringer-ingelheim-secures-global-rights-to-immunitas-first-in-class-antibody-program-for-chronic-inflammatory-diseases-in-e407-5m-deal/2026-05-13T22:25:13+08:00https://flcube.com/roche-secures-ce-mark-for-elecsys-ptau217-blood-test-first-single-assay-alzheimers-diagnostic-with-amyloid-pathology-detection/2026-05-13T22:20:31+08:00https://flcube.com/alphamab-oncology-initiates-phase-ii-trial-of-subcutaneous-co-formulation-jskn033-in-first-line-advanced-cervical-cancer/2026-05-13T22:16:16+08:00https://flcube.com/bio-theras-cd25-targeted-adc-bat8013-receives-nmpa-approval-for-advanced-solid-tumor-clinical-studies-in-china/2026-05-13T22:09:06+08:00https://flcube.com/sichuan-biokins-bispecific-adc-iza-bren-receives-nmpa-approval-for-nsclc-clinical-study-in-china/2026-05-13T21:58:00+08:00https://flcube.com/hong-kong-to-launch-fda-style-medical-products-regulation-center-by-year-end-creating-gateway-for-chinese-innovative-drugs/2026-05-13T21:52:00+08:00https://flcube.com/changchun-genescience-receives-nmpa-approval-for-firsekibart-phase-iii-trial-in-gout-flare-prevention-during-urate-lowering-therapy/2026-05-13T21:45:41+08:00https://flcube.com/macrogenics-sells-gmp-compliant-api-manufacturing-business-to-bora-pharmaceuticals-for-122-5-million/2026-05-13T21:27:21+08:00https://flcube.com/merus-bizengri-becomes-first-fda-approved-therapy-for-nrg1-fusion-positive-cholangiocarcinoma/2026-05-12T20:40:11+08:00https://flcube.com/zai-lab-secures-fda-fast-track-designation-for-dll3-targeting-adc-zocilurtatug-pelitecan-in-extrapulmonary-nec/2026-05-12T20:31:11+08:00https://flcube.com/mindray-bio-medical-re-files-for-hong-kong-listing-after-initial-application-expiration/2026-05-12T20:26:18+08:00https://flcube.com/ribo-life-science-files-ema-application-for-vortosiran-phase-iib-study-in-venous-thromboembolism-prevention/2026-05-12T20:10:55+08:00https://flcube.com/haisco-pharmaceuticals-sishujing-seeks-postoperative-pain-indication-expanding-peripheral-kappa-agonist-franchise/2026-05-12T20:04:51+08:00https://flcube.com/daiichi-sankyo-unveils-ambitious-five-year-plan-targeting-19b-revenue-and-top-five-global-oncology-position/2026-05-12T19:57:40+08:00https://flcube.com/juventas-cell-therapys-car-t-yuanruida-seeks-pediatric-all-indication-expanding-chinas-only-dual-malignancy-car-t-franchise/2026-05-12T19:51:31+08:00https://flcube.com/hengrui-and-braveheart-bio-report-positive-phase-2-results-for-next-gen-cardiac-myosin-inhibitor-hrs-1893-in-non-obstructive-hcm/2026-05-12T19:45:56+08:00https://flcube.com/akari-therapeutics-partners-with-wuxi-xdc-to-advance-novel-ph1-payload-platform-for-urothelial-cancer/2026-05-12T15:13:43+08:00https://flcube.com/nmpa-releases-105th-batch-of-generic-drug-reference-standards-adding-37-new-specifications/2026-05-12T15:08:33+08:00https://flcube.com/china-medical-system-secures-exclusive-china-rights-to-pharmacosmos-monofer-and-cosmofer-iv-iron-therapies/2026-05-12T15:06:23+08:00https://flcube.com/yifan-pharmaceutical-licenses-ryzneuta-to-french-distributor-intsel-chimos-for-exclusive-commercialization/2026-05-12T15:00:36+08:00https://flcube.com/hybio-pharmaceutical-expands-torrent-pharma-partnership-with-lanreotide-acetate-for-u-s-market/2026-05-12T14:51:32+08:00https://flcube.com/hybio-pharmaceutical-licenses-glp-1-copycats-to-mcg-pharma-for-exclusive-turkish-commercialization/2026-05-12T14:45:23+08:00https://flcube.com/tortugas-neuroscience-raises-106m-in-seed-and-series-a-financing-to-advance-cns-pipeline-from-eisai-and-hansoh/2026-05-12T14:32:36+08:00https://flcube.com/cue-biopharma-licenses-ascendant-221-anti-ige-antibody-for-691-5m-deal-excluding-greater-china/2026-05-12T14:21:20+08:00https://flcube.com/zhejiang-shapuaisi-acquires-myopia-treatment-technology-from-wenzhou-medical-university-eye-hospital-for-10-million-plus-royalties/2026-05-12T14:05:58+08:00https://flcube.com/beijing-sun-novo-partners-with-chinese-academy-of-medical-sciences-on-category-1-antibacterial-drug-imb0304/2026-05-12T13:59:26+08:00https://flcube.com/cspc-pharmaceutical-secures-second-breakthrough-therapy-designation-for-egfr-targeting-adc-sys-6010-in-esophageal-cancer/2026-05-12T13:39:39+08:00https://flcube.com/amoydx-pcr11-companion-diagnostic-approved-in-japan-for-johnson-johnsons-rybrevant-in-nsclc-with-egfr-exon-20-insertions/2026-05-12T13:20:28+08:00https://flcube.com/clinchoice-acquires-cromsource-to-expand-global-cro-footprint/2026-05-12T13:13:42+08:00https://flcube.com/cansino-biologics-five-component-pertussis-vaccine-enters-nmpa-priority-review-for-ages-6/2026-05-12T11:30:44+08:00https://flcube.com/gsk-partners-with-sino-biopharmaceuticals-cttq-subsidiary-to-commercialize-bepirovirsen-in-chinas-hepatitis-b-market/2026-05-11T15:07:22+08:00https://flcube.com/starna-therapeutics-closes-40m-series-b-round-to-advance-in-vivo-car-t-and-extrahepatic-mrna-delivery-platforms/2026-05-11T12:39:06+08:00https://flcube.com/henlius-biotech-expands-european-footprint-with-two-additional-ec-approvals-for-hansizhuang-pd-1-inhibitor/2026-05-11T12:34:10+08:00https://flcube.com/henlius-biotech-receives-fda-clearance-for-phase-i-trial-of-hlx05-n-cetuximab-biosimilar-in-metastatic-colorectal-cancer/2026-05-11T12:28:40+08:00https://flcube.com/microport-cardioflow-secures-ce-mark-for-eno-series-pacemakers-with-advanced-lbbap-capability/2026-05-11T12:25:23+08:00https://flcube.com/hansoh-pharmaceuticals-b7-h3-adc-hs-20093-receives-fifth-nmpa-breakthrough-therapy-designation-for-esophageal-cancer/2026-05-11T12:17:09+08:00https://flcube.com/cstone-pharmaceuticals-launches-first-commercial-batch-of-gavreto-in-china-following-nrdl-inclusion/2026-05-11T12:13:47+08:00https://flcube.com/nhsa-launches-2026-nrdl-adjustment-with-expanded-eligibility-criteria-and-revised-weight-standards/2026-05-11T12:04:49+08:00https://flcube.com/wenda-pharmaceutical-secures-nmpa-breakthrough-therapy-designation-for-nhwd-870-in-rare-nut-carcinoma/2026-05-09T21:39:12+08:00https://flcube.com/european-commission-approves-bristol-myers-squibbs-sotyktu-for-psoriatic-arthritis-following-fda-clearance/2026-05-09T21:28:43+08:00https://flcube.com/curegene-pharmaceutical-secures-rmb-300-million-series-c-to-advance-global-clinical-pipeline/2026-05-09T21:21:52+08:00https://flcube.com/keymed-biosciences-secures-nmpa-breakthrough-therapy-designation-for-cm336-in-al-amyloidosis/2026-05-09T21:16:03+08:00https://flcube.com/innovent-biologics-secures-third-breakthrough-therapy-designation-for-ibi363-in-mss-pmmr-colorectal-cancer/2026-05-09T21:11:47+08:00https://flcube.com/bristol-myers-squibb-reports-11-49-billion-q1-revenue-with-strong-growth-portfolio-performance/2026-05-09T21:05:29+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-clinical-approval-for-kras-g12d-inhibitor-hrs-6093-and-multiple-combination-regimens-in-advanced-solid-tumors/2026-05-09T15:19:48+08:00https://flcube.com/kelun-biotech-submits-new-nmpa-filing-for-jaitailai-in-first-line-nsclc-combination-therapy-with-keytruda/2026-05-09T15:13:56+08:00https://flcube.com/abb-bio-tech-secures-nmpa-clinical-approval-for-mrna-rsv-vaccine-addressing-critical-unmet-need-in-china/2026-05-09T15:09:35+08:00https://flcube.com/mabwell-bioscience-secures-fda-clearance-for-9mw5211-in-ibd-advances-multi-indication-autoimmune-pipeline/2026-05-09T15:06:25+08:00https://flcube.com/hengrui-pharmaceuticals-expands-greater-bay-area-presence-with-hong-kong-office-launch-and-cancer-foundation-partnership/2026-05-09T15:02:25+08:00https://flcube.com/allergan-aesthetics-secures-first-in-china-nmpa-approval-for-juvederm-voluma-temple-indication/2026-05-09T14:58:03+08:00https://flcube.com/harbour-biomed-receives-fda-clearance-for-phase-i-trial-of-novel-b7h4xcd3-bispecific-antibody-hbm7004/2026-05-09T14:51:57+08:00https://flcube.com/fosun-pharma-secures-exclusive-china-rights-to-inxmeds-fak-inhibitors-for-solid-tumor-treatment/2026-05-09T14:48:35+08:00https://flcube.com/johnson-johnson-terminates-two-car-t-development-programs-amid-portfolio-prioritization/2026-05-09T14:44:16+08:00https://flcube.com/chinas-national-drug-alliance-procurement-office-suspends-harbin-liqiangs-loxoprofen-gel-patch-production-and-imposes-18-month-vbp-ban/2026-05-08T20:11:25+08:00https://flcube.com/harbour-biomed-joins-165m-cross-financing-round-for-windward-bio-to-advance-ultra-long-acting-tslp-immunotherapies/2026-05-08T20:06:42+08:00https://flcube.com/huadong-medicines-asthma-drug-cxg87-receives-nmpa-filing-acceptance-following-successful-phase-iii-trial-against-symbicort/2026-05-08T20:00:03+08:00https://flcube.com/eli-lilly-reports-56-revenue-surge-in-q1-2026-driven-by-mounjaro-and-zepbound-dominance-raises-full-year-guidance/2026-05-08T15:10:30+08:00https://flcube.com/zai-lab-reports-q1-2026-revenue-decline-amid-zejula-impact-from-centralized-procurement-offset-by-xacduro-growth/2026-05-08T15:03:34+08:00https://flcube.com/wuxi-biologics-licenses-clinical-stage-t-cell-engager-to-zai-lab-for-solid-tumor-development/2026-05-08T14:58:35+08:00https://flcube.com/novocures-optune-pax-wins-fda-approval-for-pancreatic-cancer-zai-lab-china-rights-in-play/2026-05-08T14:58:35+08:00https://flcube.com/sciclon-licenses-augtyro-promotion-rights-from-zai-lab-for-china-market/2026-05-08T14:58:35+08:00https://flcube.com/zai-lab-reports-457m-full-year-revenue-16-growth-driven-by-xacduro-and-nuzyra-expansion/2026-05-08T14:58:35+08:00https://flcube.com/viatris-reports-8-revenue-growth-in-q1-2026-fueled-by-greater-china-surge-and-brand-portfolio-strength/2026-05-08T14:55:05+08:00https://flcube.com/gilead-sciences-reports-4-revenue-growth-in-q1-2026-driven-by-hiv-portfolio-strength-and-trodelvy-expansion/2026-05-08T14:47:26+08:00https://flcube.com/roche-acquires-pathai-for-750m-to-accelerate-digital-pathology-and-ai-driven-diagnostic-transformation/2026-05-08T14:38:41+08:00https://flcube.com/wuhan-yzy-biopharmas-bispecific-antibody-m701-receives-nmpa-acceptance-for-review-in-malignant-ascites-treatment/2026-05-08T14:26:34+08:00https://flcube.com/guangdong-zhongsheng-pharma-reports-positive-phase-iib-results-for-first-in-class-zsp1601-in-metabolic-dysfunction-associated-steatohepatitis-with-fibrosis-reversal-potential/2026-05-08T14:18:07+08:00https://flcube.com/suzhou-zelgen-biopharmaceuticals-achieves-primary-endpoint-in-phase-iii-trial-for-zesuning-in-thyroid-cancer-ablation-therapy/2026-05-08T14:14:36+08:00https://flcube.com/jiangsu-lianhuan-pharma-reports-positive-phase-iii-results-for-lh-1801-sglt-2-inhibitor-in-type-2-diabetes-treatment/2026-05-08T14:10:37+08:00https://flcube.com/chinas-seven-ministries-issue-revised-pharmaceutical-representative-management-measures-to-combat-commercial-bribery-and-strengthen-industry-oversight/2026-05-08T14:06:35+08:00https://flcube.com/chinas-nhc-unveils-16-point-pediatric-medicines-reform-to-strengthen-supply-security-and-clinical-access/2026-05-08T14:03:36+08:00https://flcube.com/bayer-to-acquire-perfuse-therapeutics-for-up-to-2-45-billion-expands-ophthalmology-portfolio-with-phase-2-endothelin-receptor-antagonist/2026-05-07T14:40:41+08:00https://flcube.com/gsk-reports-solid-q1-2026-results-specialty-medicines-and-shingrix-drive-growth-as-company-maintains-strong-2031-outlook/2026-05-07T14:34:55+08:00https://flcube.com/novo-nordisk-reports-record-q1-2026-results-wegovy-pill-achieves-strongest-ever-glp-1-launch-as-total-sales-surge-32/2026-05-07T14:31:14+08:00https://flcube.com/eli-lilly-commits-additional-4-5-billion-to-indiana-manufacturing-genetic-medicine-facility-launches-as-total-investment-exceeds-21-billion/2026-05-07T14:25:25+08:00https://flcube.com/china-elevates-pediatric-healthcare-infrastructure-nhc-expands-national-childrens-medical-center-network-to-14-facilities/2026-05-07T14:22:17+08:00https://flcube.com/kexing-pharmaceutical-launches-hkex-secondary-offering-innovative-biopharma-seeks-capital-to-advance-multimodal-pipeline/2026-05-07T14:18:26+08:00https://flcube.com/sino-biopharmaceuticals-subsidiary-tianqing-secures-expanded-nmpa-approval-for-saitanxin-first-in-class-cdk2-4-6-inhibitor-moves-to-first-line-breast-cancer/2026-05-07T14:09:45+08:00https://flcube.com/sino-biopharmaceutical-initiates-phase-iii-trial-for-lm-108-ccr8-targeted-antibody-in-gastric-cancer-following-breakthrough-therapy-designations/2026-05-07T14:00:41+08:00https://flcube.com/beone-medicines-reports-record-q1-2026-results-brukinsa-crosses-1-billion-as-total-revenue-surges-35-year-over-year/2026-05-07T13:48:21+08:00https://flcube.com/cutia-therapeutics-secures-nmpa-approval-for-cu-30101-topical-anesthetic-cream-dermatology-specialist-expands-commercial-portfolio/2026-05-07T13:36:27+08:00https://flcube.com/changchun-high-techs-subsidiary-genescience-advances-gensci155-long-acting-igf-1-analog-for-preterm-infants-and-stroke-patients/2026-05-07T13:32:28+08:00https://flcube.com/amoytop-biotech-launches-rmb-1-53-billion-convertible-bond-offering-to-fuel-rd-and-manufacturing-expansion/2026-05-07T13:27:12+08:00https://flcube.com/joincare-pharma-secures-nmpa-clinical-trial-approval-for-jkn2501-chinas-first-broad-spectrum-%ce%b2-lactamase-inhibitor-for-drug-resistant-pneumonia/2026-05-07T13:21:22+08:00https://flcube.com/amgen-secures-nmpa-approval-for-evenity-romosozumab-novel-osteoporosis-treatment-for-high-risk-postmenopausal-women-in-china/2026-05-07T13:16:34+08:00https://flcube.com/nmpa-approves-hangzhou-biosunpharmas-bewintinib-as-first-line-jak2-inhibitor-for-myelofibrosis-with-62-8-spleen-volume-response-rate/2026-05-06T21:09:43+08:00https://flcube.com/leads-biolabs-partner-dianthus-selects-sjogrens-lupus-and-dermatomyositis-as-priority-indications-for-bifunctional-autoimmune-drug-lbl-047-following-1b-licensing-deal/2026-05-06T21:05:10+08:00https://flcube.com/simcere-pharmaceutical-receives-nmpa-clinical-trial-approval-for-lrrc15-targeting-adc-sim0613-backed-by-1-06b-ipsen-global-licensing-deal/2026-05-06T21:00:38+08:00https://flcube.com/alebund-pharmaceuticals-files-for-hong-kong-ipo-leveraging-ckd-focused-portfolio-with-commercialized-mircera-and-late-stage-hyperphosphatemia-candidates/2026-05-06T20:56:50+08:00https://flcube.com/senhwa-biosciences-launches-global-phase-i-ii-trial-of-first-in-class-pidnarulex-combined-with-beones-tislelizumab-in-solid-tumors-including-pancreatic-cancer/2026-05-06T20:50:53+08:00https://flcube.com/amgen-announces-300m-additional-investment-in-us-manufacturing-network-bringing-total-recent-commitments-to-over-3-billion/2026-05-06T20:45:51+08:00https://flcube.com/pfizer-reports-q1-2026-revenues-of-14-5b-with-7-operational-growth-excluding-covid-19-products-reaffirms-full-year-guidance/2026-05-06T20:41:18+08:00https://flcube.com/chinas-nhc-establishes-regulatory-framework-for-biomedical-new-technologies-with-interim-guiding-principles-effective-may-1-2026/2026-05-06T20:36:19+08:00https://flcube.com/ucb-to-acquire-candid-therapeutics-for-2-2b-gaining-best-in-class-bcma-t-cell-engager-cizutamig-for-autoimmune-diseases/2026-05-06T20:34:05+08:00https://flcube.com/astrazenecas-truqap-receives-positive-odac-recommendation-for-pten-deficient-mhspc-based-on-capitello-281-trial-data/2026-05-06T20:31:05+08:00https://flcube.com/siranbio-inks-1-005b-licensing-deal-with-gsk-for-first-in-class-sirna-therapy-sa030-targeting-alk7-in-cardiometabolic-disease/2026-05-06T20:23:08+08:00https://flcube.com/avistone-biotechnologys-andatinib-receives-china-conditional-approval-for-egfr-ex20ins-nsclc/2026-04-30T22:47:59+08:00https://flcube.com/ge-healthcare-reports-7-4-q1-revenue-growth-to-5-1b-driven-by-imaging-and-pharmaceutical-diagnostics-strength/2026-04-30T22:44:41+08:00https://flcube.com/ge-healthcare-restructures-imaging-business-with-14-6b-ais-segment-and-new-executive-leadership/2026-04-30T22:32:28+08:00https://flcube.com/astrazeneca-reports-8-q1-revenue-growth-to-15-3b-driven-by-oncology-and-rare-disease-strength/2026-04-30T22:29:58+08:00https://flcube.com/beone-medicines-tislelizumab-zanidatamab-combo-receives-fda-priority-review-for-her2-positive-gastric-cancer/2026-04-30T15:25:51+08:00https://flcube.com/innovent-biologics-reports-50-q1-revenue-growth-to-555m-driven-by-nrdl-tkis-and-integrated-portfolio-strength/2026-04-30T15:16:06+08:00https://flcube.com/hansoh-pharmaceuticals-b7-h3-adc-hs-20093-receives-china-btd-for-advanced-prostate-cancer/2026-04-30T15:08:47+08:00https://flcube.com/teva-to-acquire-emalex-biosciences-for-700m-adding-registration-ready-tourette-syndrome-drug-ecopipam/2026-04-30T15:02:54+08:00https://flcube.com/abbvie-reports-12-4-revenue-growth-in-q1-2026-driven-by-immunology-and-neuroscience-strength/2026-04-30T14:57:34+08:00https://flcube.com/3sbio-reports-94-revenue-surge-to-2-58b-in-2025-driven-by-6b-pfizer-pd-1-vegf-bispecific-antibody-deal/2026-04-30T14:47:21+08:00https://flcube.com/eccogene-files-hong-kong-ipo-prospectus-with-thr-%ce%b2-agonist-ecc4703-leading-metabolic-disease-pipeline/2026-04-30T14:36:40+08:00https://flcube.com/lianhuan-pharmaceuticals-sglt-2-inhibitor-lh-1801-meets-primary-endpoint-in-phase-iii-type-2-diabetes-trial/2026-04-30T14:29:25+08:00https://flcube.com/allist-pharmaceuticals-secures-nmpa-approval-for-pivotal-trial-of-furmonertinib-against-standard-egfr-tkis-in-rare-nsclc-mutations/2026-04-30T14:24:44+08:00https://flcube.com/allist-pharmaceuticals-secures-china-btd-for-kras-g12c-nsclc-combination-therapy-with-71-response-rate/2026-04-30T14:15:28+08:00https://flcube.com/regeneron-reports-19-revenue-growth-in-q1-2026-driven-by-eylea-hd-transition-and-dupixent-collaboration-strength/2026-04-30T14:07:18+08:00https://flcube.com/gileads-investigational-hiv-regimen-bic-len-receives-fda-acceptance-for-review-with-decision-expected-august-2026/2026-04-30T14:00:04+08:00https://flcube.com/hengrui-pharmaceuticals-replaces-hansoh-as-exclusive-licensee-for-kiomeds-osteoarthritis-drug-in-greater-china/2026-04-30T13:56:44+08:00https://flcube.com/suzhou-basecare-medical-secures-chinas-first-nmpa-approval-for-thalassemia-preimplantation-genetic-testing-kit/2026-04-30T13:51:23+08:00https://flcube.com/hutchmeds-sovleplenib-granted-nmpa-priority-review-for-warm-antibody-autoimmune-hemolytic-anemia/2026-04-30T13:46:48+08:00https://flcube.com/novartis-q1-2026-results-show-strong-brand-momentum-offset-by-generic-erosion-fy-guidance-reaffirmed/2026-04-29T22:17:59+08:00https://flcube.com/astellas-reports-strong-fy2025-results-with-12-revenue-growth-driven-by-oncology-portfolio-expansion/2026-04-29T22:10:25+08:00https://flcube.com/fosun-pharma-reports-strong-q1-2026-results-with-22-profit-growth-and-robust-pipeline-advancement/2026-04-29T22:05:09+08:00https://flcube.com/fosun-pharma-and-arcera-life-sciences-forge-strategic-partnership-to-bridge-chinese-biotech-innovation-with-global-markets/2026-04-29T21:56:53+08:00https://flcube.com/changchun-high-new-techs-gensci161-bispecific-antibody-receives-nmpa-approval-for-non-infectious-uveitis-trial/2026-04-29T21:47:42+08:00https://flcube.com/hengrui-pharmaceuticals-partners-with-sun-yat-sen-university-to-integrate-industry-academia-innovation-ecosystem/2026-04-29T21:44:45+08:00https://flcube.com/abbott-secures-fda-clearance-and-ce-mark-for-ultreon-3-0-ai-powered-oct-imaging-platform/2026-04-29T21:40:09+08:00https://flcube.com/vivacta-biotechnology-secures-50m-series-a-financing-to-advance-in-vivo-car-t-therapy-gt801/2026-04-29T21:37:50+08:00https://flcube.com/insilico-medicine-secures-chinese-clinical-clearance-for-ai-discovered-rentosertib-inhalation-in-pulmonary-fibrosis/2026-04-29T21:24:16+08:00https://flcube.com/mindray-reports-mixed-q1-2026-results-with-strong-international-growth-offset-by-domestic-weakness/2026-04-29T21:16:07+08:00https://flcube.com/immunotech-biopharms-eal-cellular-therapy-rejected-by-nmpa-confirmatory-trials-required/2026-04-29T21:09:03+08:00https://flcube.com/glubio-pharmaceutical-advances-glb-002-molecular-glue-degrader-to-phase-ii-for-relapsed-follicular-lymphoma/2026-04-29T20:10:35+08:00https://flcube.com/henlius-biotech-secures-european-commission-approval-for-poherdy-biosimilar-to-roches-perjeta/2026-04-29T20:06:23+08:00https://flcube.com/abbvie-submits-fda-application-for-rinvoq-in-severe-alopecia-areata-expanding-jak-inhibitor-franchise/2026-04-29T20:03:02+08:00https://flcube.com/medtronic-secures-ce-mark-for-stealth-axis-surgical-system-next-generation-integrated-robotics-platform/2026-04-29T19:57:59+08:00https://flcube.com/pfizer-extends-vyndamax-patent-protection-to-2031-through-generic-settlements/2026-04-29T19:54:13+08:00https://flcube.com/santo-therapeutics-secures-dual-fda-designations-for-st002-gene-therapy-in-nf2-related-schwannomatosis-advancing-in-vivo-lentiviral-platform/2026-04-28T13:35:25+08:00https://flcube.com/johnson-johnsons-imaavy-nipocalimab-receives-fda-priority-review-for-warm-autoimmune-hemolytic-anemia-expanding-fcrn-blocker-franchise/2026-04-28T13:28:25+08:00https://flcube.com/abbvie-submits-fda-filing-for-skyrizi-subcutaneous-induction-therapy-in-crohns-disease-expanding-il-23-inhibitor-franchise/2026-04-28T13:22:52+08:00https://flcube.com/gsks-efimosfermin-receives-dual-regulatory-designations-for-mash-treatment-breakthrough-therapy-and-prime-status-support-phase-iii-development/2026-04-28T13:16:30+08:00https://flcube.com/prothenas-coramitug-receives-fda-fast-track-designation-for-attr-cm-advancing-novo-nordisks-1-2b-amyloidosis-pipeline/2026-04-28T13:12:04+08:00https://flcube.com/jecho-biopharmaceuticals-secures-fda-clearance-for-jlm019-clinical-study-in-advanced-malignant-tumors-novel-bispecific-fc-fusion-protein-targets-cold-tumors/2026-04-28T13:06:40+08:00https://flcube.com/allergan-aesthetics-secures-fourth-nmpa-approval-for-botox-in-china-expanding-aesthetic-portfolio-with-forehead-lines-indication/2026-04-28T12:59:21+08:00https://flcube.com/huahui-health-signs-1-9-billion-global-licensing-deal-with-beone-medicines-for-trispecific-antibody-hh160-targeting-pd-1-ctla-4-and-vegf-a/2026-04-28T12:41:13+08:00https://flcube.com/beones-zanidatamab-achieves-pfs-os-wins-in-herizon-gea-01-phase-3-her2-positive-cancer-trial/2026-04-28T12:37:48+08:00https://flcube.com/beone-medicines-posts-1-4-b-q3-2025-revenue-driven-by-brukinsa-momentum/2026-04-28T12:37:48+08:00https://flcube.com/beones-sonrotoclax-wins-conditional-nmpa-approval-for-bcl-2-inhibitor-in-cll-sll-and-mcl/2026-04-28T12:37:47+08:00https://flcube.com/beone-medicines-wins-fda-fast-track-for-gpc3-bispecific-in-liver-cancer/2026-04-28T12:37:47+08:00https://flcube.com/beone-medicines-names-dual-presidents-in-leadership-overhaul/2026-04-28T12:37:47+08:00https://flcube.com/beones-sotoclax-wins-fda-priority-review-for-mantle-cell-lymphoma/2026-04-28T12:37:47+08:00https://flcube.com/beone-medicines-reports-5-3b-full-year-revenue-brukinsa-drives-40-growth-2026-guidance-raised/2026-04-28T12:36:39+08:00https://flcube.com/wuxi-apptec-reports-record-q1-2026-results-with-28-8-revenue-growth-and-rmb-59-77b-backlog-chemistry-segment-leads-expansion/2026-04-28T12:28:28+08:00https://flcube.com/thermo-fisher-scientific-to-divest-microbiology-business-to-astorg-for-1-075-billion-strategic-portfolio-optimization/2026-04-28T12:05:25+08:00https://flcube.com/novartis-secures-european-commission-approval-for-rhapsido-remibrutinib-in-chronic-spontaneous-urticaria-expanding-global-btk-inhibitor-franchise/2026-04-28T11:58:08+08:00https://flcube.com/eli-lilly-to-acquire-ajax-therapeutics-for-up-to-2-3-billion-to-expand-jak-inhibitor-portfolio-in-myeloproliferative-neoplasms/2026-04-28T11:51:50+08:00https://flcube.com/aureka-biotechnologies-secures-35m-series-a-financing-to-advance-auraide-platform-for-functional-antibody-design/2026-04-28T11:38:50+08:00https://flcube.com/bebetter-medicine-secures-fda-clearance-for-bebt-701-clinical-study-first-in-class-dual-target-therapy-for-hypertension-and-high-ldl-c/2026-04-28T11:11:04+08:00https://flcube.com/hinova-pharmaceuticals-reports-positive-phase-iia-results-for-hp515-in-mash-treatment-first-thr-%ce%b2-agonist-candidate-in-china/2026-04-28T11:08:01+08:00https://flcube.com/bio-thera-solutions-reports-25-84-revenue-growth-in-2025-driven-by-biosimilar-portfolio-expansion-and-us-market-entry/2026-04-28T11:02:01+08:00https://flcube.com/hangzhous-adcoris-licenses-first-in-class-5t4-targeting-adc-acr246-to-u-s-biotech-k2-therapeutics-in-deal-worth-up-to-730-million/2026-04-27T21:59:41+08:00https://flcube.com/sino-biopharmaceuticals-chia-tai-tianqing-and-shanghai-reunion-partner-to-commercialize-respacio-hydrogel-for-cervical-cancer-radiotherapy-protection-in-china/2026-04-27T21:51:30+08:00https://flcube.com/novartis-wins-chmp-positive-opinion-for-itvisma-intrathecal-onasemnogene-abeparvovec-in-5q-spinal-muscular-atrophy-across-all-ages-in-eu/2026-04-27T21:39:51+08:00https://flcube.com/shandong-boan-biotech-advances-first-in-china-anti-cd25-antibody-ba1106-into-phase-ii-nsclc-trial-in-combination-with-nivolumab-biosimilar-ba1104/2026-04-27T21:28:16+08:00https://flcube.com/brii-biosciences-presents-promising-hbsag-rebound-data-for-elebsiran-based-regimens-at-apasl-2026-highlighting-potential-functional-cure-profile-in-chronic-hepatitis-b/2026-04-27T21:19:52+08:00https://flcube.com/cspc-pharmaceutical-receives-fda-clearance-to-launch-first-in-class-kat6-inhibitor-syh2095-clinical-trial-for-advanced-cancers/2026-04-27T21:13:57+08:00https://flcube.com/bristol-myers-squibb-and-pfizer-partner-with-mark-cubans-cost-plus-drugs-to-offer-eliquis-at-345-for-30-day-supply-expanding-access-to-blockbuster-anticoagulant/2026-04-27T21:09:20+08:00https://flcube.com/henlius-biotech-launches-phase-ii-iii-trial-in-australia-for-triple-combination-therapy-in-squamous-nsclc-featuring-novel-anti-egfr-antibody-pimurutamab-and-approved-pd-1-inhibitor-hansizhuang/2026-04-27T20:59:32+08:00https://flcube.com/novartis-secures-who-pre-qualification-for-coartem-baby-first-antimalarial-specifically-designed-for-newborns-and-infants-under-5-kg/2026-04-27T20:53:53+08:00https://flcube.com/astrazeneca-secures-fda-approval-for-subcutaneous-saphnelo-in-systemic-lupus-erythematosus-after-addressing-supplemental-data-request/2026-04-27T20:48:18+08:00https://flcube.com/beijing-ql-biopharma-files-hkex-ipo-prospectus-with-diversified-glp-1-portfolio-targeting-global-obesity-and-metabolic-disease-markets/2026-04-27T15:10:39+08:00https://flcube.com/boehringer-ingelheim-launches-pulmonary-fibrosis-care-initiative-in-china-with-cnr-news-tencent-medipedia-and-patient-groups-to-combat-underdiagnosed-fatal-lung-disease/2026-04-27T14:52:58+08:00https://flcube.com/sanofi-secures-chmp-positive-opinion-for-cenrifki-tolebrutinib-in-non-relapsing-spms-despite-fda-complete-response-letter-setback/2026-04-27T14:42:27+08:00https://flcube.com/china-resources-double-crane-to-acquire-nanjing-xinbai-pharma-from-boya-biological-for-rmb-235-5-million-expanding-injectables-portfolio/2026-04-27T14:26:41+08:00https://flcube.com/novartis-withdraws-pluvicto-pre-chemotherapy-mcrpc-application-in-eu-following-chmp-objections-on-psmafore-control-arm-design/2026-04-27T14:14:28+08:00https://flcube.com/johnson-johnson-acquires-atraverse-medical-to-expand-cardiac-ablation-portfolio-with-next-gen-left-heart-access-technology/2026-04-27T14:03:44+08:00https://flcube.com/nmpa-tightens-post-marketing-requirements-for-conditionally-approved-drugs-in-china-mandating-four-year-confirmatory-studies-and-annual-progress-reporting/2026-04-27T13:51:05+08:00https://flcube.com/sun-pharma-to-acquire-organon-for-11-75-billion-creating-global-top-25-pharmaceutical-leader-in-branded-generics/2026-04-27T13:45:55+08:00https://flcube.com/astrazeneca-secures-dual-nmpa-approvals-for-imfinzi-based-regimens-in-advanced-hepatocellular-carcinoma-and-nsclc/2026-04-27T13:38:26+08:00https://flcube.com/insilico-medicine-advances-ai-designed-prmt5-inhibitor-ism0387-for-glioblastoma-with-sub-12-month-discovery-timeline/2026-04-24T21:44:59+08:00https://flcube.com/star-sports-medicine-raises-hkd-830-million-in-hong-kong-ipo-as-chinas-leading-domestic-sports-medicine-provider/2026-04-24T21:34:10+08:00https://flcube.com/huadong-medicine-secures-nmpa-approval-for-ellanse-m-pcl-microsphere-filler-for-temple-hollowing-correction/2026-04-24T21:21:45+08:00https://flcube.com/sisram-medical-forges-strategic-alliance-for-daxxify-commercialization-in-chinas-long-acting-botulinum-toxin-market/2026-04-24T21:15:15+08:00https://flcube.com/china-medical-systems-comekibart-anti-il-4r%ce%b1-antibody-enters-nmpa-review-for-seasonal-allergic-rhinitis/2026-04-24T21:03:55+08:00https://flcube.com/abbvie-receives-fda-complete-response-letter-for-trenibote-with-manufacturing-clarifications-requested/2026-04-24T20:59:57+08:00https://flcube.com/regeneron-secures-fda-approval-for-otarmeni-gene-therapy-and-announces-landmark-u-s-pricing-agreement/2026-04-24T20:56:32+08:00https://flcube.com/thermo-fisher-scientific-reports-6-revenue-growth-in-q1-2026-driven-by-innovative-product-launches-and-strategic-ai-collaboration/2026-04-24T20:52:18+08:00https://flcube.com/chinas-national-health-commission-proposes-sweeping-reforms-to-narcotics-and-psychotropic-drugs-management-framework/2026-04-24T20:43:33+08:00https://flcube.com/sciclone-pharmaceuticals-partners-with-jd-healthcare-to-pioneer-integrated-immune-health-management-model/2026-04-24T20:41:17+08:00https://flcube.com/roche-q1-sales-rise-6-driven-by-innovative-medicines-as-china-expansion-and-diagnostics-recovery-offset-currency-headwinds/2026-04-24T15:15:08+08:00https://flcube.com/transcenta-presents-promising-pre-clinical-data-for-proprietary-liv1-antibody-drug-conjugate-at-aacr-2026/2026-04-23T22:37:03+08:00https://flcube.com/simcere-pharmaceutical-withdraws-nda-for-rademikibart-in-atopic-dermatitis-plans-resubmission-later-this-month/2026-04-23T22:32:10+08:00https://flcube.com/hengrui-pharmaceuticals-reports-strong-q1-2026-results-with-12-98-revenue-growth-and-multiple-new-drug-approvals/2026-04-23T22:28:36+08:00https://flcube.com/mebanks-divests-guangzhou-specialty-pharmacy-subsidiary-to-dashenlin-for-7-75-million-to-focus-on-higher-margin-health-insurance-and-management-businesses/2026-04-23T22:24:00+08:00https://flcube.com/kangtai-biological-initiates-phase-i-clinical-study-for-trivalent-influenza-split-vaccine-produced-in-mdck-cells/2026-04-23T22:17:56+08:00https://flcube.com/abbvie-announces-1-4-billion-advanced-manufacturing-campus-in-north-carolina-to-support-immunology-neuroscience-and-oncology-portfolio/2026-04-23T22:15:02+08:00https://flcube.com/merck-co-announces-1-billion-strategic-partnership-with-google-cloud-to-deploy-enterprise-wide-agentic-ai-platform/2026-04-23T22:12:10+08:00https://flcube.com/fda-expands-sanofis-tzield-approval-to-children-as-young-as-one-year-old-for-type-1-diabetes-prevention/2026-04-23T22:08:10+08:00https://flcube.com/boston-scientific-reports-strong-q1-2026-results-with-9-4-net-sales-growth-cardiovascular-segment-leads-performance/2026-04-23T22:02:44+08:00https://flcube.com/european-commission-grants-conditional-approval-to-ipsens-ojemda-tovorafenib-for-pediatric-low-grade-glioma-with-braf-alterations/2026-04-23T21:57:48+08:00https://flcube.com/ipsens-ipn60340-wins-fda-breakthrough-therapy-designation-for-first-line-aml-in-combination/2026-04-23T21:53:44+08:00https://flcube.com/johnson-johnson-secures-ce-mark-for-advanced-ethicon-4000-surgical-stapler-with-proprietary-3d-stapling-technology/2026-04-23T21:50:18+08:00https://flcube.com/fda-approves-sanofi-regenerons-dupilumab-for-pediatric-chronic-spontaneous-urticaria-in-children-aged-2-11-years/2026-04-23T21:45:08+08:00https://flcube.com/chinas-cde-releases-106th-batch-of-chemical-generic-reference-preparations-with-27-new-specifications-and-updated-guidelines/2026-04-23T21:38:37+08:00https://flcube.com/fda-extends-review-timeline-for-sanofis-sarclisa-subcutaneous-formulation-by-three-months-new-decision-date-set-for-july-23-2026/2026-04-23T21:36:57+08:00https://flcube.com/nmpa-suspends-colchicine-api-imports-from-indian-manufacturers-alkaloids-bioactives-and-alchem-international-over-change-management-violations/2026-04-23T21:32:19+08:00https://flcube.com/mercks-idvynso-gains-fda-approval-as-novel-dual-drug-hiv-treatment/2026-04-22T22:42:22+08:00https://flcube.com/boji-medical-sells-fluconazole-ear-drops-technology-to-chengdu-pusch-for-2m/2026-04-22T22:33:03+08:00https://flcube.com/roches-fenebrutinib-slashes-ms-relapse-rates-by-over-50-in-phase-iii-trials/2026-04-22T22:27:36+08:00https://flcube.com/novabio-therapeutics-and-obio-tech-strengthen-partnership-to-advance-treg-cell-therapies-for-neurodegenerative-diseases/2026-04-22T22:22:23+08:00https://flcube.com/gan-lees-nectin-4-adc-glr1059-clears-regulatory-hurdle-for-solid-tumor-trials/2026-04-22T22:16:00+08:00https://flcube.com/danaher-q1-earnings-beat-expectations-as-bioprocessing-strength-offsets-cepheid-weakness/2026-04-22T21:46:14+08:00https://flcube.com/leads-biolabs-enrolls-first-patient-in-phase-ii-trial-for-gastric-cancer-drug-opamtistomig/2026-04-22T21:34:41+08:00https://flcube.com/roches-gazyva-gains-fda-review-acceptance-for-systemic-lupus-erythematosus-treatment/2026-04-22T21:24:36+08:00https://flcube.com/inxmed-limited-files-for-hong-kong-ipo-with-near-commercial-fak-inhibitor-ifebemtinib/2026-04-22T20:41:04+08:00https://flcube.com/daiichi-sankyo-and-astrazeneca-launch-datroway-adc-in-china-for-hr-positive-her2-negative-breast-cancer/2026-04-22T20:27:56+08:00https://flcube.com/merck-and-eisais-litespark-012-trial-fails-to-meet-primary-endpoints-in-advanced-kidney-cancer/2026-04-22T17:30:09+08:00https://flcube.com/astrazenecas-ultomiris-shows-significant-proteinuria-reduction-in-phase-iii-iga-nephropathy-trial/2026-04-22T15:42:31+08:00https://flcube.com/chinas-drug-quality-control-system-shows-99-5-compliance-rate-in-2025-nmpa-report/2026-04-22T14:39:50+08:00https://flcube.com/neurogen-pharma-secures-exclusive-china-rights-to-tevas-ajovy-worlds-first-dual-indication-cgrp-antagonist-for-migraine-prevention/2026-04-22T14:22:49+08:00https://flcube.com/eli-lilly-to-acquire-kelonia-therapeutics-for-7-billion-to-secure-in-vivo-car-t-platform-targeting-multiple-myeloma/2026-04-21T23:22:42+08:00https://flcube.com/cspcs-albumin-bound-sirolimus-hb1901-meets-primary-endpoint-in-phase-ib-iii-trial-for-rare-pecoma-reinforcing-breakthrough-therapy-status/2026-04-21T23:17:30+08:00https://flcube.com/ai-healthtech-firm-weimai-files-for-hong-kong-ipo-touting-careai-platform-and-leadership-in-hospital-linked-disease-management/2026-04-21T22:36:21+08:00https://flcube.com/upc-appeal-court-reverses-lower-ruling-imposes-preliminary-injunction-on-sinocares-icancgm-app-in-17-european-countries-following-abbott-patent-claim/2026-04-21T21:27:52+08:00https://flcube.com/hengrui-launches-pediatric-trial-of-dual-gipr-glp-1r-agonist-hrs9531-in-overweight-and-obese-adolescents-following-nmpa-clearance/2026-04-21T20:49:11+08:00https://flcube.com/hengruis-shr-9839-hrs-4642-combo-cleared-for-advanced-crc-trials/2026-04-21T20:47:04+08:00https://flcube.com/hengruis-hrs-5346-lpa-inhibitor-gets-china-breakthrough-therapy-designation-in-1-97b-merck-deal/2026-04-21T20:47:04+08:00https://flcube.com/hengruis-hrs-7535-glp-1r-agonist-cleared-for-hypertension-with-obesity-study-in-china/2026-04-21T20:47:04+08:00https://flcube.com/hengruis-shr-1826-adc-earns-breakthrough-therapy-designation-for-c-met-overexpressed-nsclc/2026-04-21T20:47:04+08:00https://flcube.com/hengrui-pharmas-shr-7877-gets-nmpa-nod-for-small-cell-lung-cancer-trials/2026-04-21T20:47:04+08:00https://flcube.com/hengrui-pharmas-trastuzumab-rezetecan-filing-accepted-for-her2-colorectal-cancer-indication/2026-04-21T20:47:03+08:00https://flcube.com/hengrui-cancer-combo-gets-nmpa-nod-for-liver-cancer-trials/2026-04-21T20:47:03+08:00https://flcube.com/hengrui-resubmits-camrelizumab-apatinib-bla-for-hcc-to-fda/2026-04-21T20:47:03+08:00https://flcube.com/hengruis-trastuzumab-rezetecan-wins-eighth-btd-for-first-line-her2-nsclc-in-china/2026-04-21T20:47:03+08:00https://flcube.com/hengrui-ruitanning-gets-nmpa-nod-for-moderately-emetogenic-chemo-indication/2026-04-21T20:47:03+08:00https://flcube.com/hengruis-angptl3-antibody-shr-1918-nda-accepted-by-nmpa-priority-review-for-rare-disease-hofh/2026-04-21T20:47:02+08:00https://flcube.com/hengruis-trastuzumab-rezetecan-receives-cde-breakthrough-therapy-designation-for-first-line-her2-metastatic-breast-cancer-in-combination-with-pertuzumab/2026-04-21T20:31:44+08:00https://flcube.com/biogen-completes-global-consolidation-of-felzartamab-with-100m-upfront-deal-for-greater-china-rights-from-tj-biopharma/2026-04-21T20:14:28+08:00https://flcube.com/shanghai-leadingtac-secures-fda-clearance-for-phase-i-trial-of-lt-010391-first-oral-kras-g12d-degrader-in-clinical-development/2026-04-21T20:05:14+08:00https://flcube.com/china-tightens-control-over-pregabalin-and-dextromethorphan-guaifenesin-preparations-amid-abuse-concerns-nmpa-police-and-narcotics-agency-issue-joint-enforcement-directive/2026-04-21T17:52:59+08:00https://flcube.com/fda-grants-priority-review-to-merck-astellas-and-pfizers-sbla-for-padcev-pembrolizumab-combo-in-perioperative-muscle-invasive-bladder-cancer/2026-04-21T17:42:11+08:00https://flcube.com/boehringer-ingelheim-opens-ai-machine-learning-hub-in-london-commits-e150m-to-accelerate-drug-discovery-for-high-unmet-need-diseases/2026-04-21T17:37:50+08:00https://flcube.com/novo-nordisks-oral-etavopivat-meets-primary-endpoints-in-phase-iii-hibiscus-trial-for-sickle-cell-disease-regulatory-filing-planned-for-h2-2026/2026-04-21T13:38:16+08:00https://flcube.com/akesos-cadonilimab-shows-promise-in-first-line-pancreatic-cancer-at-aacr-2026-dual-pd-1-ctla-4-bispecific-gains-guideline-endorsements-across-seven-cancers/2026-04-21T13:23:54+08:00https://flcube.com/leo-pharma-secures-nmpa-approval-for-enstilar-foam-in-china-first-and-only-calcipotriol-betamethasone-foam-formulation-for-plaque-psoriasis-demonstrates-superior-efficacy-vs-ointment/2026-04-20T21:12:27+08:00https://flcube.com/sino-biopharmaceuticals-subsidiary-chia-tai-tianqing-secures-nmpa-approval-for-benmelstobart-anlotinib-combo-in-alveolar-soft-part-sarcoma-72-4-orr-and-unreached-median-pfs-in-rare-cancer/2026-04-20T21:00:20+08:00https://flcube.com/ucb-acquires-neurona-therapeutics-for-1-15-billion-to-expand-epilepsy-portfolio-regenerative-neural-cell-therapy-nrtx-1001-targets-drug-refractory-epilepsy-with-single-dose-gaba-producing-c/2026-04-20T20:50:00+08:00https://flcube.com/hansoh-pharmaceutical-presents-promising-phase-i-data-for-b7-h3-adc-risvutatug-rezetecan-combined-with-adebrelimab-at-aacr-2026-47-1-orr-and-14-0-month-pfs-in-solid-tumors/2026-04-20T20:31:27+08:00https://flcube.com/pulnovo-medical-secures-100m-oversubscribed-financing-led-by-medtronic-padn-system-for-pulmonary-hypertension-attracts-global-investor-consortium/2026-04-20T20:21:57+08:00https://flcube.com/eli-lilly-launches-omvoh-mirikizumab-in-china-for-inflammatory-bowel-disease-il-23p19-antagonist-targets-ulcerative-colitis-and-crohns-disease-following-february-approval/2026-04-20T18:27:39+08:00https://flcube.com/sensetime-raises-73-3-million-in-series-a-financing-for-ai-healthcare-platform-medical-agentic-os-and-world-model-capabilities-attract-raffles-healthcare-lion-partners/2026-04-20T18:16:01+08:00https://flcube.com/kanghong-pharmaceutical-receives-fda-clearance-for-khn921-gene-therapy-trial-in-mybpc3-associated-hypertrophic-cardiomyopathy-precision-aav-vector-targets-myocardial-tissue/2026-04-20T18:09:45+08:00https://flcube.com/mabwell-bioscience-raises-185-million-in-hong-kong-ipo-after-two-previous-failed-attempts-oncology-and-age-related-disease-developer-secures-hk1-45-billion-valuation/2026-04-20T18:06:43+08:00https://flcube.com/chinas-nmpa-proposes-new-quality-management-standards-for-drug-retail-chains-mandating-unified-systems-across-headquarters-distribution-centers-and-stores/2026-04-20T14:31:13+08:00https://flcube.com/xuanzhu-biopharmaceutical-reports-landmark-phase-iii-diamond-2-results-for-xuanfeining-dirozalkib-in-alk-positive-nsclc-31-3-month-pfs-doubles-crizotinib-standard-at-aacr-2026/2026-04-20T14:27:07+08:00https://flcube.com/sino-biopharmaceutical-reports-55-response-rate-for-pd-1-vegf-bispecific-lm-299-mk-2010-in-nsclc-at-aacr-2026/2026-04-20T14:19:09+08:00https://flcube.com/eli-lilly-in-advanced-talks-to-acquire-kelonia-therapeutics-for-over-2-billion-strengthening-car-t-cell-therapy-portfolio/2026-04-20T14:06:59+08:00https://flcube.com/abbvie-partners-with-santen-china-for-exclusive-distribution-of-five-glaucoma-franchise-products/2026-04-17T22:16:40+08:00https://flcube.com/annoroad-gene-technology-files-for-hong-kong-ipo-to-capitalize-on-integrated-molecular-diagnostics-platform/2026-04-17T22:11:35+08:00https://flcube.com/mabwell-bioscience-expands-southeast-asia-reach-with-malaysian-licensing-deal-for-denosumab-biosimilars-rexeva-and-denosu/2026-04-17T21:55:39+08:00https://flcube.com/sunshine-lake-pharma-secures-nmpa-approval-for-in-house-developed-premixed-insulin-30r-prefilled-pen/2026-04-17T21:39:39+08:00https://flcube.com/hansoh-pharmas-b7-h3-adc-hs-20093-secures-fourth-nmpa-breakthrough-therapy-designation-for-nsclc-combination-therapy/2026-04-17T21:31:55+08:00https://flcube.com/hengrui-pharmas-nectin-4-adc-shr-a2102-granted-second-nmpa-breakthrough-therapy-designation-for-cervical-cancer/2026-04-17T21:28:33+08:00https://flcube.com/abbott-reports-3-8-yoy-revenue-growth-in-q1-2026-led-by-diagnostics-and-medical-devices/2026-04-17T21:25:25+08:00https://flcube.com/tigermed-and-alibaba-cloud-forge-alliance-to-build-ai-powered-ecosystem-for-intelligent-clinical-trials/2026-04-17T21:15:44+08:00https://flcube.com/amoytop-biotech-inks-445m-deal-with-aligos-for-china-rights-to-novel-hepatitis-b-capsid-modulator-pevifoscorvir/2026-04-17T21:12:00+08:00https://flcube.com/changchun-high-new-tech-gains-nmpa-clearance-for-gensci136-phase-i-ii-trial-in-generalized-myasthenia-gravis/2026-04-17T21:09:02+08:00https://flcube.com/yifan-pharma-expands-european-footprint-licenses-long-acting-g-csf-efbemalenograstim-alfa-to-italys-molteni-farmaceutici/2026-04-17T21:02:45+08:00https://flcube.com/ge-healthcare-and-deephealth-expand-global-partnership-to-advance-ai-powered-mammography-solutions/2026-04-17T20:49:53+08:00https://flcube.com/betta-pharmaceuticals-partners-with-eversana-for-us-commercialization-of-ensartinib-in-alk-nsclc/2026-04-17T20:44:36+08:00https://flcube.com/kailera-therapeutics-debuts-on-nasdaq-with-625m-ipo-backed-by-hengruis-global-glp-1-portfolio/2026-04-17T15:07:47+08:00https://flcube.com/winhealth-pharma-secures-nmpa-approval-for-korsuva-difelikefalin-to-treat-ckd-associated-pruritus-in-chinese-hemodialysis-patients/2026-04-17T14:42:14+08:00https://flcube.com/remegen-receives-650-million-upfront-from-abbvie-in-landmark-5-6-billion-bispecific-antibody-licensing-deal/2026-04-16T23:08:01+08:00https://flcube.com/annoroad-gene-technology-files-hong-kong-ipo-prospectus-to-capitalize-on-chinas-molecular-diagnostics-growth/2026-04-16T22:14:13+08:00https://flcube.com/hengrui-pharmaceuticals-secures-nmpa-clinical-approval-for-hrs-7156-a-first-in-class-heart-failure-therapy-with-global-novelty/2026-04-16T21:53:31+08:00https://flcube.com/gan-lee-pharmaceuticals-secures-nmpa-clinical-approval-for-glr1062-chinas-first-in-class-gene-therapy-for-wet-age-related-macular-degeneration/2026-04-16T21:18:58+08:00https://flcube.com/sino-biopharmaceutical-initiates-phase-iii-trial-of-lm-302-adc-combined-with-anti-pd-1-for-cldn18-2-positive-gastric-cancer/2026-04-16T21:14:45+08:00https://flcube.com/mabwell-bioscience-secures-second-nmpa-approval-for-denosu-chinas-first-xgeva-biosimilar-expanding-indication-to-bone-metastasis-and-multiple-myeloma/2026-04-16T21:11:08+08:00https://flcube.com/cspc-pharmaceutical-secures-nmpa-clinical-trial-approval-for-sys6051-a-tissue-factor-targeted-adc-for-advanced-solid-tumors/2026-04-16T20:46:02+08:00https://flcube.com/ty-biotech-and-shenzhen-university-launch-joint-institute-for-chlamydomonas-based-biopharmaceutical-development-with-73-million-investment/2026-04-16T20:27:58+08:00https://flcube.com/insilico-medicine-and-ancestor-cell-forge-ai-stem-cell-alliance-to-accelerate-exosome-therapeutics-development/2026-04-16T18:11:38+08:00https://flcube.com/luye-pharma-initiates-phase-ii-trial-of-ly03017-for-alzheimers-associated-psychosis-in-china-following-us-clinical-clearance/2026-04-16T18:05:40+08:00https://flcube.com/gsk-acquires-35pharma-for-950-million-to-secure-best-in-class-pulmonary-arterial-hypertension-therapy-hs235/2026-04-16T18:01:20+08:00https://flcube.com/shionogi-launches-corporate-venture-capital-initiative-with-strategic-investment-in-ophthalmology-startup-restore-vision/2026-04-16T17:42:18+08:00https://flcube.com/zai-lab-and-boehringer-ingelheim-partner-on-dll3-combination-therapy-for-neuroendocrine-cancers/2026-04-16T17:34:32+08:00https://flcube.com/3sbio-and-tigermed-forge-strategic-alliance-to-create-full-chain-pharmaceutical-innovation-ecosystem/2026-04-16T17:30:16+08:00https://flcube.com/daiichi-sankyo-to-divest-healthcare-subsidiary-to-suntory-in-1-6-billion-strategic-realignment/2026-04-16T17:25:58+08:00https://flcube.com/bayer-ag-secures-nmpa-approval-for-hyrnuo-sevabertinib-to-treat-her2-mutant-nsclc-in-china/2026-04-16T17:23:50+08:00https://flcube.com/johnson-johnson-partners-with-shanghai-pharmaceuticals-for-exclusive-promotion-of-paliperidone-palmitate-long-acting-injection-in-china/2026-04-16T13:59:52+08:00https://flcube.com/novo-nordisk-partners-with-openai-to-accelerate-drug-discovery-and-transform-healthcare-operations/2026-04-15T22:49:24+08:00https://flcube.com/fosun-pharma-advances-dual-target-car-t-therapy-fkc289-into-clinical-trials-for-rare-kidney-and-blood-disorders/2026-04-15T22:44:24+08:00https://flcube.com/chinas-state-council-unveils-comprehensive-drug-pricing-reforms-to-strengthen-market-oriented-mechanisms-and-innovation-incentives/2026-04-15T22:41:06+08:00https://flcube.com/gan-lee-pharmaceuticals-doses-first-patient-in-phase-iii-trial-for-novel-long-acting-insulin-gzr33-in-type-2-diabetes/2026-04-15T22:39:14+08:00https://flcube.com/ac-immune-and-eli-lilly-amend-2018-alzheimers-partnership-to-advance-tau-morphomer-candidates/2026-04-15T22:12:30+08:00https://flcube.com/autobio-diagnostics-expands-global-ivd-footprint-with-dual-vietnam-partnerships/2026-04-15T22:09:26+08:00https://flcube.com/er-kim-secures-exclusive-cee-commercial-rights-for-loqtorzi-anti-pd-1-antibody-from-leo-pharma/2026-04-15T22:02:16+08:00https://flcube.com/ucb-secures-eu-approval-for-kygevvi-as-first-ever-treatment-for-ultra-rare-tk2-deficiency/2026-04-15T21:55:07+08:00https://flcube.com/eli-lilly-restructures-china-cardiometabolic-division-ahead-of-foundayo-oral-glp-1-launch/2026-04-15T21:43:18+08:00https://flcube.com/huadong-medicines-semaglutide-biosimilar-hdm1702-enters-nmpa-review-for-weight-management-indication/2026-04-15T21:37:33+08:00https://flcube.com/lepu-medical-acquires-betagrin-rights-from-bio-thera-in-rmb-450-million-cardiovascular-deal/2026-04-15T21:33:22+08:00https://flcube.com/eli-lilly-to-acquire-crossbridge-bio-for-up-to-300-million-to-bolster-adc-pipeline-with-novel-trop2-targeting-candidate/2026-04-15T21:27:56+08:00https://flcube.com/laekna-therapeutics-reports-breakthrough-phase-iii-results-for-lae002-akt-inhibitor-in-hr-her2-breast-cancer/2026-04-15T20:52:36+08:00https://flcube.com/johnson-johnson-reports-strong-q1-2026-sales-growth-despite-net-earnings-decline-raises-full-year-guidance/2026-04-15T20:48:56+08:00https://flcube.com/xuanzhu-biopharma-receives-nmpa-approval-for-phase-iii-trial-of-anaprazole-based-quadruple-therapy-against-h-pylori/2026-04-15T20:38:18+08:00https://flcube.com/shanghai-henlius-biotech-launches-phase-i-trial-for-hlx05-n-cetuximab-biosimilar-in-metastatic-colorectal-cancer/2026-04-15T20:30:44+08:00https://flcube.com/beijing-sinotaus-prostate-cancer-diagnostic-agent-xtr020-receives-nmpa-review-acceptance/2026-04-15T20:26:53+08:00https://flcube.com/fda-issues-draft-guidance-for-genome-editing-therapy-safety-assessment-using-next-generation-sequencing/2026-04-15T20:24:48+08:00https://flcube.com/winhealth-pharma-licenses-worlds-first-oral-arsenic-trioxide-arsenol-for-mainland-china-apl-treatment/2026-04-14T23:45:03+08:00https://flcube.com/roches-elecsys-nfl-test-gains-ce-mark-for-blood-based-multiple-sclerosis-neuroinflammation-monitoring/2026-04-14T23:41:52+08:00https://flcube.com/thermo-fishers-ppd-secures-270m-patient-healthverity-dataset-for-ai-driven-clinical-trial-optimization/2026-04-14T23:37:03+08:00https://flcube.com/ribo-life-science-advances-worlds-leading-fxi-targeting-sirna-vortosiran-into-phase-iib-for-af-stroke-prevention/2026-04-14T23:29:01+08:00https://flcube.com/daiichi-sankyo-merck-ifinatamab-deruxtecan-granted-fda-priority-review-for-extensive-stage-sclc/2026-04-14T23:05:45+08:00https://flcube.com/curegenes-cg-0255-receives-nmpa-approval-for-ischemic-stroke-trial-first-thiol-based-p2y12-inhibitor/2026-04-14T22:51:38+08:00https://flcube.com/grand-pharmaceuticals-sir-spheres-achieves-phase-iii-success-in-unresectable-hcc-supporting-china-expansion/2026-04-14T22:18:27+08:00https://flcube.com/china-resources-and-roche-partner-on-trastuzumab-emtansine-commercialization-to-expand-breast-cancer-adc-access/2026-04-14T21:42:06+08:00https://flcube.com/zelgens-jaktinib-hits-primary-endpoint-in-phase-iii-atopic-dermatitis-trial-dual-jak-acvr1-inhibitor-expands-beyond-myelofusion/2026-04-14T21:30:05+08:00https://flcube.com/chinas-nhsa-selects-31-innovative-drugs-for-historic-reference-drug-pre-communication-program/2026-04-14T21:25:13+08:00https://flcube.com/cttq-and-teva-partner-on-treanda-commercialization-to-expand-bendamustine-access-in-chinas-nhl-market/2026-04-14T20:54:10+08:00https://flcube.com/erasca-exercises-option-to-secure-global-rights-to-pan-ras-molecular-glue-eras-0015-from-joyo-pharmatech/2026-04-14T20:48:33+08:00https://flcube.com/zuellig-pharma-acquires-cialis-rights-for-hong-kong-macau-and-south-korea-from-eli-lilly/2026-04-14T20:40:51+08:00https://flcube.com/olymvax-biopharmaceuticals-and-westlake-university-launch-universal-influenza-vaccine-collaboration/2026-04-14T20:34:30+08:00https://flcube.com/tasly-pharma-partners-with-beijing-neurosurgical-institute-on-dual-target-car-t-therapy-rmb-240m-investment-advances-cd44-cd133-autologous-treatment-for-recurrent-glioblastoma/2026-04-14T20:30:50+08:00https://flcube.com/mannerchem-secures-exclusive-china-rights-to-kintors-ai-discovered-whitening-ingredient-oximidol-kt-939/2026-04-14T20:27:48+08:00https://flcube.com/youcare-pharmaceutical-advances-dual-mrna-vaccine-pipeline-with-nmpa-approvals-for-rsv-and-herpes-zoster-candidates/2026-04-14T15:33:30+08:00https://flcube.com/glyconex-and-nippon-kayaku-collaborate-on-next-generation-protease-activated-adc-gnx201-for-solid-tumors/2026-04-14T14:55:34+08:00https://flcube.com/harbin-gloria-pharmaceuticals-acquires-neurodegenerative-disease-candidate-from-capital-medical-university-for-rmb-14-15m/2026-04-14T14:30:41+08:00https://flcube.com/menarini-group-partners-with-shanghai-angel-baby-foundation-on-three-year-pediatric-scar-care-initiative-dermatix-ultra-gel-expertise-extended-to-public-welfare-collaboration/2026-04-14T14:23:50+08:00https://flcube.com/eli-lillys-jaypirca-combination-therapy-demonstrates-significant-pfs-benefit-in-phase-iii-cll-sll-trial-non-covalent-btk-inhibitor-shows-promise-regardless-of-prior-treatment-history/2026-04-14T14:10:42+08:00https://flcube.com/sanofi-secures-ec-approval-for-dupixent-in-pediatric-chronic-spontaneous-urticaria-first-biologic-therapy-for-children-2-11-years/2026-04-14T14:05:34+08:00https://flcube.com/astrazenecas-imjudo-gains-nmpa-approval-for-first-line-nsclc-in-china-backed-by-poseidon-data/2026-04-13T20:55:05+08:00https://flcube.com/remegens-disitamab-vedotin-wins-worlds-first-her2-adc-approval-for-first-line-advanced-urothelial-carcinoma/2026-04-13T20:49:51+08:00https://flcube.com/henlius-biotech-doses-first-patient-in-phase-i-trial-for-hlx319-a-biosimilar-to-roches-phesgo/2026-04-13T20:45:23+08:00https://flcube.com/abbvie-secures-nmpa-label-expansion-for-rinvoq-in-china-clarifying-use-in-uc-and-crohns-disease/2026-04-13T20:42:14+08:00https://flcube.com/iaso-biotherapeutics-partners-with-brazils-butantan-institute-to-localize-car-t-therapy-for-hematological-cancers/2026-04-13T20:34:45+08:00https://flcube.com/cansino-biologics-secures-nmpa-approval-for-pankangxin-chinas-first-three-component-acellular-dtap-vaccine/2026-04-13T20:26:58+08:00https://flcube.com/zhejiang-medicine-plans-hkex-spin-off-of-novocodex-biopharmaceuticals-to-unlock-adc-pipeline-value/2026-04-13T20:19:40+08:00https://flcube.com/cutia-therapeutics-cu-20101-meets-phase-iii-endpoints-demonstrating-non-inferiority-to-botox-for-glabellar-lines/2026-04-13T20:04:15+08:00https://flcube.com/hotgen-biotechs-novel-treg-targeting-bispecific-antibody-sgt003-clears-nmpa-filing-hurdle/2026-04-13T20:00:36+08:00https://flcube.com/haisco-pharma-licenses-nav1-8-pain-program-to-abbvie-in-745m-deal-retaining-greater-china-rights/2026-04-13T19:56:51+08:00https://flcube.com/fda-accepts-nda-for-telixs-pixclara-tlx101-px-glioma-imaging-agent-decision-expected-september-2026/2026-04-13T19:53:20+08:00https://flcube.com/gsks-b7-h4-adc-mocertatug-rezetecan-shows-62-67-response-rates-in-phase-i-ovarian-and-endometrial-cancer-trials/2026-04-13T19:46:21+08:00https://flcube.com/merck-kgaa-closes-acquisition-of-jsr-life-sciences-chromatography-business-bolstering-antibody-purification-portfolio/2026-04-13T19:40:42+08:00https://flcube.com/boehringer-ingelheim-and-biontech-launch-phase-ib-ii-trial-of-novel-t-cell-engager-and-bispecific-antibody-combo-for-es-sclc/2026-04-13T19:35:19+08:00https://flcube.com/gaush-meditech-secures-ce-mark-for-corneal-confocal-microscope-paving-way-for-eu-commercial-launch/2026-04-13T15:33:59+08:00https://flcube.com/neurocrine-biosciences-to-acquire-soleno-therapeutics-for-2-9-billion-adding-three-first-in-class-commercial-assets/2026-04-13T15:25:30+08:00https://flcube.com/nanjing-pharma-launches-110m-corporate-fund-to-acquire-controlling-stakes-in-datsing-bio-and-kejian-tech/2026-04-13T15:18:56+08:00https://flcube.com/telix-and-regeneron-forge-575m-radiopharmaceutical-alliance-to-advance-precision-oncology/2026-04-13T14:07:36+08:00https://flcube.com/sun-pharma-in-advanced-talks-to-acquire-organon-for-12-billion-bolstering-womens-health-portfolio/2026-04-13T13:44:42+08:00https://flcube.com/duality-biologics-files-nmpa-market-approval-for-db-1303-her2-adc-phase-iii-study-beats-t-dm1-in-metastatic-breast-cancer/2026-04-12T22:28:30+08:00https://flcube.com/oricell-therapeutics-raises-110m-in-pre-ipo-round-accelerates-global-expansion-of-first-in-class-car-t-for-liver-cancer/2026-04-12T22:25:21+08:00https://flcube.com/sino-biopharm-doses-first-patient-in-phase-ii-study-of-kylo-11-first-in-class-sirna-targeting-lpa-for-cardiovascular-disease/2026-04-12T22:21:22+08:00https://flcube.com/peijia-medical-doses-first-patient-in-us-early-feasibility-study-for-geminione-teer-system-expands-global-mitral-regurgitation-pipeline/2026-04-12T11:50:15+08:00https://flcube.com/henlius-biotech-secures-two-new-nmpa-approvals-for-hanlikang-expands-rituximab-biosimilar-into-dlbcl-combination-therapies/2026-04-12T11:43:48+08:00https://flcube.com/gilead-exercises-option-on-kymeras-kt-200-for-45m-advances-cdk2-molecular-glue-degrader-to-ind-enabling-studies/2026-04-12T11:38:49+08:00https://flcube.com/konruns-pharma-wins-nmpa-approval-for-kc1036-phase-iii-in-esophageal-cancer-multi-target-tki-advances-in-2l-escc/2026-04-12T11:35:34+08:00https://flcube.com/sinocelltech-to-raise-rmb-900m-via-private-placement-funds-working-capital-for-biologics-pipeline/2026-04-12T11:32:34+08:00https://flcube.com/norrdia-medical-raises-rmb-100m-to-complete-bellco-acquisition-builds-global-blood-purification-platform/2026-04-12T11:26:50+08:00https://flcube.com/vivatides-therapeutics-closes-54m-series-a-to-advance-extrahepatic-oligonucleotide-delivery-platform-led-by-qiming-venture-partners/2026-04-12T11:22:34+08:00https://flcube.com/c4-therapeutics-and-roche-forge-1b-dac-collaboration-to-pioneer-degrader-antibody-conjugates-in-oncology/2026-04-10T23:53:37+08:00https://flcube.com/roche-reports-7-sales-growth-to-chf-61-5b-driven-by-pharma-and-china/2026-04-10T23:39:45+08:00https://flcube.com/roches-fenebrutinib-hits-phase-iii-endpoint-in-ms-btk-inhibitor-cuts-relapse-rate-51-vs-standard-of-care/2026-04-10T23:39:44+08:00https://flcube.com/sanegenebio-partners-with-genentech-on-rnai-therapy-in-1-7b-deal/2026-04-10T23:39:44+08:00https://flcube.com/lynk-pharmaceuticals-jak1-inhibitor-zemprocitinib-enters-nmpa-review-for-atopic-dermatitis/2026-04-10T23:35:17+08:00https://flcube.com/thermo-fisher-scientific-partners-with-singapores-precise-to-power-landmark-proteomics-study-precise-sg100k/2026-04-10T23:32:32+08:00https://flcube.com/shanghai-ark-bio-advances-ak0406-a-next-gen-long-acting-influenza-adfc-into-phase-i-trial-in-australia/2026-04-10T23:21:25+08:00https://flcube.com/beone-medicines-secures-nmpa-conditional-approval-for-imdelltra-tarlatamab-in-heavily-pretreated-small-cell-lung-cancer/2026-04-10T23:17:45+08:00https://flcube.com/oricell-therapeutics-secures-110m-pre-ipo-round-to-advance-first-in-class-car-t-for-liver-cancer/2026-04-10T13:21:30+08:00https://flcube.com/duality-biologics-her2-targeted-adc-db-1303-bnt323-enters-nmpa-review-for-metastatic-breast-cancer/2026-04-10T13:09:21+08:00https://flcube.com/intuitivefosun-partners-with-sinopharm-cdmc-to-advance-surgical-robotics-adoption-in-china/2026-04-10T13:00:14+08:00https://flcube.com/haisco-pharmas-hsk42360-selected-for-nmpa-spark-program-first-braf-v600-inhibitor-for-pediatric-glioma-in-china/2026-04-09T20:52:34+08:00https://flcube.com/luye-pharma-doses-first-patient-in-phase-ii-study-of-ly03020-worlds-first-dual-target-taar1-5-ht2cr-agonist-for-schizophrenia/2026-04-09T20:49:15+08:00https://flcube.com/sino-biopharm-wins-fda-approval-for-pan-kras-inhibitor-tqb3205-first-in-human-trial-in-advanced-malignancies/2026-04-09T20:43:12+08:00https://flcube.com/genfleet-therapeutics-secures-first-ever-nmpa-breakthrough-designation-for-kras-g12d-inhibitor-in-pancreatic-cancer/2026-04-09T20:38:50+08:00https://flcube.com/gan-lee-licenses-bonfaglutide-to-jw-pharma-for-81-1m-expands-glp-1-footprint-into-south-korea/2026-04-09T20:26:35+08:00https://flcube.com/grand-pharma-partners-with-hku-on-anti-infective-drug-discovery-exclusive-license-deal-targets-novel-antibacterial-therapies/2026-04-09T20:19:30+08:00https://flcube.com/sino-biopharms-chia-tai-tianqing-secures-gdmpa-approval-for-naldemedine-in-greater-bay-area-worlds-first-oral-oic-therapy-enters-china/2026-04-09T20:15:26+08:00https://flcube.com/unixell-biotechnology-secures-nmpa-ind-approval-for-ux-gip001-worlds-first-ipsc-derived-cell-therapy-for-drug-resistant-epilepsy/2026-04-09T20:06:01+08:00https://flcube.com/shionogi-secures-119m-barda-contract-for-fetroja-antibiotic-as-biothreat-countermeasure/2026-04-09T19:53:03+08:00https://flcube.com/ascletis-pharma-advances-oral-glp-1r-amylin-receptor-dual-agonist-combination-asc30-asc39-for-obesity-targeting-q3-fda-ind-submission/2026-04-08T21:43:56+08:00https://flcube.com/basecare-medical-secures-nmpa-category-iii-approval-for-gems-series-ivf-culture-media-expanding-chinas-domestic-embryo-culture-solutions/2026-04-08T21:39:27+08:00https://flcube.com/wuhan-ammunition-life-tech-files-hong-kong-ipo-prospectus-pioneering-methylation-based-early-cancer-detection-with-liver-and-urothelial-cancer-tests/2026-04-08T21:32:47+08:00https://flcube.com/joincare-pharmaceutical-receives-nmpa-approval-to-initiate-jkn2401-clinical-study-in-crswnp-expanding-tslp-targeting-biologic-development-across-respiratory-indications/2026-04-08T21:21:51+08:00https://flcube.com/haisco-pharmaceutical-secures-nmpa-breakthrough-therapy-designation-for-hsk39004-inhalation-powder-in-copd-following-successful-phase-ii-lung-function-data/2026-04-08T21:16:00+08:00https://flcube.com/insilico-medicine-advances-ai-discovered-nr3c1-antagonist-ism6200-into-clinical-development-for-ovarian-cancer-and-cortisol-excess-disorders/2026-04-08T21:11:21+08:00https://flcube.com/sanofis-bispecific-nanobody-lunsekimig-achieves-primary-endpoints-in-asthma-and-crswnp-phase-ii-studies-shows-mixed-results-in-atopic-dermatitis/2026-04-08T21:04:43+08:00https://flcube.com/gilead-sciences-to-acquire-tubulis-for-3-15b-upfront-adding-next-generation-adcs-tub-040-and-tub-030-to-oncology-pipeline/2026-04-08T20:58:29+08:00https://flcube.com/biogen-licenses-alloy-therapeutics-anticlastic-aso-platform-to-advance-next-generation-antisense-therapy-research/2026-04-08T20:54:36+08:00https://flcube.com/simceres-cdh6-targeting-adc-sim0505-receives-fda-fast-track-designation-for-platinum-resistant-ovarian-cancer-advancing-global-development-with-nextcure/2026-04-08T20:50:05+08:00https://flcube.com/everest-medicines-to-acquire-eversea-medicines-singapore-for-250m-expanding-asia-pacific-chronic-disease-portfolio/2026-04-08T20:46:46+08:00https://flcube.com/takeda-terminates-neuroscience-partnership-with-denali-returns-frontotemporal-dementia-candidate-dnl593-for-strategic-realignment/2026-04-08T20:41:33+08:00https://flcube.com/gsks-exdensur-secures-second-nmpa-approval-in-china-for-chronic-rhinosinusitis-with-nasal-polyps-expanding-type-2-inflammation-portfolio/2026-04-08T20:32:20+08:00https://flcube.com/beijing-unveils-32-point-framework-to-accelerate-healthcare-innovation-ai-integration-and-medical-device-development/2026-04-08T13:57:45+08:00https://flcube.com/aidea-pharmas-novel-hiv-1-capsid-inhibitor-acc085-cleared-for-prep-trial-in-china-targeting-long-acting-prevention/2026-04-07T22:01:30+08:00https://flcube.com/gan-lee-pharmaceuticals-launches-chinas-first-ar-targeting-protac-into-phase-i-trial-for-advanced-prostate-cancer/2026-04-07T21:45:15+08:00https://flcube.com/amgens-subcutaneous-tepezza-via-on-body-injector-meets-phase-iii-endpoint-in-thyroid-eye-disease-with-77-proptosis-response/2026-04-07T21:40:38+08:00https://flcube.com/china-imposes-historic-four-year-vbp-ban-on-fu-kang-ren-hetero-labs-for-supply-failures-hehe-and-tiantaishan-also-penalized/2026-04-07T21:24:27+08:00https://flcube.com/genesis-medtech-acquires-controlling-stake-in-tuge-healthcare-gaining-chinas-first-domestic-4k3dfluorescence-endoscopic-platform/2026-04-07T21:09:06+08:00https://flcube.com/sansure-biotech-to-acquire-wwhs-biotech-gaining-exclusive-infrared-fluorescence-platform-for-full-scenario-ivd-expansion/2026-04-07T20:54:58+08:00https://flcube.com/conmind-medical-raises-29m-in-series-c-to-advance-brain-computer-interface-and-cardio-cerebral-integrated-care-platform/2026-04-07T20:51:12+08:00https://flcube.com/siemens-healthineers-partners-with-shanghais-ruijin-hospital-on-worlds-first-ai-powered-liver-fat-quantification-software/2026-04-04T23:14:17+08:00https://flcube.com/zhuhai-rundus-higenamine-receives-nmpa-approval-as-chinas-first-category-1-cardiac-stress-test-agent/2026-04-04T23:09:00+08:00https://flcube.com/youcare-pharmas-ykyy018-inhalation-therapy-expands-to-covid-19-clinical-study-following-rsv-development-success-2/2026-04-04T23:02:59+08:00https://flcube.com/binhui-biopharmaceutical-submits-hong-kong-ipo-prospectus-with-pioneering-oncolytic-virus-pipeline/2026-04-04T22:24:12+08:00https://flcube.com/youcare-pharmas-ykyy018-inhalation-therapy-expands-to-covid-19-clinical-study-following-rsv-development-success/2026-04-04T22:09:23+08:00https://flcube.com/shanghai-huilun-pharma-launches-hong-kong-ipo-with-integrated-pharmaceutical-platform-and-robust-pipeline/2026-04-04T22:04:55+08:00https://flcube.com/mercks-keytruda-receives-eu-approval-for-platinum-resistant-ovarian-cancer-in-combination-regimen/2026-04-04T21:55:11+08:00https://flcube.com/merck-launches-pivotal-phase-2b-3-trial-for-mk-8748-bispecific-antibody-in-wet-amd-treatment/2026-04-04T21:48:53+08:00https://flcube.com/staidson-pharma-announces-182m-private-placement-to-advance-innovative-biologics-pipeline/2026-04-04T21:45:49+08:00https://flcube.com/bio-thera-solutions-gains-nmpa-clearance-for-phase-i-ii-trial-of-pd-1-biosimilar-bat3306-combined-with-trop2-adc-bat8008-in-advanced-solid-tumors/2026-04-04T21:22:27+08:00https://flcube.com/zhifei-biological-renews-exclusive-china-distribution-pact-with-merck-for-gardasil-9-rotateq-and-pneumovax-shifts-to-demand-driven-supply-model/2026-04-03T16:55:18+08:00https://flcube.com/xellar-biosystems-closes-rmb-200m-series-a-led-by-china-life-investment-to-build-3d-bio-intelligence-platform/2026-04-03T16:47:21+08:00https://flcube.com/regeneron-partners-with-trinetx-in-200m-deal-to-expand-world-leading-genomic-phenotypic-data-platform/2026-04-03T16:36:23+08:00https://flcube.com/astrazenecas-imfinzi-imjudo-combo-with-lenvatinib-and-tace-shows-significant-pfs-benefit-in-early-stage-liver-cancer-emerald-3-trial-reveals/2026-04-03T15:52:48+08:00https://flcube.com/remegen-secures-nmpa-approval-for-phase-i-iia-trial-of-bispecific-adc-rc288-targeting-psma-and-b7h3-in-solid-tumors/2026-04-02T23:13:43+08:00https://flcube.com/biocytogen-and-sihuan-pharma-forge-strategic-partnership-to-accelerate-innovative-drug-development-including-weight-management-therapies/2026-04-02T23:02:38+08:00https://flcube.com/sanli-pharmaceutical-transfers-marketing-rights-for-16-drugs-to-hanfang-pharmaceutical-in-rmb-2-million-deal/2026-04-02T22:41:21+08:00https://flcube.com/fosun-pharma-secures-nmpa-approval-for-phase-i-trial-of-hlx319-biosimilar-to-roches-phesgo-for-her2-positive-breast-cancer/2026-04-02T21:25:01+08:00https://flcube.com/nmpa-approves-worlds-first-broad-spectrum-tumor-imaging-agent-99mtc-3prgd2-from-radio-medicinal/2026-04-02T21:18:12+08:00https://flcube.com/sichuan-biokin-receives-nmpa-approval-for-phase-ii-iii-trials-of-first-in-class-bispecific-adc-iza-bren-in-prostate-and-ovarian-cancers/2026-04-02T16:57:31+08:00https://flcube.com/zai-lab-and-amgen-partner-to-evaluate-adc-bite-combination-therapy-for-extensive-stage-small-cell-lung-cancer/2026-04-02T16:50:35+08:00https://flcube.com/chinas-cde-releases-105th-batch-of-reference-preparations-for-generic-drug-evaluation-adds-8-new-drugs/2026-04-02T16:42:56+08:00https://flcube.com/eli-lilly-secures-fda-approval-for-foundayo-orforglipron-in-obesity-treatment-shipments-begin-april-6/2026-04-02T16:39:27+08:00https://flcube.com/eisai-expands-dayvigo-access-in-china-with-14-tablet-specification-across-e-commerce-and-digital-health-platforms/2026-04-02T13:56:02+08:00https://flcube.com/chinas-nmpa-unveils-ambitious-ai-drug-regulation-roadmap-through-2035/2026-04-02T12:54:26+08:00https://flcube.com/shanghai-bdgene-secures-hundreds-of-millions-in-financing-to-advance-dual-gene-therapy-platforms/2026-04-02T12:49:30+08:00https://flcube.com/fosun-pharma-secures-nmpa-clearance-for-two-novel-therapeutics-pd-1-il-2-fusion-fxb0871-and-recombinant-hyaluronidase-hlxte-haase02/2026-04-01T23:49:46+08:00https://flcube.com/rui-therapeutics-secures-nmpa-approval-for-kn5501-car-nk-therapy-in-autoimmune-diseases/2026-04-01T23:44:16+08:00https://flcube.com/changchun-high-new-receives-nmpa-approval-for-gensci161-clinical-study-in-endometriosis-and-hidradenitis-suppurativa/2026-04-01T23:39:23+08:00https://flcube.com/sirius-therapeutics-files-hong-kong-ipo-application-with-sirna-pipeline-targeting-coagulation-and-cardiometabolic-diseases/2026-04-01T23:35:29+08:00https://flcube.com/alphamab-oncologys-anbenitamab-meets-primary-endpoint-in-phase-iii-her2-breast-cancer-neoadjuvant-study/2026-04-01T23:29:17+08:00https://flcube.com/sanofi-secures-eu-conditional-approval-for-rezurock-in-chronic-graft-versus-host-disease/2026-04-01T21:33:40+08:00https://flcube.com/gilead-and-galapagos-forge-2-175-billion-t-cell-engager-collaboration-for-autoimmune-diseases-following-ouro-medicines-acquisition/2026-04-01T21:26:57+08:00https://flcube.com/merck-co-partners-with-infinimmune-for-838-million-antibody-discovery-collaboration-using-human-first-platform/2026-04-01T21:20:40+08:00https://flcube.com/biogen-secures-fda-approval-for-high-dose-spinraza-regimen-in-spinal-muscular-atrophy/2026-04-01T21:15:55+08:00https://flcube.com/astrazeneca-reports-positive-phase-iii-results-for-efzimfotase-alfa-in-hypophosphatasia-across-pediatric-and-adult-populations/2026-04-01T21:10:27+08:00https://flcube.com/otsuka-pharmaceutical-to-acquire-transcend-therapeutics-for-up-to-1-225-billion-to-expand-neuropsychiatric-pipeline/2026-04-01T21:07:24+08:00https://flcube.com/novo-nordisk-launches-wegovy-subscription-program-to-improve-obesity-treatment-access-and-affordability/2026-04-01T20:32:30+08:00https://flcube.com/gan-lee-pharmaceuticals-once-weekly-insulin-gzr4-demonstrates-superior-hba1c-reduction-in-phase-iii-trials/2026-04-01T20:27:11+08:00https://flcube.com/abbisko-therapeutics-secures-ema-orphan-drug-designation-for-irpagratinib-in-hepatocellular-carcinoma/2026-04-01T20:21:04+08:00https://flcube.com/microport-scientific-returns-to-profitability-as-global-access-platform-drives-78-8-revenue-surge/2026-04-01T16:55:24+08:00https://flcube.com/amoy-diagnostics-and-hutchmed-secure-worlds-first-nmpa-approval-for-met-amplification-companion-diagnostic/2026-03-31T21:37:33+08:00https://flcube.com/abbott-integrates-precision-oncology-portfolio-into-flatirons-oncoemr-platform-to-streamline-cancer-care/2026-03-31T21:14:33+08:00https://flcube.com/fosun-pharma-secures-nmpa-approval-for-phase-i-trial-of-attenukine-therapy-fxb0871-in-solid-tumors/2026-03-31T20:43:23+08:00https://flcube.com/boston-scientific-secures-fda-510k-clearance-for-asurys-fluid-management-system-in-kidney-stone-procedures/2026-03-31T20:35:29+08:00https://flcube.com/kailera-therapeutics-plans-ipo-to-fund-obesity-pipeline-after-burning-through-usd-347m-in-development-costs/2026-03-31T20:13:27+08:00https://flcube.com/abbisko-therapeutics-secures-fda-clearance-for-absk061-pediatric-achondroplasia-trial-advancing-oral-fgfr2-3-inhibitor/2026-03-31T20:04:43+08:00https://flcube.com/luye-pharma-reports-31-1-profit-surge-driven-by-new-product-growth-and-oncology-cns-segment-strength/2026-03-31T20:00:38+08:00https://flcube.com/luye-pharma-subsidiary-boan-bio-reports-8-1-revenue-growth-driven-by-multiple-product-approvals-in-2025/2026-03-31T19:55:25+08:00https://flcube.com/immuneonco-doses-first-patient-in-phase-iii-trial-of-worlds-first-cd47-cd20-bispecific-for-follicular-lymphoma/2026-03-31T19:49:59+08:00https://flcube.com/mercks-oral-pcsk9-inhibitor-enlicitide-shows-superior-ldl-c-reduction-in-coralreef-addon-trial/2026-03-31T19:46:49+08:00https://flcube.com/teva-secures-fda-approval-for-prolia-biosimilar-ponlimsi-advances-xolair-copycat-through-regulatory-channels/2026-03-31T19:43:28+08:00https://flcube.com/biocytogen-licenses-rennano-antibody-platform-to-japans-taisho-pharmaceutical-in-strategic-partnership/2026-03-31T19:31:58+08:00https://flcube.com/aim-vaccine-plans-beijing-stock-exchange-ipo-to-strengthen-capital-base-and-expand-operations/2026-03-31T16:37:54+08:00https://flcube.com/roche-launches-cobas-mpx-e-test-in-ce-markets-consolidating-four-virus-detection-for-enhanced-blood-safety/2026-03-31T16:29:23+08:00https://flcube.com/nmpa-approves-gsks-exdensur-as-first-ultra-long-acting-biologic-for-severe-eosinophilic-asthma/2026-03-31T16:22:03+08:00https://flcube.com/kexing-biopharma-secures-fda-clearance-for-gb19-clinical-trial-in-lupus-targeting-novel-bdca2-pathway/2026-03-31T16:12:19+08:00https://flcube.com/shaanxi-micot-files-hkse-listing-application-to-advance-bifunctional-peptide-drug-pipeline/2026-03-31T15:10:25+08:00https://flcube.com/nmpa-finalizes-conditional-drug-approval-framework-to-accelerate-access-to-critical-medicines/2026-03-31T14:30:34+08:00https://flcube.com/dizal-pharmaceutical-reports-record-sales-growth-driven-by-nrdl-inclusion-of-sunvozertinib-and-golidocitinib/2026-03-31T14:27:18+08:00https://flcube.com/nmpa-expands-generic-quality-consistency-evaluation-program-with-36-new-reference-drug-specifications/2026-03-31T14:01:42+08:00https://flcube.com/salubris-pharma-licenses-sintanovos-peripherally-restricted-kor-agonist-stc007-for-pruritus-and-pain-across-greater-china/2026-03-30T22:05:06+08:00https://flcube.com/chinas-largest-healthcare-ma-fund-acquires-pediatrix-therapeutics-bolstering-pediatric-specialty-pharma-portfolio/2026-03-30T21:57:19+08:00https://flcube.com/hansoh-pharmas-uplizna-gains-third-nmpa-approval-in-china-for-generalized-myasthenia-gravis-expanding-cd19-antibody-franchise/2026-03-30T21:49:19+08:00https://flcube.com/insilico-medicine-and-eli-lilly-forge-2-75b-ai-drug-discovery-partnership-centered-on-best-in-class-oral-therapeutic/2026-03-30T21:15:41+08:00https://flcube.com/huadong-medicines-yy001-becomes-worlds-first-recombinant-botulinum-toxin-approved-in-china-for-glabellar-lines/2026-03-30T21:04:40+08:00https://flcube.com/astrazenecas-tezspire-gains-dual-nmpa-approvals-in-china-for-severe-asthma-and-nasal-polyps-based-on-pivotal-phase-iii-data/2026-03-30T20:38:19+08:00https://flcube.com/medtronics-stealth-axis-surgical-system-gains-fda-approval-for-cranial-and-ent-procedures-expanding-beyond-spine/2026-03-30T19:13:27+08:00https://flcube.com/jenscare-completes-first-in-human-study-of-ijensrobo-robot-assisted-tricuspid-valve-replacement-system/2026-03-30T19:02:40+08:00https://flcube.com/clover-biopharmaceuticals-completes-enrollment-in-phase-ii-trial-of-trimer-tag-respiratory-combination-vaccines-for-older-adults/2026-03-30T18:44:18+08:00https://flcube.com/jjs-darzalex-sc-becomes-first-oncology-injectable-in-europe-approved-for-patient-self-administration/2026-03-30T18:28:55+08:00https://flcube.com/novartis-to-acquire-excellergy-for-up-to-2-billion-adding-next-gen-anti-ige-antibody-exl-111-to-immunology-pipeline/2026-03-30T18:13:25+08:00https://flcube.com/gsks-bepirovirsen-receives-ema-review-acceptance-for-chronic-hepatitis-b-pioneering-triple-mechanism-aso-therapy/2026-03-30T18:08:32+08:00https://flcube.com/astrazenecas-tozorakimab-reduces-copd-exacerbations-in-phase-iii-trials-targeting-il-33-in-first-in-class-approach/2026-03-30T17:56:44+08:00https://flcube.com/jjs-icotyde-sustains-and-improves-complete-skin-clearance-in-psoriasis-through-52-weeks-outperforming-deucravacitinib-on-safety/2026-03-30T16:43:42+08:00https://flcube.com/takedas-zasocitinib-demonstrates-superior-efficacy-over-apremilast-and-placebo-in-phase-iii-psoriasis-trials-with-unprecedented-tyk2-selectivity/2026-03-30T16:29:12+08:00https://flcube.com/huahai-pharma-and-almirall-strike-340m-monoclonal-antibody-licensing-deal-targeting-dermatology-and-beyond/2026-03-30T16:20:35+08:00https://flcube.com/sinovac-biotech-and-indonesias-bio-farma-forge-strategic-alliance-to-expand-vaccine-access-across-developing-markets/2026-03-30T15:58:20+08:00https://flcube.com/remegen-posts-89-revenue-surge-in-2025-returns-to-profitability-on-strength-of-taiai-and-disitamab-vedotin/2026-03-30T15:51:31+08:00https://flcube.com/eli-lillys-taltz-zepbound-combo-shows-superior-efficacy-in-obese-psoriatic-arthritis-patients-in-phase-iiib-together-psa-trial/2026-03-30T15:13:36+08:00https://flcube.com/hansoh-pharma-reports-22-6-revenue-growth-in-2025-driven-by-oncology-and-4-54b-in-global-licensing-deals/2026-03-30T14:55:46+08:00https://flcube.com/insilico-medicine-reports-56-2m-revenue-in-2025-amid-strategic-pipeline-buildout-cash-reserves-stand-at-393m/2026-03-30T14:44:36+08:00https://flcube.com/eli-lillys-lebrikizumab-demonstrates-four-year-sustained-efficacy-in-atopic-dermatitis-reinforcing-il-13-as-core-therapeutic-target/2026-03-30T14:09:00+08:00https://flcube.com/brainaurora-medical-partners-with-tokyo-lifestyle-to-launch-ai-powered-digital-health-platform-for-elderly-cognitive-care-across-asia/2026-03-30T14:00:45+08:00https://flcube.com/ucbs-bimzelx-wins-nmpa-approval-for-two-new-indications-il-17a-f-dual-target-antibody-expands-into-psoriasis-and-hidradenitis-suppurativa/2026-03-28T21:30:09+08:00https://flcube.com/enhertu-wins-china-approval-for-her2-early-breast-cancer-adc-sequential-therapy-shows-67-pcr-rate-in-phase-iii-destiny-breast11/2026-03-28T21:24:46+08:00https://flcube.com/fda-approves-rocket-pharmas-kresladi-first-gene-therapy-for-severe-leukocyte-adhesion-deficiency-type-i/2026-03-28T21:07:15+08:00https://flcube.com/c-ray-therapeutics-partners-with-shine-technologies-lu-177-supply-agreement-targets-china-radiopharmaceutical-market/2026-03-27T15:49:09+08:00https://flcube.com/novo-nordisks-awiqli-wins-fda-approval-worlds-first-once-weekly-basal-insulin-for-type-2-diabetes/2026-03-27T15:21:07+08:00https://flcube.com/hengrui-pharmas-hrs9531-wins-nmpa-approval-for-cardiovascular-outcomes-trial-dual-gipr-glp-1r-agonist-targets-mace-reduction/2026-03-27T13:26:41+08:00https://flcube.com/cstone-pharma-2025-revenue-rmb-269-6m-down-34-nrdl-price-adjustment-hits-pralsetinib-licensing-fees-decline/2026-03-27T13:04:24+08:00https://flcube.com/chengdu-kanghongs-khn922-wins-nmpa-approval-dual-payload-her3-adc-targets-advanced-solid-tumors-with-anti-resistance-mechanism/2026-03-27T12:57:14+08:00https://flcube.com/huadong-medicines-hdm2024-wins-nmpa-approval-egfr-her3-bispecific-adc-targets-advanced-solid-tumors/2026-03-27T12:47:20+08:00https://flcube.com/biocytogens-neok002-wins-fda-approval-for-phase-i-egfr-muc1-bispecific-adc-targets-solid-tumors/2026-03-27T12:39:59+08:00https://flcube.com/grand-pharma-2025-revenue-hkd-12-28b-innovative-products-hit-50-of-sales-radiopharma-soars-61/2026-03-27T12:26:23+08:00https://flcube.com/joincare-pharmas-jkn2404-wins-nmpa-approval-for-asthma-trial-next-gen-inhaled-corticosteroid-targets-improved-safety-profile/2026-03-27T12:23:04+08:00https://flcube.com/pulmongenes-pmg1015-wins-fda-fast-track-designation-first-in-class-areg-antibody-targets-idiopathic-pulmonary-fibrosis/2026-03-26T20:07:02+08:00https://flcube.com/china-state-council-mandates-long-term-care-insurance-system-0-3-contribution-rate-targets-severe-disability-coverage-within-three-years/2026-03-26T16:45:05+08:00https://flcube.com/simcere-pharma-2025-revenue-rmb-7-7b-innovative-drugs-drive-28-growth-profit-surges-86/2026-03-26T16:40:11+08:00https://flcube.com/gsk-partners-with-sph-keyuan-trade-to-relaunch-engerix-b-hepatitis-b-vaccine-targets-chinas-adult-self-paid-market/2026-03-26T16:17:54+08:00https://flcube.com/lees-pharma-wins-nmpa-approval-for-intrarosa-estrogen-free-dhea-pessary-targets-postmenopausal-vulvovaginal-atrophy/2026-03-26T16:02:32+08:00https://flcube.com/boehringer-ingelheim-2024-revenue-eur-27-8b-jardiance-drives-8-7-growth-rd-intensity-hits-22-9/2026-03-26T15:56:20+08:00https://flcube.com/united-laboratories-novo-nordisk-report-positive-phase-ii-data-for-ubt251-triple-glp-1-gip-gcg-agonist-achieves-19-7-weight-los/2026-03-26T15:36:00+08:00https://flcube.com/ascentage-pharma-2025-revenue-rmb-574m-olverembatinib-nrdl-inclusion-drives-81-growth-lisaftoclax-launches/2026-03-26T15:32:00+08:00https://flcube.com/msd-to-acquire-terns-pharmaceuticals-for-6-7-billion-tern-701-bcrabl1-inhibitor-targets-chronic-myeloid-leukemia/2026-03-26T15:09:33+08:00https://flcube.com/daiichi-sankyo-partners-with-tempus-ai-foundation-models-target-adc-biomarker-discovery-and-patient-stratification/2026-03-26T15:06:21+08:00https://flcube.com/hengrui-pharma-2025-revenue-rmb-31-6b-innovative-drugs-drive-58-of-sales-out-licensing-hits-rmb-3-4b/2026-03-26T15:03:07+08:00https://flcube.com/thermo-fisher-partners-with-shl-medical-autoinjector-manufacturing-expansion-targets-u-s-drug-device-combination-market/2026-03-26T14:57:40+08:00https://flcube.com/xtalpi-achieves-first-profitability-ai-drug-discovery-revenue-surges-418-to-rmb-538m-global-sales-hit-rmb-803m/2026-03-26T14:54:46+08:00https://flcube.com/everest-medicines-revenue-surges-142-to-rmb-1-7b-nefecon-becomes-first-non-oncology-drug-to-hit-rmb-1b-in-first-nrdl-year/2026-03-26T14:49:36+08:00https://flcube.com/cstones-sugemalimab-wins-esmo-i-a-recommendation-pd-l1-inhibitor-targets-stage-iii-nsclc-consolidation-therapy-in-europe/2026-03-26T14:44:38+08:00https://flcube.com/sinomab-bioscience-reports-positive-phase-i-bridging-data-for-sm17-first-in-class-il-25-receptor-antibody-advances-route-conversion/2026-03-26T14:40:28+08:00https://flcube.com/innocare-pharma-reports-2025-profitability-revenue-surges-135-to-rmb-2-37b-on-global-bd-success/2026-03-26T14:34:42+08:00https://flcube.com/insilico-medicine-expands-ai-collaboration-with-tenacia-bio-94-75m-deal-targets-cns-drug-discovery-with-blood-brain-barrier-penetration/2026-03-26T14:29:16+08:00https://flcube.com/shyndec-pharmaceutical-licenses-eisai-myonal-generic-from-scienpharm-rmb-10-5-million-deal-targets-muscle-relaxant-market/2026-03-25T22:07:42+08:00https://flcube.com/msd-reportedly-eyes-6-billion-terns-pharma-acquisition-bcr-abl-inhibitor-tern-701-targets-post-keytruda-oncology-pipelinew333333/2026-03-25T21:58:40+08:00https://flcube.com/zhifei-bio-initiates-phase-i-study-for-dtap-hib-quadrivalent-vaccine-component-combination-targets-pediatric-immunization-compliance/2026-03-25T15:46:31+08:00https://flcube.com/changchun-high-tech-wins-fda-orphan-drug-designation-for-gensci128-tp53-y220c-reactivator-targets-gastric-cancer/2026-03-25T15:34:13+08:00https://flcube.com/china-nhc-elevates-chikungunya-and-sfts-to-category-b-status-enhanced-surveillance-and-control-measures-effective-april-2026/2026-03-25T15:24:23+08:00https://flcube.com/gan-lees-bonfaglutide-wins-nmpa-approval-for-osa-study-biweekly-glp-1-expands-to-sleep-apnea-indication/2026-03-25T15:20:03+08:00https://flcube.com/clover-bio-reports-positive-scb-1019-phase-i-data-rsv-pref-vaccine-demonstrates-superior-booster-response-vs-gsks-arexvy/2026-03-25T14:59:48+08:00https://flcube.com/merck-kgaa-inaugurates-china-rd-center-beijing-biopark-hub-targets-first-tier-global-drug-launch-status/2026-03-25T14:50:30+08:00https://flcube.com/atom-therapeutics-files-hong-kong-ipo-urat1-inhibitor-abp-671-targets-first-line-gout-treatment-market/2026-03-25T14:43:54+08:00https://flcube.com/asieris-pharma-partners-with-sph-keyuan-to-commercialize-cevira-worlds-first-non-surgical-cervical-precancer-treatment-launches-in-china/2026-03-25T14:30:41+08:00https://flcube.com/henlius-biotech-wins-health-canada-approval-for-denosumab-biosimilars-bildyos-and-tuzemty-expand-organon-partnership-to-canada/2026-03-25T14:16:59+08:00https://flcube.com/qilu-pharmas-qls31905-wins-fda-orphan-drug-designation-first-in-class-claudin18-2-cd3-bispecific-enters-phase-iii-for-pancreatic-cancer/2026-03-25T13:57:25+08:00https://flcube.com/wuxi-biologics-reports-2025-revenue-growth-16-7-net-profit-surges-46-3-on-record-209-new-projects/2026-03-25T13:50:49+08:00https://flcube.com/bayer-regenerons-eylea-hd-wins-japan-approval-for-rvo-third-indication-nod-with-extended-dosing-demonstrates-3-fewer-injections/2026-03-25T13:38:15+08:00https://flcube.com/sciwind-biosciences-files-hong-kong-ipo-prospectus-glp-1-obesity-pipeline-targets-rd-funding-for-weight-management-franchise/2026-03-25T13:20:57+08:00https://flcube.com/sanofis-dupixent-wins-japan-approval-for-bullous-pemphigoid-seventh-indication-expands-il-4-il-13-franchise/2026-03-25T13:05:30+08:00https://flcube.com/haixi-pharma-advances-hxp056-to-phase-ii-oral-multi-selective-therapy-for-wet-amd-and-hemorrhagic-retinal-diseases/2026-03-25T13:00:29+08:00https://flcube.com/iaso-bio-wins-japan-pmda-approval-for-fucaso-car-t-bcma-therapy-enters-phase-iii-in-relapsed-refractory-multiple-myeloma/2026-03-25T12:55:08+08:00https://flcube.com/kelun-biotech-reports-2025-revenue-rmb-2-06-billion-four-drugs-commercialized-30-pipeline-assets-drive-diversification/2026-03-25T12:48:36+08:00https://flcube.com/hope-medicine-doses-first-patient-in-hmi-115-phase-iii-first-in-class-non-hormonal-endometriosis-therapy-advances-in-china/2026-03-25T12:24:19+08:00https://flcube.com/kelun-biotechs-skb103-wins-nmpa-approval-novel-taa-pd-l1-bispecific-adc-enters-clinical-trials-for-advanced-solid-tumors/2026-03-25T12:20:54+08:00https://flcube.com/fosun-pharma-reports-2025-results-innovative-drug-revenue-surges-30-to-rmb-9-9-billion-overseas-sales-hit-rmb-13-billion/2026-03-24T22:46:34+08:00https://flcube.com/alphamab-oncology-doses-first-patient-in-phase-iii-kn026-study-bispecific-her2-antibody-targets-adjuvant-breast-cancer/2026-03-24T20:08:55+08:00https://flcube.com/gilead-to-acquire-ouro-medicines-for-2-175-billion-keymed-biosciences-secures-320-million-from-cm336-tce-deal/2026-03-24T20:03:39+08:00https://flcube.com/shenzhen-salubris-wins-nmpa-approval-for-sal0150-oral-long-acting-diabetes-obesity-drug-targets-weekly-dosing-regimen/2026-03-24T19:54:08+08:00https://flcube.com/roche-opens-institute-of-human-biology-chf-1-4-billion-basel-investment-targets-human-model-systems-for-drug-discovery-revolution/2026-03-24T19:47:47+08:00https://flcube.com/kali-therapeutics-licenses-kt501-to-sanofi-1-23b-deal-for-trispecific-t-cell-engager-targets-autoimmune-diseases/2026-03-24T19:40:22+08:00https://flcube.com/gsks-risvutatug-rezetecan-wins-japan-odd-b7-h3-adc-targets-small-cell-lung-cancer-with-phase-1-durable-responses/2026-03-24T19:33:52+08:00https://flcube.com/belief-biomed-partners-with-grand-life-sciences-on-bbm-h803-aav-gene-therapy-for-hemophilia-a-targets-greater-china-market/2026-03-24T19:30:45+08:00https://flcube.com/hanmi-pharmaceutical-partners-with-chongqing-zhongfu-amlodipine-losartan-fixed-dose-combo-targets-china-out-of-hospital-digital-market/2026-03-24T19:25:52+08:00https://flcube.com/sinomune-pharma-licenses-seysara-from-almirall-exclusive-china-rights-to-tetracycline-acne-antibiotic/2026-03-24T19:19:13+08:00https://flcube.com/chipscreen-biosciences-licenses-epidaza-to-nizhpharm-29m-deal-expands-hdac-inhibitor-into-central-asia-and-eastern-europe/2026-03-24T19:16:17+08:00https://flcube.com/tenacia-bio-licenses-ztalmy-to-golden-age-health-bain-backed-cns-specialist-partners-on-rare-epilepsy-drug-in-china/2026-03-24T19:10:39+08:00https://flcube.com/formosa-pharmaceuticals-licenses-app13007-to-arrotex-nanoparticle-ophthalmic-steroid-gains-australia-new-zealand-rights/2026-03-24T19:08:46+08:00https://flcube.com/rapport-therapeutics-licenses-rap-219-to-tenacia-bio-328m-deal-targets-greater-china-epilepsy-and-bipolar-markets/2026-03-24T19:02:52+08:00https://flcube.com/lexbio-partners-with-hiteck-biopharma-ai-enabled-drug-discovery-alliance-targets-inflammatory-disease-small-molecules/2026-03-24T18:58:38+08:00https://flcube.com/chongqing-maile-bio-pharm-partners-with-main-luck-pharma-on-hematoporphyrin-commercialization-photodynamic-therapy-targets-superficial-cancers/2026-03-24T18:52:16+08:00https://flcube.com/shanghai-pharmaceuticals-licenses-mcb-166-antidepressant-from-sjtu-novel-mechanism-drug-candidate-targets-mental-health-pipeline/2026-03-24T18:44:36+08:00https://flcube.com/insilico-medicine-launches-pandaclaw-ai-agent-platform-transforms-biological-research-with-natural-language-interface/2026-03-24T14:27:55+08:00https://flcube.com/insilico-medicine-partners-with-aska-pharma-ai-driven-target-discovery-collaboration-targets-gynecological-diseases/2026-03-24T14:14:18+08:00https://flcube.com/qilu-pharmas-qls1317-wins-nmpa-approval-first-in-class-msi-h-targeted-therapy-enters-solid-tumor-clinical-trials/2026-03-24T14:07:49+08:00https://flcube.com/nhsa-unveils-drg-3-0-grouping-scheme-roadmap-systematic-upgrade-targets-2027-implementation/2026-03-24T14:02:16+08:00https://flcube.com/biocytogen-partners-with-moonlight-bio-antibody-cell-therapy-collaboration-targets-difficult-to-treat-cancers/2026-03-24T13:57:25+08:00https://flcube.com/innovents-ibi302-hits-star-trial-primary-endpoint-dual-vegf-complement-inhibitor-shows-16-week-dosing-and-50-macular-atrophy-reduction-in-namd/2026-03-24T13:47:58+08:00https://flcube.com/bio-thera-expands-intas-partnership-to-india-bat2506-golimumab-biosimilar-now-licensed-across-us-canada-and-india/2026-03-24T13:20:04+08:00https://flcube.com/sanofi-upgrades-shanghai-rd-center-to-legal-entity-largest-china-translational-medicine-hub-anchors-global-network/2026-03-24T13:15:09+08:00https://flcube.com/remegen-secures-fourth-nmpa-approval-for-disitamab-vedotin-her2-low-breast-cancer-with-liver-metastases-indication-expands-adc-franchise/2026-03-24T13:07:31+08:00https://flcube.com/novartis-commits-rmb-3-3-billion-china-investment-expands-radioligand-therapy-ecosystem-with-policy-push/2026-03-23T16:31:15+08:00https://flcube.com/henlius-biotechs-hlx18-wins-nmpa-approval-nivolumab-biosimilar-enters-phase-i-solid-tumor-trials-in-china/2026-03-23T16:26:29+08:00https://flcube.com/everest-medicines-acquires-etripamil-rights-from-corxel-usd-50-million-deal-for-first-in-class-psvt-nasal-spray-in-greater-china/2026-03-23T16:23:02+08:00https://flcube.com/lepu-biopharma-wins-nmpa-approval-for-perioperative-hnscc-trial-first-in-world-egfr-adc-pd-1-combination-advances-to-clinic/2026-03-23T16:17:35+08:00https://flcube.com/henlius-biotech-reports-2025-revenue-growth-16-5-ex-china-business-doubles-as-global-expansion-accelerates/2026-03-23T16:12:08+08:00https://flcube.com/biokin-pharmas-bl-arc002-wins-nmpa-approval-first-in-class-antibody-radionuclide-conjugate-enters-solid-tumor-trials/2026-03-23T16:05:45+08:00https://flcube.com/hansoh-pharma-wins-nmpa-approval-for-two-category-1-drugs-hs-20152-and-hs-10587-enter-clinical-trials-in-rare-disease-and-oncology/2026-03-23T15:58:50+08:00https://flcube.com/novartis-acquires-snv4818-from-synnovation-usd-3-billion-deal-for-pan-mutant-pi3k%ce%b1-inhibitor-in-breast-cancer/2026-03-23T15:54:38+08:00https://flcube.com/grand-pharma-wins-nmpa-approval-for-gpn01768-first-targeted-therapy-for-demodex-blepharitis-in-china/2026-03-23T15:49:19+08:00https://flcube.com/gsk-wins-fda-approval-for-lynavoy-first-us-treatment-for-pbc-cholestatic-pruritus-as-alfasigma-acquisition-nears-close/2026-03-23T15:43:14+08:00https://flcube.com/eli-lilly-submits-obesity-policy-recommendations-at-china-development-forum-advocates-for-weight-management-in-15th-five-year-plan/2026-03-23T15:35:20+08:00https://flcube.com/xuanzhu-biopharma-completes-anaprazole-phase-iii-enrollment-500-subject-reflux-esophagitis-trial-advances-novel-ppi/2026-03-23T15:29:18+08:00https://flcube.com/hengrui-pharmas-shr-3836-wins-nmpa-approval-for-multiple-myeloma-first-in-class-anti-tumor-agent-enters-clinical-development/2026-03-23T15:18:29+08:00https://flcube.com/hengrui-pharmas-her2-adc-shr-a1811-wins-nmpa-approval-for-breast-cancer-second-indication-expands-trastuzumab-rezetecan-franchise/2026-03-23T15:11:59+08:00https://flcube.com/innovent-biologics-doses-first-patient-in-phase-3-tigulixostat-study-next-gen-xanthine-oxidase-inhibitor-targets-gout-market/2026-03-23T15:04:34+08:00https://flcube.com/dizal-reports-positive-wu-kong28-results-zegfrovy-first-line-win-positions-as-first-chemo-free-egfr-exon20ins-nsclc-therapy/2026-03-23T15:00:03+08:00https://flcube.com/cspc-pharmas-syh2082-wins-nmpa-approval-long-acting-glp-1-gip-dual-biased-agonist-enters-obesity-clinical-trials/2026-03-23T14:51:10+08:00https://flcube.com/haihe-biopharma-wins-japan-approval-for-risovalisib-first-pi3k%ce%b1-inhibitor-for-ovarian-clear-cell-carcinoma/2026-03-23T14:41:34+08:00https://flcube.com/china-nhc-issues-medical-technology-evaluation-procedures-new-framework-triggers-restrictions-or-bans-on-controversial-clinical-practices/2026-03-23T14:28:58+08:00https://flcube.com/medtronic-completes-first-penditure-implant-in-greater-bay-area-recapturable-laa-closure-system-leverages-hk-macao-access-policy/2026-03-20T14:05:50+08:00https://flcube.com/3sbio-wins-nmpa-approval-for-sss06-extended-half-life-erythropoietin-enables-biweekly-dosing-in-dialysis-anemia/2026-03-20T13:47:17+08:00https://flcube.com/alphamab-oncology-doses-first-patient-in-jskn016-phase-iii-her3-trop2-adc-targets-heavily-pretreated-triple-negative-breast-cancer/2026-03-20T13:38:46+08:00https://flcube.com/belief-biomed-secures-macao-approval-for-bbm-h901-chinas-first-hemophilia-b-gene-therapy-expands-to-greater-china-with-takeda/2026-03-20T13:24:18+08:00https://flcube.com/sanofi-opens-chengdu-innovation-hub-600-headcount-china-operations-center-to-drive-rd-and-commercial-excellence/2026-03-20T13:19:37+08:00https://flcube.com/astrazeneca-to-build-radioligand-therapy-manufacturing-hub-in-guangzhou-actinium-225-facility-targets-asia-pacific-cancer-market/2026-03-20T12:59:03+08:00https://flcube.com/novo-nordisk-wins-fda-approval-for-wegovy-hd-7-2-mg-higher-dose-semaglutide-delivers-21-weight-loss-in-step-up-trial/2026-03-20T12:44:03+08:00https://flcube.com/eli-lillys-retatrutide-delivers-2-0-a1c-reduction-and-36-6-lbs-weight-loss-in-phase-3-diabetes-trial-triple-agonist-shows-best-in-class-efficacy/2026-03-20T12:39:37+08:00https://flcube.com/pfizer-reports-positive-talapro-3-results-talzenna-xtandi-combo-hits-primary-endpoint-in-hrr-mutated-prostate-cancer/2026-03-20T12:35:33+08:00https://flcube.com/luzhu-biotechnology-reports-2025-results-lz901-shingles-vaccine-nears-commercialization-with-shingrix-beating-data/2026-03-20T12:14:42+08:00https://flcube.com/samsung-bioepis-expands-sandoz-partnership-global-deal-for-five-biosimilars-including-entyvio-copycat-sb36/2026-03-20T11:54:46+08:00https://flcube.com/abbisko-therapeutics-wins-fda-orphan-drug-designation-for-absk061-oral-fgfr2-3-inhibitor-targets-achondroplasia-in-pediatric-patients/2026-03-19T23:39:10+08:00https://flcube.com/huahai-pharmaceutical-initiates-phase-iii-trial-for-hb0025-pd-l1-vegf-bispecific-targets-first-line-endometrial-cancer/2026-03-19T23:32:24+08:00https://flcube.com/konruns-pharma-wins-nmpa-phase-iii-approval-for-kc1036-multi-target-vegfr2-axl-inhibitor-targets-thymic-carcinoma/2026-03-19T23:24:51+08:00https://flcube.com/inventisbios-d-2570-wins-fda-phase-ii-clearance-oral-tyk2-inhibitor-targets-moderate-to-severe-plaque-psoriasis/2026-03-19T22:35:57+08:00https://flcube.com/kintor-pharmas-kx-826-hits-phase-iii-endpoint-in-hair-loss-androgen-receptor-antagonist-tincture-shows-15-33-hairs-cm%c2%b2-growth-vs-placebo/2026-03-19T22:33:21+08:00https://flcube.com/super-vision-technology-wins-nmpa-approval-for-ocular-neurostimulator-first-in-class-implantable-device-treats-congenital-nystagmus/2026-03-19T22:29:59+08:00https://flcube.com/ge-healthcare-closes-2-3-billion-intelerad-acquisition-medical-imaging-software-deal-expands-ambulatory-and-cloud-first-capabilities/2026-03-19T22:24:41+08:00https://flcube.com/leveragen-partners-with-daiichi-sankyo-in-vivo-antibody-discovery-collaboration-targets-advanced-biologics/2026-03-19T22:18:12+08:00https://flcube.com/jjs-icotyde-wins-fda-approval-first-oral-il-23-receptor-antagonist-targets-moderate-to-severe-plaque-psoriasis/2026-03-19T21:56:26+08:00https://flcube.com/sanofis-venglustat-wins-fda-breakthrough-therapy-designation-oral-brain-penetrant-gcsi-targets-gaucher-disease-type-3-neurological-symptoms/2026-03-19T21:35:08+08:00https://flcube.com/medbanks-acquires-jianyi-tech-for-rmb-360-million-insurance-tech-deal-strengthens-corporate-health-security-platform/2026-03-19T21:24:26+08:00https://flcube.com/transthera-sciences-doses-first-patient-in-phase-ii-tinengotinib-combination-study-multi-kinase-inhibitor-plus-fulvestrant-targets-hr-her2-breast-cancer/2026-03-19T21:16:13+08:00https://flcube.com/walvax-bio-raises-rmb-2-billion-via-private-placement-tengyun-xinwo-bio-to-become-controlling-shareholder/2026-03-19T14:12:34+08:00https://flcube.com/viva-biotech-partners-with-nvidia-to-optimize-ai-drug-design-proteina-complexa-model-targets-actriia-mini-binders/2026-03-19T14:07:01+08:00https://flcube.com/fda-releases-draft-guidance-on-nams-accelerating-shift-from-animal-testing-to-human-relevant-drug-safety-assessment/2026-03-19T13:59:37+08:00https://flcube.com/jiuyuan-gene-engineering-secures-nmpa-approval-for-jy47-sirp%ce%b1-antibody-enters-mash-clinical-development/2026-03-18T16:40:52+08:00https://flcube.com/alebund-pharma-licenses-ap306-to-r1-therapeutics-usd-100-million-deal-for-first-in-class-hyperphosphatemia-drug/2026-03-18T16:35:21+08:00https://flcube.com/ark-biopharma-files-hong-kong-ipo-roche-licensed-rsv-and-ipf-pipeline-targets-respiratory-and-pediatric-markets/2026-03-18T16:07:09+08:00https://flcube.com/everest-medicines-signs-loi-to-acquire-haisen-pharmaceutical-rmb-200-million-deposit-for-14-product-apac-commercial-platform/2026-03-18T16:02:19+08:00https://flcube.com/pfizer-reports-positive-fourlight-1-results-for-atirmociclib-cdk4-inhibitor-shows-pfs-benefit-in-post-cdk4-6-breast-cancer/2026-03-18T14:15:01+08:00https://flcube.com/astrazeneca-secures-eu-approval-for-imfinzi-in-gastric-cancer-perioperative-regimen-cuts-death-risk-22-in-matterhorn-trial/2026-03-18T14:06:53+08:00https://flcube.com/kintor-pharma-partners-with-chicmax-to-accelerate-kt-939-commercialization-active-cosmetic-ingredient-targets-whitening-market/2026-03-18T14:00:41+08:00https://flcube.com/unixell-bio-secures-fda-approval-for-ux-gip001-first-ipsc-allogeneic-cell-therapy-for-epilepsy-enters-us-clinical-trials/2026-03-18T13:52:53+08:00https://flcube.com/simcere-pharma-reports-positive-sim0237-phase-i-ii-data-80-cr-rate-in-bcg-unresponsive-bladder-cancer/2026-03-18T13:47:15+08:00https://flcube.com/bio-heart-bio-expands-iberis-rdn-registration-to-thailand-worlds-only-dual-access-renal-denervation-system/2026-03-18T13:42:25+08:00https://flcube.com/eli-lilly-rolls-out-usd-299-zepbound-kwikpen-via-lillydirect-self-pay-pricing-for-dual-target-obesity-drug/2026-03-18T13:31:41+08:00https://flcube.com/peijia-medical-secures-first-fda-510k-clearance-for-dcwire-micro-guidewire-us-market-entry-milestone/2026-03-18T13:26:45+08:00https://flcube.com/shanghai-pharmaceuticals-and-henlius-forge-strategic-alliance-hospital-market-expansion-and-global-commercial-collaboration-targeted/2026-03-17T18:08:30+08:00https://flcube.com/henlius-wins-nmpa-approval-for-hlx07-combination-trial-anti-egfr-biologic-plus-serplulimab-targets-squamous-nsclc/2026-03-17T18:01:11+08:00https://flcube.com/cspc-pharma-secures-dual-nmpa-fda-approval-for-pde4b-inhaler-syh2059-first-in-class-ild-candidate-enters-global-clinical-development/2026-03-17T16:35:39+08:00https://flcube.com/basecare-medical-secures-nmpa-approval-for-first-domestic-platform-pgt-a-kit-milestone-for-china-ivf-genetic-testing-independence/2026-03-17T16:32:23+08:00https://flcube.com/alphamab-oncology-doses-first-patient-in-jskn027-phase-i-trial-first-in-class-pd-l1-vegfr2-bispecific-adc-enters-clinic/2026-03-17T16:28:56+08:00https://flcube.com/china-unveils-nhsa-grassroots-healthcare-reform-14-point-guidance-targets-rmb-fund-flow-shift-to-primary-care-institutions/2026-03-17T16:25:35+08:00https://flcube.com/pegbio-inks-rmb10-billion-paidakang-commercialization-deal-with-tenry-pharma-exclusive-china-partnership-for-weekly-glp-1-diabetes-drug/2026-03-17T14:12:18+08:00https://flcube.com/ascentage-pharma-and-haisco-secure-cde-spark-inclusion-for-pediatric-oncology-candidates-apg-115-and-hsk42360-target-high-unmet-need-childhood-cancers/2026-03-17T14:02:42+08:00https://flcube.com/roche-deploys-2176-nvidia-gpus-in-global-ai-factory-largest-pharma-gpu-footprint-expands-to-3500-blackwell-units/2026-03-17T13:49:26+08:00https://flcube.com/beone-innovation-center-and-voyagers-capital-launch-fund-early-stage-drug-investment-vehicle-targets-guangzhou-biotech/2026-03-17T13:23:53+08:00https://flcube.com/sino-biopharms-trd221-wins-nmpa-approval-novel-polysaccharide-drug-targets-osteoarthritis-via-complement-inhibition/2026-03-17T13:18:25+08:00https://flcube.com/abb-bio-tech-partners-with-walvax-for-overseas-push-first-china-approved-trivalent-subunit-influenza-vaccine-targets-global-markets/2026-03-16T20:15:50+08:00https://flcube.com/cms-secures-nmpa-approval-for-desidustat-first-domestic-hif-phi-for-non-dialysis-ckd-anemia-enters-china-market/2026-03-16T20:11:08+08:00https://flcube.com/hengruis-irinotecan-liposome-ii-wins-nmpa-phase-ii-approval-adjuvant-pancreatic-cancer-study-vs-gemcitabine-capecitabine/2026-03-16T16:36:31+08:00https://flcube.com/3sbio-wins-nmpa-approval-for-eltrombopag-generic-tpo-ra-copycat-targets-novartis-revolade-in-china-itp-saa-market/2026-03-16T16:19:46+08:00https://flcube.com/chipscreen-biosciences-cs08399-wins-nmpa-approval-prmt5-mta-inhibitor-targets-mtap-deficient-solid-tumors-and-lymphomas/2026-03-16T16:16:12+08:00https://flcube.com/chinas-basic-medical-insurance-covers-1-33-billion-in-2025-nhsa-reports-rmb-3-6-trillion-fund-inflows-114-new-drugs-added-to-nrdl/2026-03-16T16:10:46+08:00https://flcube.com/novartis-cosentyx-wins-fda-pediatric-approval-only-il-17a-inhibitor-for-hidradenitis-suppurativa-in-adolescents-12/2026-03-16T14:27:54+08:00https://flcube.com/cutia-therapeutics-cu-40105-wins-nmpa-approval-topical-dutasteride-targets-androgenetic-alopecia-with-reduced-systemic-exposure/2026-03-16T14:21:06+08:00https://flcube.com/jjs-erda-idrs-shows-89-complete-response-in-nmibc-intravesical-erdafitinib-system-advances-to-phase-ii-iii/2026-03-16T14:17:59+08:00https://flcube.com/bebetter-medicines-ifupinostat-wins-nmpa-approval-for-ptcl-trial-first-hdac-pi3k%ce%b1-dual-inhibitor-enters-first-line-lymphoma-study/2026-03-16T14:14:07+08:00https://flcube.com/abbiskos-irpagratinib-doses-first-patient-in-phase-ii-hcc-trial-fgfr4-inhibitor-plus-toripalimab-bevacizumab-targets-first-line-liver-cancer/2026-03-16T14:10:52+08:00https://flcube.com/junshi-biosciences-reports-rmb-2-5-billion-2025-revenue-toripalimab-drives-40-drug-sales-growth-as-losses-narrow/2026-03-16T14:05:44+08:00https://flcube.com/yoltechs-yolt-202-wins-fda-phase-ii-iii-approval-in-vivo-base-editing-gene-therapy-targets-alpha-1-antitrypsin-deficiency/2026-03-16T13:59:36+08:00https://flcube.com/gsks-arexvy-wins-fda-label-expansion-rsv-vaccine-now-covers-high-risk-adults-aged-18-49/2026-03-16T13:55:12+08:00https://flcube.com/biogens-salanersen-shows-75-nfl-reduction-in-sma-phase-ib-once-yearly-aso-advances-to-phase-iii/2026-03-16T13:48:32+08:00https://flcube.com/kintor-pharmaceutical-partners-with-fonow-medicine-kt-939-cosmetic-collaboration-targets-china-whitening-and-melasma-market/2026-03-13T22:00:56+08:00https://flcube.com/sino-biopharms-tqb3454-hits-phase-iii-endpoints-in-idh1-biliary-tract-cancer-chinas-first-idh1-inhibitor-poised-for-nda-filing/2026-03-13T21:54:10+08:00https://flcube.com/cms-launches-opzelura-nationwide-first-topical-jak-inhibitor-for-vitiligo-reaches-1300-pharmacies-across-30-chinese-provinces/2026-03-13T21:48:41+08:00https://flcube.com/essight-bios-es502-wins-fda-phase-i-approval-first-tcrxcd3-bispecific-targeting-ras-g12v-mutations-enters-clinic/2026-03-13T21:43:15+08:00https://flcube.com/apc-group-and-youcare-pharmaceutical-forge-strategic-partnership-global-distribution-alliance-targets-china-india-pharma-collaboratio/2026-03-13T21:39:12+08:00https://flcube.com/wuxi-biologics-partners-with-earendil-labs-integrated-cdmo-services-for-bispecific-antibodies-and-adcs-targeting-autoimmune-and-oncology-indications/2026-03-13T21:34:08+08:00https://flcube.com/everest-medicines-reports-positive-phase-iia-data-for-vis-101-dual-vegf-a-ang-2-inhibitor-shows-best-in-class-potential-in-wamd/2026-03-13T21:30:17+08:00https://flcube.com/luye-pharma-signs-strategic-partnership-with-sinopharm-mimeixin-distribution-deal-targets-chinas-severe-pain-market/2026-03-13T21:27:25+08:00https://flcube.com/porton-advanced-partners-with-tl-biotechnology-cgt-one-stop-solution-targets-global-cell-and-gene-therapy-market/2026-03-13T21:09:31+08:00https://flcube.com/china-nmpa-approves-worlds-first-invasive-bci-medical-device-brain-computer-interface-hand-motor-system-targets-spinal-cord-injury-patients/2026-03-13T20:58:43+08:00https://flcube.com/changchun-genesciences-gensci128-wins-fda-orphan-drug-designation-tp53-y220c-reactivator-targets-pancreatic-cancer/2026-03-12T13:30:55+08:00https://flcube.com/sino-biopharms-tqb3205-wins-nmpa-approval-first-china-developed-pan-kras-inhibitor-enters-clinic-for-advanced-cancers/2026-03-12T13:27:16+08:00https://flcube.com/sandoz-forms-global-biosimilars-unit-metzger-led-division-targets-accelerated-portfolio-growth/2026-03-12T13:19:59+08:00https://flcube.com/eli-lilly-commits-3-billion-to-china-manufacturing-orforglipron-production-capacity-and-local-supply-chain-expansion/2026-03-12T13:10:38+08:00https://flcube.com/huadong-medicines-hdm2017-wins-fda-orphan-drug-designation-cdh17-adc-targets-three-gastrointestinal-cancers/2026-03-12T12:58:16+08:00https://flcube.com/hengruis-shr-2524-wins-nmpa-phase-i-approval-novel-subcutaneous-formulation-plus-bevacizumab-targets-first-line-liver-cancer/2026-03-12T12:51:23+08:00https://flcube.com/boehringer-ingelheims-jascayd-nerandomilast-launches-in-shanghai-first-pde4b-inhibitor-for-idiopathic-pulmonary-fibrosis/2026-03-12T12:04:58+08:00https://flcube.com/huadong-medicines-hdm2024-wins-fda-phase-i-approval-first-in-class-egfr-her3-bispecific-adc-targets-advanced-solid-tumors/2026-03-12T11:59:45+08:00https://flcube.com/eli-lilly-partners-with-who-foundation-on-global-obesity-health-systems-1-68-million-commitment-through-2029/2026-03-11T16:38:29+08:00https://flcube.com/jjs-akeega-wins-eu-approval-for-mhspc-parp-abiraterone-combo-expands-to-earlier-line-prostate-cancer/2026-03-11T16:31:59+08:00https://flcube.com/abbiskos-absk061-wins-fda-rare-pediatric-disease-designation-fgfr2-3-inhibitor-targets-achondroplasia/2026-03-11T16:25:10+08:00https://flcube.com/zelgens-zesuning-launches-nationwide-first-china-approved-recombinant-tsh-for-thyroid-cancer-follow-up/2026-03-11T16:21:36+08:00https://flcube.com/fosun-pharmas-tenapanor-vteglea-issues-first-china-prescription-nhe3-inhibitor-targets-hyperphosphatemia-in-dialysis-patients/2026-03-11T16:14:24+08:00https://flcube.com/pfizers-tilrekimig-hits-phase-2-primary-endpoint-il-4-il-13-tslp-trispecific-shows-52-easi-75-response-in-atopic-dermatitis/2026-03-11T14:06:33+08:00https://flcube.com/fda-accepts-enhertu-sbla-with-priority-review-her2-adc-seeks-early-breast-cancer-approval-with-53-recurrence-risk-reduction/2026-03-11T14:02:18+08:00https://flcube.com/jj-files-tecvayli-line-extension-with-ema-bcma-bispecific-seeks-earlier-use-in-second-line-multiple-myeloma/2026-03-11T13:55:26+08:00https://flcube.com/hightide-therapeutics-htd1801-nda-accepted-by-nmpa-first-in-class-ampk-nlrp3-dual-target-drug-for-type-2-diabetes/2026-03-11T13:49:04+08:00https://flcube.com/astrazeneca-initiates-clarity-gastric-02-phase-iii-sonesitatug-vedotin-combo-triggers-45-million-milestone-from-kym-biosciences/2026-03-11T13:45:43+08:00https://flcube.com/bayer-co-lab-adds-arbele-and-alphelix-china-innovation-cluster-reaches-12-resident-biotech-startups/2026-03-11T13:40:31+08:00https://flcube.com/fda-approves-gsks-wellcovorin-for-cerebral-folate-deficiency-first-treatment-for-rare-folr1-genetic-disorder/2026-03-11T13:28:25+08:00https://flcube.com/astellas-xospata-fails-phase-iii-primary-endpoint-in-frontline-aml-flt3-inhibitor-misses-os-benefit-vs-midostaurin/2026-03-11T13:21:13+08:00https://flcube.com/keymed-biosciences-initiates-cmg901-phase-iii-astrazeneca-triggers-45-million-milestone-for-claudin-18-2-adc/2026-03-11T13:14:26+08:00https://flcube.com/sicagenes-sg12-aso-wins-nmpa-approval-antisense-oligonucleotide-targets-hepatitis-b-functional-cure/2026-03-10T16:43:48+08:00https://flcube.com/kelun-biotechs-skb575-hbm7575-wins-nmpa-approval-long-acting-tslp-bispecific-targets-atopic-dermatitis-with-q3-dosing-potential/2026-03-10T16:37:28+08:00https://flcube.com/henlius-biotechs-hlx3901-wins-nmpa-approval-first-in-class-tetra-specific-antibody-targets-dll3-positive-solid-tumors/2026-03-10T16:32:41+08:00https://flcube.com/qyuns-therapeutics-qx002n-nda-accepted-by-nmpa-il-17a-antibody-targets-ankylosing-spondylitis-market/2026-03-10T16:28:51+08:00https://flcube.com/gsk-licenses-linerixibat-to-alfasigma-for-300-million-upfront-ibat-inhibitor-targets-pbc-pruritus-with-690-million-total-deal-value/2026-03-10T16:25:30+08:00https://flcube.com/fda-streamlines-biosimilar-development-new-guidance-cuts-pk-study-costs-by-50-accelerates-path-to-market/2026-03-10T16:21:00+08:00https://flcube.com/everest-medicines-launches-etrasimod-in-china-next-gen-s1p-modulator-hits-market-for-ulcerative-colitis/2026-03-10T16:18:18+08:00https://flcube.com/fda-advances-section-804-drug-importation-program-states-meet-agency-on-canadian-prescription-import-pathway/2026-03-10T15:59:32+08:00https://flcube.com/novo-nordisk-settles-with-hims-hers-ozempic-wegovy-distribution-deal-ends-patent-litigation-eliminates-compounded-glp-1-advertising/2026-03-10T14:14:55+08:00https://flcube.com/nmpa-removes-ocaliva-from-gqce-reference-list-obeticholic-acid-stripped-over-safety-concerns-benefit-risk-profile/2026-03-10T13:51:48+08:00https://flcube.com/hutchmed-withdraws-tazverik-from-china-safety-concerns-drive-global-recall-of-epizyme-ipsen-ezh2-inhibitor/2026-03-10T13:48:33+08:00https://flcube.com/fosun-pharmas-hlx316-wins-nmpa-approval-first-in-class-b7-h3-sialidase-heterodimer-targets-advanced-solid-tumors/2026-03-10T13:41:18+08:00https://flcube.com/hengruis-hrs9531-wins-nmpa-approval-for-ckd-trial-dual-gipr-glp-1r-agonist-expands-beyond-diabetes-and-obesity/2026-03-10T13:24:18+08:00https://flcube.com/merck-kgaa-cuts-springworks-hippo-inhibitor-and-hengrui-parp1-program-rd-pipeline-optimization-ditches-e3-7-billion-in-acquired-assets/2026-03-10T13:01:01+08:00https://flcube.com/bristol-myers-squibbs-sotyktu-wins-fda-label-extension-tyk2-inhibitor-expands-to-psoriatic-arthritis/2026-03-09T13:40:50+08:00https://flcube.com/servier-to-acquire-day-one-biopharmaceuticals-for-2-5-billion-french-pharma-expands-u-s-oncology-presence-with-adc-assets/2026-03-09T13:26:11+08:00https://flcube.com/hengruis-adebrelimab-wins-nmpa-approval-for-two-perioperative-cancer-trials-pd-l1-ctla-4-combo-targets-rectal-and-gastric-gej-cancers/2026-03-09T13:20:16+08:00https://flcube.com/leads-biolabs-opamtistomig-enters-phase-ii-in-first-line-esophageal-cancer-pd-l1-4-1bb-bispecific-with-btd-odd-designations/2026-03-09T13:11:27+08:00https://flcube.com/cspcs-syh2059-inhalation-powder-wins-fda-ind-approval-pde4b-inhibitor-targets-pulmonary-fibrosis-with-enhanced-delivery/2026-03-09T13:07:32+08:00https://flcube.com/astrazeneca-china-reorganizes-biopharma-operations-omni-channel-unit-and-early-oncology-pipeline-restructuring/2026-03-09T12:55:32+08:00https://flcube.com/haiscos-hsk39297-nmpa-filing-accepted-oral-factor-b-inhibitor-targets-paroxysmal-nocturnal-hemoglobinuria-market/2026-03-09T12:50:01+08:00https://flcube.com/cf-pharmtech-wins-nmpa-approval-for-olopatadine-mometasone-combo-trial-fixed-dose-nasal-spray-targets-moderate-to-severe-allergic-rhinitis/2026-03-09T12:44:56+08:00https://flcube.com/dongcheng-pharma-doses-first-patient-in-225ac-lnc1011-phase-i-ii-trial-psma-targeted-alpha-radiotherapy-for-metastatic-prostate-cancer/2026-03-09T12:37:12+08:00https://flcube.com/bio-thera-wins-nmpa-approval-for-bat8008-bat1006-trastuzumab-combo-trial-dual-her2-trop2-targeting-in-advanced-solid-tumors/2026-03-09T12:33:29+08:00https://flcube.com/novo-nordisks-icosema-wins-nmpa-approval-once-weekly-insulin-semaglutide-combo-targets-china-type-2-diabetes-market/2026-03-09T12:27:27+08:00https://flcube.com/roches-petrelintide-hits-10-7-weight-loss-in-phase-ii-zupreme-1-trial-amylin-analog-shows-sustained-efficacy-through-week-42/2026-03-06T16:35:48+08:00https://flcube.com/sciwinds-ecnoglutide-wins-nmpa-approval-for-weight-loss-worlds-first-camp-biased-glp-1-agonist-targets-china-obesity-market/2026-03-06T16:29:04+08:00https://flcube.com/roches-xofluza-wins-nmpa-approval-for-pediatric-expansion-oral-suspension-cleared-for-children-under-5-years/2026-03-06T16:19:48+08:00https://flcube.com/merck-kgaa-reports-e21-1-billion-2025-sales-healthcare-drives-3-7-organic-growth-amid-currency-headwinds/2026-03-06T16:01:05+08:00https://flcube.com/jjs-tecvayli-wins-fda-approval-in-earlier-line-myeloma-bcma-bite-plus-daratumumab-combo-expands-addressable-market/2026-03-06T15:43:34+08:00https://flcube.com/fosun-pharmas-hlx97-wins-nmpa-phase-i-approval-first-in-class-kat6a-b-inhibitor-targets-advanced-solid-tumors/2026-03-06T14:00:40+08:00https://flcube.com/fosun-pharmas-luvometinib-cleared-for-phase-ii-nsclc-combination-trial-mek-inhibitor-plus-anlotinib-targets-kras-mutations/2026-03-06T13:58:39+08:00https://flcube.com/insilico-medicines-ai-driven-ism4808-hits-phase-i-milestone-taigen-doses-first-subject-in-ckd-anemia-trial/2026-03-06T13:53:06+08:00https://flcube.com/boan-biotech-partners-with-dp-technology-on-ai4s-drug-discovery-antibody-adc-and-tce-pipeline-acceleration/2026-03-06T13:25:11+08:00https://flcube.com/hutchmed-reports-548-5-million-2025-revenue-fruzaqla-drives-26-growth-amid-china-market-headwinds/2026-03-06T13:12:04+08:00https://flcube.com/hutchmed-initiates-phase-i-iia-trial-for-hmpl-a580-second-antibody-targeted-triggered-conjugate-targets-egfr-solid-tumors/2026-03-05T17:14:29+08:00https://flcube.com/abbvies-skyrizi-hits-affirm-study-endpoints-in-crohns-disease-55-clinical-remission-vs-30-placebo-at-week-12/2026-03-05T17:01:03+08:00https://flcube.com/chinas-2026-government-work-report-unveils-healthcare-overhaul-vbp-optimization-tcm-innovation-and-300m-long-term-care-expansion/2026-03-05T16:51:30+08:00https://flcube.com/astragenomics-and-kactus-forge-gene-editing-partnership-global-commercial-rights-and-manufacturing-scale-up-for-nucleic-acid-therapeutics/2026-03-05T15:58:02+08:00https://flcube.com/abb-bio-tech-wins-fda-ind-approval-for-mrna-mpox-vaccine-chinas-first-u-s-cleared-candidate-targets-immunocompromised-populations/2026-03-05T15:53:40+08:00https://flcube.com/novo-nordisks-cagrisema-fails-non-inferiority-test-against-lillys-zepbound-in-phase-iii-redefine-4-trial-23-vs-25-5-weight-loss/2026-03-05T15:50:19+08:00https://flcube.com/bayer-reports-eur-45-6-billion-2025-sales-nubeqa-and-kerendia-drive-pharma-growth-amid-xarelto-patent-cliff/2026-03-05T15:44:26+08:00https://flcube.com/gilead-foundation-commits-12-million-to-community-health-worker-hiv-prevention-initiative-33-organizations-across-15-u-s-jurisdictions/2026-03-05T15:39:48+08:00https://flcube.com/eli-lillys-eloralintide-wins-cde-approval-for-phase-iii-trials-in-china-weekly-amylin-agonist-targets-weight-management-market/2026-03-05T14:05:14+08:00https://flcube.com/pyrotech-therapeutics-ptt-936-wins-nmpa-approval-novel-alpk1-agonist-targets-bladder-cancer/2026-03-05T13:50:24+08:00https://flcube.com/konruns-pharmas-kc1036-wins-nmpa-approval-dual-target-vegfr2-axl-inhibitor-enters-io-combination-trials/2026-03-05T13:45:15+08:00https://flcube.com/rallybio-to-acquire-candid-therapeutics-in-700m-merger-creates-leading-autoimmune-t-cell-engager-company/2026-03-05T13:41:24+08:00https://flcube.com/sichuan-biokins-cd33-adc-bl-m11d1-wins-nmpa-approval-expands-into-myelodysplastic-syndromes/2026-03-05T13:34:56+08:00https://flcube.com/cmss-cms-d008-wins-nmpa-approval-inhbe-sirna-targets-fat-selective-weight-loss/2026-03-05T13:31:43+08:00https://flcube.com/sanyou-medicals-3d-printed-swingo-3d-lumbar-cage-wins-fda-510k-advances-spinal-fusion-technology/2026-03-05T13:28:04+08:00https://flcube.com/edding-genor-expands-angptl3-sirna-rights-to-global-restructures-napeptide-partnership/2026-03-04T23:11:43+08:00https://flcube.com/sihuan-pharmas-bireociclib-wins-nmpa-approval-for-first-line-hr-her2-breast-cancer-cdk2-4-6-inhibitor-expands-label/2026-03-04T16:42:59+08:00https://flcube.com/aidea-pharma-raises-rmb-1-28b-111m-allocated-to-global-hiv-integrase-inhibitor-development/2026-03-04T14:01:23+08:00https://flcube.com/bio-theras-stelara-biosimilar-usymro-wins-uk-approval-expands-european-market-access-via-gedeon-richter/2026-03-04T13:55:13+08:00https://flcube.com/star-sports-medicine-files-hong-kong-ipo-sports-medical-device-maker-targets-soft-tissue-injury-market/2026-03-04T13:47:57+08:00https://flcube.com/kexing-biopharmas-gb19-wins-nmpa-approval-for-cutaneous-lupus-bdca2-targeted-therapy-expands-autoimmune-pipeline/2026-03-04T13:39:11+08:00https://flcube.com/jjs-nipocalimab-wins-fda-fast-track-for-lupus-fcrn-blocker-targets-autoantibody-diseases/2026-03-04T13:35:11+08:00https://flcube.com/leman-biotech-raises-rmb-200m-series-a-advances-ultra-low-dose-metabolically-armored-car-t/2026-03-04T13:24:21+08:00https://flcube.com/insilico-medicine-launches-ai-powered-automated-partnering-system-transforms-biotech-business-development/2026-03-04T13:14:39+08:00https://flcube.com/teva-secures-400m-blackstone-funding-for-duvakitug-tl1a-antibody-advances-in-ibd-phase-iii/2026-03-04T13:09:09+08:00https://flcube.com/asieris-pharmas-cevira-wins-nmpa-approval-worlds-first-non-surgical-photodynamic-therapy-for-cervical-lesions/2026-03-04T13:03:01+08:00https://flcube.com/antengene-licenses-atg-201-to-ucb-in-1-1b-deal-cd19-cd3-t-cell-engager-targets-autoimmune-diseases/2026-03-04T12:55:25+08:00https://flcube.com/sino-biopharma-licenses-rovadicitinib-to-sanofi-in-1-53b-deal-first-in-class-jak-rock-inhibitor-goes-global/2026-03-04T12:50:38+08:00https://flcube.com/immuneoncos-imm0306s-wins-nmpa-approval-subcutaneous-cd47xcd20-bispecific-for-lupus-enters-clinic/2026-03-04T12:44:34+08:00https://flcube.com/microport-endovasculars-hector-wins-fda-breakthrough-designation-multi-branch-stent-graft-targets-complex-aortic-arch-lesions/2026-03-03T16:22:40+08:00https://flcube.com/huadong-medicines-dr30206-wins-nmpa-approval-triple-target-fusion-protein-for-nsclc-enters-phase-ii/2026-03-03T16:17:58+08:00https://flcube.com/hua-medicines-dorzagliatin-wins-hong-kong-approval-first-in-class-gka-enters-market-for-type-2-diabetes/2026-03-03T14:05:27+08:00https://flcube.com/lepu-medicals-sirna-mwx401-wins-nmpa-approval-rnai-therapy-targets-primary-hypertension/2026-03-03T13:54:49+08:00https://flcube.com/xellsmarts-ipsc-neural-therapy-cleared-by-nmpa-and-fda-first-off-the-shelf-cell-therapy-for-msa-p-enters-clinic/2026-03-03T13:51:22+08:00https://flcube.com/lynk-pharmas-zemprocitinib-hits-phase-iii-endpoints-in-atopic-dermatitis-best-in-class-jak1-inhibitor-shows-superior-efficacy-2/2026-03-03T13:48:21+08:00https://flcube.com/revir-therapeutics-doses-first-patient-in-rtx-117-trial-chinas-first-ai-rna-small-molecule-enters-clinic/2026-03-03T13:44:40+08:00https://flcube.com/nanjing-novlead-bio-files-hong-kong-ipo-nitric-oxide-therapy-specialist-targets-critical-care-market/2026-03-03T13:38:02+08:00https://flcube.com/sanofis-rilzabrutinib-wins-japan-orphan-designation-for-igg4-rd-btk-inhibitor-expands-rare-disease-portfolio/2026-03-03T13:23:30+08:00https://flcube.com/boehringer-ingelheim-licenses-sitryx-autoimmune-program-500m-deal-for-oral-disease-modifying-therapy/2026-03-03T12:59:07+08:00https://flcube.com/cspc-pharmas-syhx2011g1-wins-fda-ind-approval-instant-release-albumin-bound-paclitaxel-for-metastatic-breast-cancer/2026-03-03T12:53:30+08:00https://flcube.com/arkbio-partners-with-qilu-pharma-on-azstarys-china-commercialization-adhd-therapy-market-entry/2026-03-03T12:49:31+08:00https://flcube.com/gan-lees-ar-protac-glr2037-wins-nmpa-approval-first-in-class-prostate-cancer-therapy-enters-clinic/2026-03-03T12:43:13+08:00https://flcube.com/hotgen-biotech-doses-first-patient-in-aa001-phase-ib-anti-a%ce%b2-mab-targets-early-alzheimers-disease/2026-03-03T12:39:26+08:00https://flcube.com/novo-nordisk-invests-e432m-in-ireland-facility-expands-oral-glp-1-manufacturing-for-global-markets/2026-03-03T12:36:13+08:00https://flcube.com/lynk-pharmas-zemprocitinib-hits-phase-iii-endpoints-in-atopic-dermatitis-best-in-class-jak1-inhibitor-shows-superior-efficacy/2026-03-02T14:20:07+08:00https://flcube.com/healzens-btk-inhibitor-hz-a-018-wins-nmpa-approval-for-csu-phase-ii-expands-autoimmune-pipeline/2026-03-02T14:16:49+08:00https://flcube.com/ribo-life-sciences-pcsk9-sirna-rbd7022-enters-phase-iii-qilu-pharma-advances-cholesterol-lowering-drug/2026-03-02T14:11:14+08:00https://flcube.com/genfleets-gfh375-wins-cde-breakthrough-therapy-designation-oral-kras-g12d-inhibitor-for-nsclc/2026-03-02T14:07:22+08:00https://flcube.com/innocares-zurletrectinib-wins-priority-review-for-pediatric-ntrk-tumors-next-gen-trk-inhibitor-expands-label/2026-03-02T14:00:51+08:00https://flcube.com/sino-biopharmas-rovadicitinib-wins-nmpa-approval-first-in-class-jak-rock-inhibitor-for-myelofibrosis/2026-03-02T13:51:52+08:00https://flcube.com/antengenes-xpovio-secures-second-south-korea-reimbursement-selinexor-combo-approved-for-multiple-myeloma/2026-03-02T13:45:20+08:00https://flcube.com/hangyu-pharmas-sosimerasib-wins-nmpa-approval-first-kras-g12c-inhibitor-for-post-therapy-nsclc-in-china/2026-03-02T13:40:11+08:00https://flcube.com/nmpa-cde-launches-caring-program-extension-pilot-accelerates-rare-disease-drug-development-pathway/2026-03-02T13:29:20+08:00https://flcube.com/ql-biopharma-raises-500m-rmb-series-c-orbimed-leads-round-for-monthly-glp-1-zovigrutide/2026-03-02T13:26:19+08:00https://flcube.com/hansoh-pharmas-mirdametinib-plus-almonertinib-nda-accepted-by-nmpa-dual-target-combination-for-egfr-mutant-nsclc/2026-03-02T13:19:11+08:00https://flcube.com/china-sco-metabolic-disease-cooperation-center-established-at-ruijin-hospital-first-national-level-sco-platform-in-shanghai/2026-03-02T13:12:47+08:00https://flcube.com/dupixent-wins-two-nmpa-approvals-in-china-first-biologic-for-bullous-pemphigoid-and-pediatric-asthma-expansion/2026-02-28T15:18:05+08:00https://flcube.com/olumiant-wins-chmp-positive-opinion-for-pediatric-alopecia-jak-inhibitor-nears-eu-approval-for-teens-with-severe-aa/2026-02-28T15:09:16+08:00https://flcube.com/henlius-hlx11-wins-chmp-positive-opinion-perjeta-biosimilar-nears-eu-approval-for-her2-breast-cancer/2026-02-28T14:50:47+08:00https://flcube.com/shionogi-files-corectim-lotion-for-japan-approval-expands-topical-jak-inhibitor-franchise-in-atopic-dermatitis/2026-02-28T14:36:25+08:00https://flcube.com/dupixent-wins-chmp-positive-opinion-for-pediatric-csu-eu-approval-nears-for-children-aged-2-11-years/2026-02-28T14:22:53+08:00https://flcube.com/asieris-apl-1702-maa-accepted-by-ema-first-photodynamic-therapy-for-cervical-hsil-nears-eu-approval/2026-02-28T14:11:29+08:00https://flcube.com/novartis-remibrutinib-wins-chmp-positive-opinion-oral-btk-inhibitor-nears-eu-approval-for-chronic-urticaria/2026-02-28T14:07:39+08:00https://flcube.com/tonghua-dongbao-partners-with-huisheng-biopharma-secures-china-rights-to-first-domestic-insulin-degludec-biosimilars/2026-02-27T20:46:35+08:00https://flcube.com/gan-lees-insulin-biosimilars-win-chmp-positive-opinion-bysumlog-and-dazparda-near-eu-market-entry/2026-02-27T20:09:43+08:00https://flcube.com/kanghong-pharmas-orexin-antagonist-khn707-cleared-for-insomnia-trials-first-in-class-sleep-disorder-candidate/2026-02-27T20:04:03+08:00https://flcube.com/akesos-manfidokimab-nda-accepted-by-nmpa-anti-il-4r%ce%b1-mab-targets-moderate-to-severe-atopic-dermatitis/2026-02-27T19:53:59+08:00https://flcube.com/jumpcan-pharma-secures-china-rights-to-thedermas-tap-1503-first-ahr-modulator-for-atopic-dermatitis/2026-02-27T19:28:30+08:00https://flcube.com/fda-approves-boehringers-zongertinib-in-record-44-days-first-oral-her2-tki-wins-cnpv-fast-track/2026-02-27T19:13:30+08:00https://flcube.com/wuxi-xdc-licenses-wuxitecan-2-technology-to-earendil-labs-885m-deal-powers-ai-driven-adc-development/2026-02-27T19:09:02+08:00https://flcube.com/msds-prevymis-wins-nmpa-approval-for-200-day-pediatric-cmv-prophylaxis-extended-post-transplant-protection/2026-02-27T19:05:07+08:00https://flcube.com/steincares-partners-with-shilpa-biologicals-on-latin-america-biosimilar-deal-regional-commercialization-agreement/2026-02-26T16:28:02+08:00https://flcube.com/nmpa-approves-76-innovative-medical-devices-in-2025-17-yoy-growth-driven-by-ai-and-priority-review-surge/2026-02-26T16:20:14+08:00https://flcube.com/fosun-pharma-licenses-hpv-dna-drug-vgx-3100-from-apollobio-for-greater-china/2026-02-26T16:11:55+08:00https://flcube.com/nmpa-cde-opens-public-consultation-for-104th-reference-listed-drugs-catalog-63-specifications-under-review/2026-02-26T16:06:33+08:00https://flcube.com/danaher-to-acquire-masimo-for-9-9b-expands-diagnostics-platform-with-pulse-oximetry-leader/2026-02-26T16:00:24+08:00https://flcube.com/novartis-to-build-23b-rlt-manufacturing-site-in-texas-expands-radioligand-therapy-production-capacity/2026-02-26T14:21:51+08:00https://flcube.com/novo-nordisk-partners-with-vivtex-on-2-1b-oral-biologics-deal-targets-obesity-and-diabetes-delivery-innovation/2026-02-26T14:14:37+08:00https://flcube.com/3sbios-ssgj-611-nda-accepted-by-nmpa-anti-il-4r%ce%b1-mab-targets-moderate-to-severe-atopic-dermatitis/2026-02-26T14:07:14+08:00https://flcube.com/kexing-biopharmas-gb19-wins-nmpa-ind-approval-novel-bdca2-targeted-therapy-for-lupus-enters-clinic/2026-02-26T14:01:09+08:00https://flcube.com/lepu-biopharmas-gpc3-adc-mrg006a-wins-nmpa-approval-for-hcc-combination-trials-first-in-class-asset-advances/2026-02-26T13:09:10+08:00https://flcube.com/gsk-to-acquire-35pharma-for-950m-adds-potential-best-in-class-pah-asset-hs235/2026-02-26T13:01:51+08:00https://flcube.com/fda-approves-astrazenecas-calquence-plus-venetoclax-for-cll-sll-first-all-oral-fixed-duration-regimen/2026-02-25T16:55:37+08:00https://flcube.com/dupixent-wins-fda-approval-for-allergic-fungal-rhinosinusitis-first-targeted-therapy-for-afrs-expands-dupilumab-label/2026-02-25T16:36:20+08:00https://flcube.com/united-labs-ubt251-achieves-19-7-weight-loss-in-phase-ii-triple-target-glp-1-gip-gcg-agonist-shows-blockbuster-potential/2026-02-25T15:06:22+08:00https://flcube.com/astellas-and-vir-biotechnology-partner-on-1-7b-pro-xten-tce-deal-vir-5500-targets-psma-in-prostate-cancer/2026-02-25T14:56:29+08:00https://flcube.com/bio-theras-bat4406f-bla-accepted-by-nmpa-next-gen-anti-cd20-mab-for-rare-disease-nmosd/2026-02-25T14:46:36+08:00https://flcube.com/mgi-tech-sells-complete-genomics-to-swiss-rockets-for-50m-divests-us-unit-to-mitigate-geopolitical-risks/2026-02-25T14:41:01+08:00https://flcube.com/abbvie-invests-380m-in-illinois-api-manufacturing-ai-enabled-facilities-for-neuroscience-and-obesity-drugs/2026-02-25T14:27:56+08:00https://flcube.com/novo-nordisk-to-cut-semaglutide-list-prices-by-35-50-wegovy-ozempic-rybelsus-standardized-at-675-month/2026-02-25T14:22:35+08:00https://flcube.com/dartsbio-licenses-pacap-antibody-ds009-to-slate-medicines-130m-series-a-fuels-global-migraine-development/2026-02-25T14:13:07+08:00https://flcube.com/henlius-licenses-serplulimab-to-abbott-for-emerging-markets-expands-anti-pd-1-global-footprint/2026-02-25T14:02:04+08:00https://flcube.com/sinomabs-first-in-class-il-25r-antibody-sm17-wins-nmpa-ind-approval-novel-ibd-therapy-enters-clinic/2026-02-25T13:51:08+08:00https://flcube.com/pharscin-pharmas-parp7-inhibitor-hsn002066c1-wins-nmpa-ind-approval-first-class-1-1-innovative-drug-enters-clinic/2026-02-25T13:36:02+08:00https://flcube.com/cansino-biologics-wins-nmpa-approval-for-menhycia-age-expansion-mcv4-now-covers-children-up-to-6-years/2026-02-25T13:31:05+08:00https://flcube.com/insilico-medicine-partners-with-mskcc-to-discover-gastroesophageal-cancer-targets-ai-driven-multi-omics-analysis/2026-02-25T13:15:29+08:00https://flcube.com/yoltech-partners-with-xtalpi-to-build-ai-driven-mrna-and-car-t-screening-platform-closed-loop-dry-wet-lab-integration/2026-02-24T18:17:08+08:00https://flcube.com/jj-invests-1b-in-pennsylvania-cell-therapy-facility-expands-manufacturing-for-cancer-and-neurology-pipeline/2026-02-24T18:12:39+08:00https://flcube.com/frontier-biotech-licenses-two-sirna-assets-to-gsk-in-1b-deal-expands-global-rnai-partnership/2026-02-24T18:07:18+08:00https://flcube.com/jjs-rybrevant-sc-dosing-approved-by-ec-expands-subcutaneous-options-across-all-nsclc-indications/2026-02-24T18:02:10+08:00https://flcube.com/harbour-biomed-licenses-hbm4003-to-solstice-oncology-in-1-2b-deal-expands-global-footprint-for-ctla-4-asset/2026-02-24T17:56:32+08:00https://flcube.com/cspc-pharmaceutical-wins-nmpa-approval-for-phase-ii-study-of-sys6023-her3-adc-in-metastatic-breast-cancer/2026-02-24T17:51:34+08:00https://flcube.com/trinomabs-retavibart-nda-accepted-by-nmpa-first-long-acting-rsv-mab-for-infant-protection-in-china/2026-02-24T17:27:06+08:00https://flcube.com/sichuan-biokins-iza-bren-hits-pfs-and-os-endpoints-in-phase-iii-tnbc-study-first-bispecific-adc-to-show-dual-survival-benefit/2026-02-24T17:01:08+08:00https://flcube.com/fda-issues-draft-guidance-on-plausible-mechanism-framework-accelerates-approval-pathway-for-individualized-genetic-therapies/2026-02-24T16:40:50+08:00https://flcube.com/gilead-sciences-to-acquire-arcellx-for-7-8b-bolsters-car-t-pipeline-with-bcma-targeted-anito-cel/2026-02-24T15:58:17+08:00https://flcube.com/pfizer-partners-with-sciwind-biosciences-for-ecnoglutide-china-rights-495m-deal-marks-metabolic-market-entry/2026-02-24T15:49:54+08:00https://flcube.com/merck-restructures-human-health-into-oncology-and-specialty-units-appoints-oosthuizen-and-foard-to-lead-new-divisions/2026-02-24T15:43:55+08:00https://flcube.com/sino-biopharmas-benmelstobart-secures-fourth-nmpa-approval-for-stage-iii-nsclc-expanding-pd-l1-franchise-in-china/2026-02-14T16:51:01+08:00https://flcube.com/mabworks-obexelimab-%ce%b2-wins-nmpa-approval-as-first-domestic-nmosd-therapy/2026-02-14T16:40:05+08:00https://flcube.com/findcure-bio-raises-14-5-million-series-b-to-advance-radiopharmaceutical-platform/2026-02-14T16:32:17+08:00https://flcube.com/siemens-healthineers-deepens-mayo-clinic-partnership-on-ai-neurology-and-precision-oncology/2026-02-14T11:31:07+08:00https://flcube.com/vivavision-biotech-files-hong-kong-ipo-to-advance-ophthalmology-pipeline/2026-02-14T11:25:23+08:00https://flcube.com/astellas-ventana-cldn18-assay-wins-nmpa-approval-as-first-companion-diagnostic-for-vyloy/2026-02-14T11:20:13+08:00https://flcube.com/genhouse-bio-partners-with-gilead-on-1-5-billion-synthetic-lethal-cancer-project-gh31/2026-02-14T11:13:31+08:00https://flcube.com/3sbios-amdokitug-wins-nmpa-approval-for-moderate-to-severe-plaque-psoriasis/2026-02-14T11:08:45+08:00https://flcube.com/bio-theras-gotenfia-wins-european-approval-as-simponi-biosimilar/2026-02-13T19:30:51+08:00https://flcube.com/first-imaging-raises-14-5-million-to-advance-ai-powered-intraoperative-imaging/2026-02-13T19:24:02+08:00https://flcube.com/carsgen-therapeutics-to-invest-54-million-in-shanghai-car-t-manufacturing-facility/2026-02-13T19:00:11+08:00https://flcube.com/gsk-reports-7-revenue-growth-to-44-7-billion-in-2025-oncology-surges-43/2026-02-13T18:56:06+08:00https://flcube.com/china-medical-system-licenses-teikokus-lidoderm-for-postherpetic-neuralgia-in-china/2026-02-13T13:24:03+08:00https://flcube.com/organon-reports-2025-revenue-decline-to-6-2-billion-jada-sale-and-portfolio-pressures-weigh/2026-02-13T13:16:54+08:00https://flcube.com/salubris-pharma-files-hong-kong-ipo-for-secondary-listing-to-expand-cardiorenal-metabolic-franchise/2026-02-13T13:10:35+08:00https://flcube.com/sanofi-appoints-belen-garijo-as-new-ceo-to-drive-rd-innovation-and-productivity/2026-02-13T13:00:39+08:00https://flcube.com/immunofoco-bio-files-hong-kong-ipo-for-solid-tumor-car-t-pipeline/2026-02-13T12:55:12+08:00https://flcube.com/amgens-uplizna-wins-european-approval-for-generalized-myasthenia-gravis/2026-02-13T12:49:47+08:00https://flcube.com/innovent-biologics-initiates-phase-3-hericare-breast01-study-for-ibi354-in-her2-breast-cancer/2026-02-13T12:44:52+08:00https://flcube.com/ribo-life-science-licenses-4-4-billion-mash-sirna-portfolio-to-madrigal-pharmaceuticals/2026-02-12T22:37:23+08:00https://flcube.com/novartis-secures-long-term-actinium-225-supply-from-niowave-for-radioligand-therapy-expansion/2026-02-12T22:33:32+08:00https://flcube.com/therom-fishers-ppd-partners-with-datavant-to-integrate-real-world-data-into-clinical-trials/2026-02-12T22:29:11+08:00https://flcube.com/msds-keytruda-wins-fda-approval-for-platinum-resistant-ovarian-cancer/2026-02-12T22:21:34+08:00https://flcube.com/sanofi-invests-30-million-in-glubios-sickle-cell-tpd-programs/2026-02-12T22:13:40+08:00https://flcube.com/henlius-biotech-initiates-phase-ib-ii-study-for-hlx43-adc-combinations-in-colorectal-cancer/2026-02-12T22:07:19+08:00https://flcube.com/jingxin-pharmaceutical-files-hong-kong-ipo-for-dual-listing-strategy/2026-02-12T22:03:05+08:00https://flcube.com/novo-nordisk-to-launch-wegovy-vial-version-in-price-war-with-eli-lilly/2026-02-12T21:53:17+08:00https://flcube.com/panacro-pharma-files-hong-kong-ipo-to-expand-digital-clinical-research-platform/2026-02-12T21:46:00+08:00https://flcube.com/eli-lillys-jaypirca-wins-nmpa-approval-for-cll-sll-post-btk-inhibitor-therapy/2026-02-12T21:35:42+08:00https://flcube.com/eli-lillys-mounjaro-wins-nmpa-monotherapy-approval-for-type-2-diabetes-in-china/2026-02-12T21:25:40+08:00https://flcube.com/guangji-pharma-to-raise-87-million-via-private-placement-to-controlling-shareholder/2026-02-12T21:20:06+08:00https://flcube.com/ubrigene-biosciences-partners-with-bristar-immunotech-on-universal-star-t-cell-therapy-cdmo/2026-02-12T21:14:51+08:00https://flcube.com/newsoara-biopharma-expands-global-rights-to-vtvs-pde4-inhibitor-hpp737-in-135-million-deal/2026-02-11T23:09:30+08:00https://flcube.com/siemens-healthineers-partners-with-northwestern-medicine-to-advance-precision-cancer-care/2026-02-11T23:04:58+08:00https://flcube.com/sciclones-tasurgratinib-nda-accepted-by-nmpa-for-fgfr2-biliary-tract-cancer/2026-02-11T22:34:18+08:00https://flcube.com/cascade-pharma-raises-72-million-to-advance-mash-and-obesity-pipeline-to-phase-iii/2026-02-11T22:27:38+08:00https://flcube.com/gsks-rsv-vaccine-filing-accepted-by-nmpa-for-china-market-entry/2026-02-11T22:11:14+08:00https://flcube.com/ubrigene-biosciences-partners-with-innovec-biotherapeutics-on-aav-gene-therapy-for-hereditary-eye-diseases/2026-02-11T22:06:44+08:00https://flcube.com/fda-cracks-down-on-compounded-glp-1-apis-novo-nordisk-sues-hims-hers-for-patent-infringement/2026-02-11T22:01:06+08:00https://flcube.com/chinas-nhsa-launches-reference-drug-pre-communication-system-to-streamline-reimbursement-pathway/2026-02-11T21:51:05+08:00https://flcube.com/astrazeneca-reports-8-revenue-growth-to-58-7-billion-in-2025-oncology-leads-with-17-surge/2026-02-11T21:38:26+08:00https://flcube.com/gilead-reports-2025-revenue-growth-to-29-4-billion-on-hiv-strength-veklury-plunges-49/2026-02-11T21:26:56+08:00https://flcube.com/pfizers-cresemba-wins-nmpa-pediatric-approval-for-invasive-fungal-infections/2026-02-11T21:17:39+08:00https://flcube.com/eli-lillys-omvoh-wins-nmpa-approval-for-crohns-disease-and-ulcerative-colitis-in-china/2026-02-11T21:11:29+08:00https://flcube.com/china-resources-pharma-to-divest-17-87-stake-in-tianmai-bio-for-205-million/2026-02-11T00:31:30+08:00https://flcube.com/changchun-high-techs-gensci136-wins-nmpa-approval-for-iga-nephropathy-clinical-trial/2026-02-11T00:27:03+08:00https://flcube.com/sanofis-wayrilz-wins-fda-breakthrough-and-japan-orphan-designation-for-rare-blood-disorder/2026-02-11T00:23:23+08:00https://flcube.com/tangji-medtech-files-hong-kong-ipo-for-first-nmpa-approved-endoscopic-obesity-device/2026-02-11T00:20:24+08:00https://flcube.com/eisai-biogens-leqembi-subcutaneous-autoinjector-wins-nmpa-priority-review-in-china/2026-02-11T00:12:44+08:00https://flcube.com/hemony-pharma-partners-with-insud-pharma-to-advance-fourth-generation-oral-contraceptive-in-china/2026-02-10T23:57:46+08:00https://flcube.com/overseas-pharma-partners-with-south-american-pharma-group-on-global-extended-release-drug-development/2026-02-10T23:53:35+08:00https://flcube.com/xianju-pharmaceutical-and-adamerck-grant-aspen-china-rights-to-aomeikesong-neuromuscular-reversal-agent/2026-02-10T23:50:36+08:00https://flcube.com/zhendong-pharmaceutical-secures-china-promotion-rights-to-ferrings-sodium-picosulfate/2026-02-10T23:44:08+08:00https://flcube.com/genassist-therapeutic-partners-with-indian-dart-foundation-on-duchenne-muscular-dystrophy-base-editing/2026-02-10T23:38:58+08:00https://flcube.com/foresee-pharmaceuticals-licenses-mmp-12-inhibitor-portfolio-to-primevera-for-584-5-million/2026-02-10T23:36:10+08:00https://flcube.com/formosa-pharmaceuticals-licenses-app13007-eye-drops-to-samil-pharma-for-south-korea-market/2026-02-10T23:32:35+08:00https://flcube.com/nanjing-hanxin-licenses-ac02-acth-analogue-to-amphastar-for-151-million-us-canada-deal/2026-02-10T23:26:53+08:00https://flcube.com/chia-tai-fenghai-licenses-fhnd5032-mir-124-inducer-to-formation-bio-for-500-million/2026-02-10T23:22:07+08:00https://flcube.com/henlius-biotech-secures-global-rights-to-u-mabs-il-1rap-antibody-in-licensing-deal/2026-02-10T23:18:41+08:00https://flcube.com/zhongsheng-pharma-licenses-ray1225-glp-1-gip-dual-agonist-to-qilu-pharma-for-144-million/2026-02-10T22:35:39+08:00https://flcube.com/kintor-pharma-signs-exclusive-china-distribution-deal-for-anti-hair-loss-foam-with-dekai-med/2026-02-10T22:31:14+08:00https://flcube.com/huadong-medicine-and-shian-biotech-advance-sirna-obesity-therapy-to-preclinical-stage/2026-02-10T22:27:01+08:00https://flcube.com/bao-pharma-partners-with-shanghai-raas-to-develop-subcutaneous-blood-products-using-hyaluronidase-technology/2026-02-10T22:21:32+08:00https://flcube.com/delonix-bioworks-dx-104-becomes-first-china-approved-engineered-omv-vaccine-targets-1-3-billion-menb-market/2026-02-09T22:29:11+08:00https://flcube.com/peijia-medical-files-ce-mark-for-geminione-teer-system-in-european-mitral-regurgitation-market/2026-02-09T21:41:09+08:00https://flcube.com/novartis-breaks-ground-on-23-billion-us-biomedical-research-center-in-san-diego/2026-02-09T21:35:48+08:00https://flcube.com/sino-biopharm-completes-phase-iii-enrollment-for-lm-302-adc-in-gastric-cancer/2026-02-09T21:30:58+08:00https://flcube.com/gileads-kite-pharma-secures-fda-label-expansion-for-yescarta-in-primary-cns-lymphoma/2026-02-09T21:26:53+08:00https://flcube.com/jenscare-scientifics-lux-valve-plus-wins-fda-nod-for-us-pivotal-trial-in-tricuspid-regurgitation/2026-02-09T21:21:12+08:00https://flcube.com/hengrui-pharmas-hrs-4642-wins-breakthrough-therapy-designation-for-kras-g12d-pancreatic-cancer/2026-02-09T21:11:07+08:00https://flcube.com/pfizers-hympavzi-wins-fda-priority-review-for-pediatric-hemophilia-expansion/2026-02-09T21:04:54+08:00https://flcube.com/zhongsheng-pharma-reports-positive-phase-iii-data-for-onradivir-pediatric-and-adolescent-influenza-trials/2026-02-09T20:59:17+08:00https://flcube.com/innocare-pharmas-icp-538-becomes-first-vav1-molecular-glue-degrader-to-enter-china-clinical-trials/2026-02-09T20:55:05+08:00https://flcube.com/betta-pharma-secures-nmpa-approval-for-beizeting-first-domestic-pertuzumab-biosimilar-in-china/2026-02-09T20:20:55+08:00https://flcube.com/kelun-biotechs-jiatailai-secures-fourth-nmpa-approval-for-hr-her2-breast-cancer-indication/2026-02-09T20:16:05+08:00https://flcube.com/guangdong-unveils-expanded-2025-greater-bay-area-access-list-for-115-hong-kong-and-macao-drugs-and-devices/2026-02-09T20:07:13+08:00https://flcube.com/insight-lifetech-debuts-on-shanghai-star-market-with-3-billion-valuation-breaking-import-monopoly-in-cardiovascular-imaging/2026-02-06T22:30:30+08:00https://flcube.com/fosun-pharmas-fumaining-wins-priority-review-for-nf1-adult-indication-in-china/2026-02-06T22:25:07+08:00https://flcube.com/hengrui-pharma-secures-nmpa-nod-for-shr-1894-atopic-dermatitis-trial/2026-02-06T22:18:51+08:00https://flcube.com/akesos-ivonescimab-secures-fifth-breakthrough-therapy-designation-for-biliary-tract-cancer-in-china/2026-02-06T22:14:21+08:00https://flcube.com/ascentage-pharma-secures-nmpa-approval-for-apg-3288-btk-degrader-trial-in-hematologic-malignancies/2026-02-06T22:08:39+08:00https://flcube.com/hightide-therapeutics-reports-positive-phase-iib-centricity-data-for-htd1801-in-mash-patients/2026-02-06T21:51:27+08:00https://flcube.com/knature-biopharmaceutical-files-hong-kong-ipo-to-advance-mitochondrial-medicine-and-nad-therapeutics/2026-02-06T21:47:36+08:00https://flcube.com/xtalpi-partners-with-visen-pharma-to-accelerate-ai-driven-endocrine-drug-discovery/2026-02-06T21:36:06+08:00https://flcube.com/chinas-nhsa-opens-nrdl-to-ai-and-digital-health-innovation-unveils-scenario-driven-reimbursement-reform/2026-02-06T21:30:44+08:00https://flcube.com/jj-darzalex-faspro-gets-nmpa-approval-for-transplant-eligible-myeloma-patients/2026-02-06T21:26:16+08:00https://flcube.com/everest-medicines-files-velsipity-for-ulcerative-colitis-in-china/2026-02-06T21:13:29+08:00https://flcube.com/bristol-myers-squibb-growth-portfolio-drives-17-revenue-increase-in-2025/2026-02-06T21:08:06+08:00https://flcube.com/keytruda-wins-20th-china-approval-for-endometrial-cancer-in-first-line-setting/2026-02-06T21:00:32+08:00https://flcube.com/give-kids-a-chance-act-extends-fda-pediatric-research-authority-and-prv-program/2026-02-06T20:54:09+08:00https://flcube.com/eli-lilly-revenue-surges-45-to-65-2b-on-incretin-portfolio-strength/2026-02-05T21:20:14+08:00https://flcube.com/novartis-revenue-growth-hits-8-despite-entresto-and-promacta-generic-erosion/2026-02-05T21:14:05+08:00https://flcube.com/everest-medicines-licenses-micots-mt1013-for-secondary-hyperparathyroidism-in-178m-deal/2026-02-05T21:08:41+08:00https://flcube.com/ge-healthcare-revenue-grows-5-to-20-6b-on-imaging-and-diagnostics-strength/2026-02-05T21:05:05+08:00https://flcube.com/meditrust-mabwell-insurance-ecosystem-partnership/2026-02-05T20:56:41+08:00https://flcube.com/hanx-biopharma-hx111-adc-begins-phase-i-trial-for-lymphoma-and-solid-tumors/2026-02-05T20:49:14+08:00https://flcube.com/pfizer-launches-migraine-management-zone-at-china-pharmacy/2026-02-05T20:46:04+08:00https://flcube.com/shouyaos-sy-9453-mat2a-inhibitor-gets-nmpa-nod-for-mtap-deleted-tumors/2026-02-05T20:38:54+08:00https://flcube.com/innovent-biologics-revenue-surges-45-on-oncology-portfolio-expansion/2026-02-05T20:36:25+08:00https://flcube.com/huadong-medicine-dr10624-gets-nmpa-nod-for-hypertriglyceridemia-study/2026-02-05T20:30:03+08:00https://flcube.com/beijing-online-consultation-pilot-gets-nhc-approval-for-childrens-care/2026-02-05T20:23:39+08:00https://flcube.com/astrazeneca-saphnelo-faces-fda-setback-with-complete-response-letter/2026-02-05T20:20:50+08:00https://flcube.com/abbvie-immunology-portfolio-drives-61-2b-revenue-in-2025/2026-02-05T20:15:41+08:00https://flcube.com/mirxes-partners-with-xtalpi-and-signet-on-ai-driven-gastric-cancer-system/2026-02-05T20:07:48+08:00https://flcube.com/lishan-biopharma-licenses-evogenes-ls-lbp-002-for-global-oncology-development/2026-02-05T20:04:03+08:00https://flcube.com/pfizer-revenue-drops-2-to-62-6b-amid-covid-decline-non-covid-portfolio-grows/2026-02-04T23:43:16+08:00https://flcube.com/merck-keytruda-revenue-drives-65-5b-sales-despite-gardasil-china-slump/2026-02-04T23:25:46+08:00https://flcube.com/hualan-biologicals-hl08-glp-1-drug-gets-nmpa-nod-for-obesity-trial/2026-02-04T23:09:43+08:00https://flcube.com/bio-thera-licenses-keytruda-biosimilar-bat3306-to-avalon-for-middle-east-north-africa/2026-02-04T23:05:27+08:00https://flcube.com/marubeni-launches-xenleta-in-china-after-complex-licensing-journey/2026-02-04T22:59:58+08:00https://flcube.com/cms-d017-gets-nmpa-approval-for-complement-mediated-kidney-disease-study/2026-02-04T22:55:01+08:00https://flcube.com/akeso-licenses-yixining-to-jumpcan-for-pcsk9-promotion-in-china/2026-02-04T22:50:26+08:00https://flcube.com/united-laboratories-ubt251-gets-nmpa-nod-for-sleep-apnea-trial/2026-02-04T22:46:16+08:00https://flcube.com/wuhan-yzy-biopharma-gets-fda-nod-for-m701-phase-ib-ii-mpe-study/2026-02-04T22:32:10+08:00https://flcube.com/amgen-q4-revenue-grows-9-to-9-9b-on-strong-product-sales/2026-02-04T22:25:56+08:00https://flcube.com/grand-pharmaceutical-to-acquire-api-firms-for-rmb-316-million/2026-02-04T21:22:01+08:00https://flcube.com/novo-nordisk-sales-reach-dkk-309-billion-on-glp-1-and-obesity-surge/2026-02-04T21:17:37+08:00https://flcube.com/simcere-receives-40m-milestone-from-abbvie-for-trispecific-myeloma-drug/2026-02-04T21:09:02+08:00https://flcube.com/medtronic-to-acquire-cathworks-for-585m-expand-ai-based-ffrangio-system/2026-02-04T21:04:53+08:00https://flcube.com/tennor-therapeutics-files-hong-kong-ipo-for-anti-infective-pipeline/2026-02-04T20:48:38+08:00https://flcube.com/bebetter-med-bebt-701-approved-for-hypertension-sirna-trial/2026-02-04T20:37:06+08:00